



(51) International Patent Classification:

A61K 31/506 (2006.01) **A61K 31/47** (2006.01)
A61K 45/06 (2006.01) **A61K 31/496** (2006.01)
A61P 31/04 (2006.01) **A61K 31/4965** (2006.01)
A61P 31/06 (2006.01) **A61K 31/498** (2006.01)
A61K 31/132 (2006.01) **A61K 31/5377** (2006.01)
A61K 31/454 (2006.01)

(21) International Application Number:

PCT/US2013/050564

(22) International Filing Date:

15 July 2013 (15.07.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/673,109 18 July 2012 (18.07.2012) US
 61/782,496 14 March 2013 (14.03.2013) US

(71) Applicant: VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 130 Waverly Street, Cambridge, MA 02139 (US).

(72) Inventors; and

(71) Applicants : **LOCHER, Christopher, Phillip** [US/US]; 242 Grove Street, Lexington, MA 02420 (US). **BEN-NANI, Youssef, Laafiret** [US/CA]; 35 Chemin De Hom-bourg, Lorraine, QC J6Z 4N2 (CA). **GRILLOT, Anne-Laure** [FR/US]; 242 Woodland Road, Milton, MA 02186 (US). **O'DOWD, Hardwin** [GB/US]; 21 Worm-wood Street, Unit 516, Boston, MA 02210 (US). **PER-OLA, Emanuele** [IT/US]; 6 Lanark Road, Unit 3, Brook-line, MA 02445 (US). **LE TIRAN, Arnaud** [FR/FR]; 14 Rue Van Gogh, F-78290 Croissy Sur Seine (FR).

(74) Agent: **NEY, Joshua, E.**; Brinks Hofer Gilson & Lione, P.O. Box 10087, Chicago, IL 60610 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: COMBINATION THERAPY COMPRISING 1-ETHYL-3-[5-[2-{1-HYDROXY-1-METHYL-ETHYL}PYRIMIDIN-5-YL]-7-(TETRA HYDROFURAN-2-YL)-1-H-BENZIMIDAZOL-2-YL]UREA AND DERIVATIVES THEREOF TO TREAT MYCOBACTERIUM DISEASES





FIG. 1

(57) Abstract: The present invention relates to combination therapies comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein X and R are as defined herein. The compounds of formula (I) are useful as gyrase and/or topoisomerase IV inhibitors for treating bacterial infections. The compounds of formula (I) either possess a broad range of anti-bacterial activity and advantageous toxicological properties or are prodrugs of compounds having said activity.



(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

COMBINATION THERAPY
COMPRISING 1-ETHYL-3-[5-[2-{1-HYDROXY-1-METHYL-ETHYL}PYRIMIDIN-5-YL]-7-(TETRA
HYDROFURAN-2-YL)-1H-BENZIMIDAZOL-2-YL]UREA AND DERIVATIVES THEREOF TO
TREAT MYCOBACTERIUM DISEASES

BACKGROUND OF THE INVENTION

[0001] *Mycobacterium tuberculosis*, the bacterium which causes tuberculosis (TB), remains a major cause of death in the world in spite of relatively effective treatments with multi-drug combinations due to the lack of treatment accessibility, HIV co-infection, and the lengthy treatment time. Combinations of multiple drugs are required to prevent the emergence of drug resistance and to effectively treat the infection. Drug sensitive TB is treated with isoniazid, rifampicin, pyrazinamide and ethambutol or streptomycin. Importantly, there are many side effects associated with the drugs making compliance difficult and tolerability challenging. For example, isoniazid causes peripheral nervous system disorder and induces serious liver dysfunction in some people when used in combination with rifampicin; rifampicin can cause liver dysfunction or hepatopathy, malaise, drug allergy, and its use with other drugs such as HIV protease inhibitors, is compromised due to P450-associated enzyme induction. In summary, tolerability remains a major challenge for current TB drug treatment regimens.

[0002] A revitalized effort to develop new drug treatments and combinations of drugs has been inspired by medical philanthropy and cooperative efforts of public private partnerships. In addition, in spite of the total number of cases of TB having decreased in most countries, the lack of accessibility of treatment of multi-drug resistant (MDR-TB) and extensively drug resistant (XDR-TB) combined with the emergence of extremely drug resistant (XXDR-TB) or totally drug resistant (TDR-TB) raises global concerns about the sustainability of the current control measures. Furthermore, there remain too few combinations that have the potential to shorten the treatment time of drug sensitive and drug resistant TB infection (currently from six months to two years, respectively), which remains critical to treatment compliance and preventing the emergence of drug resistance. Moreover, there is mechanistic and chemical redundancy for compounds currently in clinical development and safety liabilities for most classes of drugs reflecting a lack of bold and innovative approaches. For example, two fluoroquinolones in phase 3 clinical trials do not address the problem of XDR-TB and may exacerbate drug resistance; three oxazolidinones in phase 2 clinical trials have not proven to shorten the time of treatment; and two nitroimidazoles in clinical development may be incompatible with some of the front line treatment drugs. Thus, there remains an overall dearth of drug candidates for the treatment of tuberculosis; see WGND pipeline as reference <http://www.newtbdrugs.org/pipeline.php>.

[0003] As a result of the need to combat drug-resistant bacteria and the increasing failure of the available drugs, there has been a resurgent interest in discovering new antibiotics. One attractive strategy for developing new antibiotics is to inhibit DNA gyrase and/or topoisomerase IV, bacterial enzymes necessary for DNA replication, and therefore, necessary for bacterial cell growth and division. Gyrase and/or topoisomerase IV activity are also associated with events in DNA transcription, repair and recombination. Gyrase is one of the topoisomerases, a group of enzymes which catalyze the interconversion of topological isomers of DNA (see generally, Kornberg and Baker, *DNA Replication*, 2d Ed., Chapter 12, 1992, W. H. Freeman and Co.; Drlica, *Molecular Microbiology*, 1992, 6, 425; Drlica and Zhao, *Microbiology and Molecular Biology Reviews*, 1997, 61, pp. 377-392). Gyrase itself controls DNA supercoiling and relieves topological stress that occurs when the DNA strands of a parental duplex are untwisted during the replication process. Gyrase also catalyzes the conversion of relaxed, closed circular duplex DNA to a negatively superhelical form which is more favorable for recombination. The mechanism of the supercoiling reaction involves the wrapping of gyrase around a region of the DNA, double strand breaking in that region, passing a second region of the DNA through the break, and rejoining the broken strands. Such a cleavage mechanism is characteristic of a type II topoisomerase. The supercoiling reaction is driven by the binding of ATP to gyrase. The ATP is then hydrolyzed during the reaction. This ATP binding and subsequent hydrolysis cause conformational changes in the DNA-bound gyrase that are necessary for its activity. It has also been found that the level of DNA supercoiling (or relaxation) is dependent on the ATP/ADP ratio. In the absence of ATP, gyrase is only capable of relaxing supercoiled DNA.

[0004] Bacterial DNA gyrase is a 400 kilodalton protein tetramer consisting of two A (GyrA) and two B subunits (GyrB). Binding and cleavage of the DNA is associated with GyrA, whereas ATP is bound and hydrolyzed by the GyrB protein. GyrB consists of an amino-terminal domain which has the ATPase activity, and a carboxy-terminal domain which interacts with GyrA and DNA. By contrast, eukaryotic type II topoisomerases are homodimers that can relax negative and positive supercoils, but cannot introduce negative supercoils. Ideally, an antibiotic based on the inhibition of bacterial DNA gyrase and/or topoisomerase IV would be selective for these enzymes and be relatively inactive against the eukaryotic type II topoisomerases.

[0005] Topoisomerase IV primarily resolves linked chromosome dimers at the conclusion of DNA replication.

[0006] The widely-used quinolone antibiotics inhibit bacterial DNA gyrase (GyrA) and/or Topoisomerase IV (ParC). Examples of the quinolones include the early compounds such as nalidixic acid and oxolinic acid, as well as the later, more potent fluoroquinolones such as norfloxacin, ciprofloxacin, and trovafloxacin. These compounds bind to GyrA and/or ParC and stabilize the cleaved complex, thus inhibiting overall gyrase function, leading to cell death. The fluoroquinolones inhibit the catalytic subunits of gyrase (GyrA) and/or Topoisomerase IV (ParC) (see Drlica and Zhao, *Microbiology and Molecular Biology Reviews*, 1997, 61, 377-392). However, drug resistance has also been recognized as a problem for this class of compounds (WHO Report, "Use of Quinolones in Food Animals and Potential Impact on Human Health", 1998). With the quinolones, as with other classes of antibiotics, bacteria exposed to earlier compounds often quickly develop cross-resistance to more potent compounds in the same class. The associated subunits responsible for supplying the energy necessary for catalytic turnover/resetting of the enzymes via ATP hydrolysis are GyrB (gyrase) and ParE (topoisomerase IV), respectively (see, Champoux, J.J., *Annu. Rev. Biochem.*, 2001, 70, pp. 369-413). Compounds that target these same ATP binding sites in the GyrB and ParE subunits would be useful for treating various bacterial infections (see, Charifson et al., *J. Med. Chem.*, 2008, 51, pp. 5243-5263).

[0007] There are fewer known inhibitors that bind to GyrB. Examples include the coumarins, novobiocin and coumermycin A1, cyclothialidine, cinodine, and clerocidin. The coumarins have been shown to bind to GyrB very tightly. For example, novobiocin makes a network of hydrogen bonds with the protein and several hydrophobic contacts. While novobiocin and ATP do appear to bind within the ATP binding site, there is minimal overlap in the bound orientation of the two compounds. The overlapping portions are the sugar unit of novobiocin and the ATP adenine (Maxwell, *Trends in Microbiology*, 1997, 5, 102).

[0008] For coumarin-resistant bacteria, the most prevalent point mutation is at a surface arginine residue that binds to the carbonyl of the coumarin ring (Arg136 in *E. coli* GyrB). While enzymes with this mutation show lower supercoiling and ATPase activity, they are also less sensitive to inhibition by coumarin drugs (Maxwell, *Mol. Microbiol.*, 1993, 9, 681).


[0009] Despite being potent inhibitors of gyrase supercoiling, the coumarins have not been widely used as antibiotics. They are generally not suitable due to their low permeability in bacteria, eukaryotic toxicity, and poor water solubility (Maxwell, *Trends in Microbiology*, 1997, 5, 102). It would be desirable to have a new, effective GyrB and ParE inhibitor that overcomes these drawbacks and, preferably does not rely on binding to Arg136 for activity.

Such an inhibitor would be an attractive antibiotic candidate, without a history of resistance problems that plague other classes of antibiotics.

[0010] As bacterial resistance to antibiotics has become an important public health problem, there is a continuing need to develop newer and more potent antibiotics. More particularly, there is a need for antibiotics that represent a new class of compounds not previously used to treat bacterial infection. Compounds that target the ATP binding sites in both the GyrB (gyrase) and ParE (topoisomerase IV) subunits would be useful for treating various bacterial infections. Such compounds would be particularly useful in treating nosocomial infections in hospitals where the formation and transmission of resistant bacteria are becoming increasingly prevalent. Furthermore, there is a need for new antibiotics having a broad spectrum of activity with advantageous toxicological properties.

SUMMARY OF THE INVENTION

[0011] The present invention is directed to a method of controlling, treating or reducing the advancement, severity or effects of a mycobacterium disease comprising administering to a patient in need thereof a therapeutically effective amount of gyrase and/or topoisomerase IV inhibitors of formula



wherein R is hydrogen or fluorine;

X is hydrogen, $-\text{PO}(\text{OH})_2$, $-\text{PO}(\text{OH})\text{O}^-\text{M}^+$, $-\text{PO}(\text{O}^-)_2 \cdot 2\text{M}^+$, or $-\text{PO}(\text{O}^-)_2 \cdot \text{D}^{2+}$; M^+ is a pharmaceutically acceptable monovalent cation; and D^{2+} is a pharmaceutically acceptable divalent cation; or a pharmaceutically acceptable salt thereof; in combination with one or more antibiotic compounds comprising a diarylquinolone, rifapentine, rifalazil, a nitroimidazole, a benzothiazinone, capreomycin, clofazimine, cycloserine, dapsone, a

thiocarbamide, ethambutol, DC-159a, a nitrobenzthiazole, sutezolid (PNU-100480), AZD-5847, posizolid (AZD-2563), para-aminosalicylic acid, SQ-109, SQ-609, a capuramycin, a caprazene nucleoside, an isothiazoloquinolone, thioridazine, thiacetazone, dirithromycin, roxithromycin, telithromycin, azithromycin, clarithromycin, erythromycin, amikacin, kanamycin, streptomycin, levofloxacin, moxifloxacin, gatifloxacin, linezolid, rifalazil, meropenem, clavulanate, or isoniazid, with the proviso that when the one or more antibiotic compounds is thioridazine, azithromycin, clarithromycin, erythromycin, amikacin, kanamycin, streptomycin, levofloxacin, moxifloxacin, gatifloxacin, linezolid, rifalazil, meropenem, clavulanate, or isoniazid, then an additional antibiotic is also present in the combination.

[0012] In one embodiment, the one or more antibiotic compounds comprises bedaquiline (TMC-207), delamanid (OPC67683), PA 824, TBA-354, SKLB-TB37, BTZ-043, SQ-641, cycloserine, dapsone, ethionamide, prothionamide, para-aminosalicylic acid, CPZEN45, ACH-702 or ACH-710. In another embodiment, the one or more antibiotic compounds comprises bedaquiline, rifapentine, moxifloxacin, linezolid, delamanid, or PA 824. In a further embodiment, the one or more antibiotic compounds comprises moxifloxacin, linezolid, rifalazil, meropenem, clavulanate, pyrazinamide, or isoniazid. In some embodiments, the combination further comprises pyrazinamide.

[0013] In one embodiment, the the mycobacterial disease is caused by *M. tuberculosis*, *M. avium intracellulare*, *M. ulcerans*, *M. kansasii*, *M. fortuitum*, *M. abscesses*, *M. leprae*, *M. africanum*, *M. marinum*, *M. avium paratuberculosis*, or *M. bovis*, *M. chelonae*, *M. scrofulaceum*, *M. xenopi*, *M. intracellulare*, or *M. microti*. In a further embodiment, the mycobacterium disease is tuberculosis. In some embodiments, the compound of formula (I) is administered with only one antibiotic selected from rifapentine, TMC-207, SQ-109, a nitroimidazole, and an oxazolidinone.

[0014] In one embodiment, the present invention is directed to a method of inhibiting the growth of drug sensitive and drug resistant mycobacteria cells wherein the mycobacteria cell is drug sensitive and drug resistant *M. tuberculosis*, drug resistant *M. tuberculosis*, *M. avium intracellulare*, *M. ulcerans*, *M. kansasii*, *M. fortuitum*, *M. abscesses*, *M. leprae*, *M. africanum*, *M. marinum*, *M. avium paratuberculosis*, or *M. bovis*.

BRIEF DESCRIPTION OF THE DRAWINGS

[0015] FIG. 1 is a thermal ellipsoid plot of two symmetry independent molecules of compound **12**.

[0016] FIG. 2 is a thermal ellipsoid plot of two symmetry independent molecules of compound **23**.

DETAILED DESCRIPTION

[0017] The present invention is directed to gyrase and/or topoisomerase IV inhibitors and pharmaceutically acceptable salts thereof, in combination with one or more antibiotics and optionally pyrazinamide.

[0018] The present invention provides methods and compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more antibiotic agents and, optionally, pyrazinamide effective in treatment and prevention of disease caused by microorganisms including, but not limited to, mycobacteria. In particular, the methods and compositions of the present invention are effective in inhibiting the growth of the microorganism, *M. tuberculosis*.

[0019] As used herein, the term "tuberculosis" comprises disease states usually associated with infections caused by mycobacteria species comprising *M. tuberculosis* complex. The term "tuberculosis" is also associated with mycobacterial infections caused by mycobacteria other than *M. tuberculosis* (MOTT). Other mycobacterial species include *M. avium-intracellulare*, *M. kansasii*, *M. fortuitum*, *M. chelonae*, *M. leprae*, *M. africanum*, and *M. microti*, *M. avium paratuberculosis*, *M. intracellulare*, *M. scrofulaceum*, *M. xenopi*, *M. marinum*, *M. ulcerans*.

[0020] The present invention further provides methods and compositions useful for the treatment of infectious disease, including but not limited to, tuberculosis, leprosy, Crohn's Disease, acquired immunodeficiency syndrome, Lyme disease, cat-scratch disease, Rocky Mountain Spotted Fever and influenza.

[0021] In one embodiment, the one or more antibiotic compounds comprise a diarylquinolone, rifapentine, rifalazil, a nitroimidazole, a benzothiazinone, capreomycin, clofazimine, cycloserine, dapsone, a thiocarbamide, ethambutol, DC-159a, a nitrobenzthiazole, sutezolid (PNU-100480), AZD-5847, posizolid (AZD-2563), para-aminosalicylic acid, SQ-109, SQ-609, a capuramycin, a caprazene nucleoside, an isothiazoloquinolone, thioridazine, thiacetazone, dirithromycin, roxithromycin, telithromycin,

azithromycin, clarithromycin, erythromycin, amikacin, kanamycin, streptomycin, levofloxacin, moxifloxacin, gatifloxacin, linezolid, rifalazil, meropenem, clavulanate, or isoniazid, with the proviso that when the one or more antibiotic compounds is thioridazine, azithromycin, clarithromycin, erythromycin, amikacin, kanamycin, streptomycin, levofloxacin, moxifloxacin, gatifloxacin, linezolid, rifalazil, meropenem, clavulanate, or isoniazid, then an additional antibiotic is also present in the combination.

[0022] The combinations of the present invention are effective against disease caused by infectious organisms, including mycobacteria. One embodiment of the invention provides methods and compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more antibiotic agents and, optionally, pyrazinamide.

[0023] Another embodiment of the invention provides methods and compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more antibiotic agents and optionally pyrazinamide that have MIC values of 50 μM or lower for mycobacterial organisms. Another embodiment of the present invention comprises compositions that have an MIC value of 25 μM or lower for mycobacterial organisms. Yet another embodiment of the present invention comprises compositions that have an MIC value of 12.5 μM or lower for mycobacterial organisms. Another embodiment of the present invention comprises compositions that have an MIC value of 5 μM or lower for mycobacterial organisms. In another embodiment of the present invention, the methods and compositions comprise the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more antibiotic agents and, optionally, pyrazinamide having HTS Luc activity of 10% or greater.

[0024] The present invention contemplates treatment for animals, including, but not limited to, humans. Thus, it is an object of the present invention to provide methods and compositions for the treatment and prevention of diseases caused by mycobacteria such as tuberculosis.

[0025] Yet another object of the present invention is to provide methods and compositions for the treatment and prevention of infectious diseases using compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more antibiotic agents and, optionally, pyrazinamide.

[0026] Another object of the present invention is to provide methods and compositions for the treatment and prevention of mycobacterial disease using compositions comprising the

compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more antibiotic agents and, optionally, pyrazinamide.

[0027] Still another object of the present invention is to provide methods and compositions for the treatment and prevention of tuberculosis using compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more antibiotic agents and, optionally, pyrazinamide.

[0028] Another object of the present invention is to provide methods and compositions for the treatment and prevention of tuberculosis using compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more antibiotic agents and, optionally, pyrazinamide, wherein the composition has an MIC value of 50 μ M, or less.

[0029] Another object of the present invention is to provide methods and compositions for the treatment and prevention of tuberculosis using compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more antibiotic agents and, optionally, pyrazinamide, wherein the composition has an MIC value of 25 μ M, or less.

[0030] Another object of the present invention is to provide methods and compositions for the treatment and prevention of tuberculosis using compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more antibiotic agents and, optionally, pyrazinamide, wherein the composition has an MIC value of 12.5 μ M, or less.

[0031] Yet another object of the present invention is to provide methods and compositions for the treatment and prevention of tuberculosis using compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more antibiotic agents and, optionally, pyrazinamide, wherein the composition has an MIC value of 5 μ M, or less.

[0032] Yet another object of the present invention is to provide methods and compositions for the treatment and prevention of tuberculosis using compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more antibiotic agents and, optionally, pyrazinamide, wherein the composition has HTS/Luc activity of 10% or greater.

[0033] Yet another object of the present invention is to provide compositions for therapeutic formulations for the treatment and prevention of mycobacterial disease.

[0034] Another object of the present invention is to provide compositions for therapeutic formulations for the treatment and prevention of mycobacterial disease caused by mycobacterial species comprising *M. tuberculosis* complex, *M. avium intracellulare*, *M. kansasii*, *M. fortuitum*, *M. chelonoe*, *M. leprae*, *M. africanum*, *M. microti*, *M. bovis* BCG or *M. bovis*.

[0035] Still another object of the present invention is to provide compositions and methods for the treatment or prevention of infectious disease caused by *Mycobacterium fortuitum*, *Mycobacterium marinum*, *Helicobacter pylori*, *Streptococcus pneumoniae* and *Candida albicans*.

[0036] As used herein, the terms “in combination with” and “combinations” refer to the use of two or more agents in one treatment regardless of whether the agents are in a single formulation or in multiple formulations. The use of the term “in combination with” and “combinations” do not restrict the order in which treatments are administered to a subject being treated for a disease caused by a mycobacterium.. The administration of the multiple agents may be simultaneous or sequential. A first treatment can be administered prior to, concurrently with, after, or within any cycling regimen involving the administration of a second or third treatment to a subject with a disease or a condition caused by a mycobacterium. For example, one treatment may be administered 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks before one or more treatments; or one treatment may be administered 5 minutes, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, or 12 weeks after one or more treatments. Such treatments include, for example, the administration of compounds having Formula I in combination with pyrazinamide and one or more antibiotic agents.


[0037] As used herein, the term “halogen” means F, Cl, Br, or I.

[0038] Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure; i.e., the R and S configurations for each asymmetric center. Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the invention.

[0039] Isotopically-labeled forms of compounds of formula (I) wherein one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature are also included herein. Examples of


isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, and fluorine, such as ^2H , ^3H , ^{13}C , ^{14}C , ^{15}N , ^{18}O , and ^{17}O . Such radio-labeled and stable-isotopically labeled compounds are useful, for example, as research or diagnostic tools or gyrase and/or topoisomerase IV inhibitors with improved therapeutic profile. The structures also encompass zwitterionic forms of the compounds or salts, where appropriate.

[0040] The gyrase and/or topoisomerase IV inhibitors of the present invention may be represented by formula (I) or salts thereof:




wherein R is hydrogen or fluorine; X is hydrogen, $-\text{PO}(\text{OH})_2$, $-\text{PO}(\text{OH})\text{O}^-\text{M}^+$, $-\text{PO}(\text{O}^-)_2 \cdot 2\text{M}^+$, or $-\text{PO}(\text{O}^-)_2 \cdot \text{D}^{2+}$; M^+ is a pharmaceutically acceptable monovalent cation; and D^{2+} is a pharmaceutically acceptable divalent cation. The compounds of formula (I) either possess a broad range of anti-bacterial activity and advantageous toxicological properties or are prodrugs of compounds having said activity.

[0041] The gyrase and/or topoisomerase IV inhibitors of the present invention may be represented by formula (IA):




wherein R is hydrogen or fluorine. The compounds of formula (IA) possess a broad range of anti-bacterial activity and advantageous toxicological properties.

[0042] The gyrase and/or topoisomerase IV inhibitors of the present invention may be represented by formula (IB):




wherein X is $-\text{PO}(\text{OH})_2$, $-\text{PO}(\text{OH})\text{O}^-\text{M}^+$, $-\text{PO}(\text{O}^-)_2 \cdot 2\text{M}^+$, or $-\text{PO}(\text{O}^-)_2 \cdot \text{D}^{2+}$; M^+ is a pharmaceutically acceptable monovalent cation; and D^{2+} is a pharmaceutically acceptable divalent cation. The compounds of formula (IB) are phosphate ester prodrugs of the compound (*R*)-1-ethyl-3-(6-fluoro-5-(2-(2-(hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea, which possesses a broad range of anti-bacterial activity and advantageous toxicological properties.

[0043] In one embodiment, compounds of formula (I) include compounds of formula (IC)




wherein R is as defined above.

[0044] In another embodiment, compounds of formula (I) include compounds of formulae (ID) and (IE) as set forth below:



[0045] (*R*)-1-ethyl-3-(5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea, or a pharmaceutically acceptable salt thereof; and



[0046] (*R*)-1-ethyl-3-(6-fluoro-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea, or a pharmaceutically acceptable salt thereof. Unless otherwise stated, the phrase “compounds of formula (I)” is intended to include other formulae set forth herein that are encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0047] The compounds of formula (IB) are prodrugs of their parent compound, 1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2*R*)-tetrahydrofuran-2-yl]-1H-benzimidazol-2-yl]urea. Thus, the activity exhibited upon administration of the prodrug is principally due to the presence of the parent compound that results from cleavage of the prodrug.

[0048] An additional object of the present invention provides embodiments in which the one or more antibiotic compounds comprise a diarylquinolone, rifapentine, rifalazil, a nitroimidazole, a benzothiazinone, capreomycin, clofazimine, cycloserine, dapsone, a thiocarbamide, ethambutol, DC-159a, a nitrobenzthiazole, sutezolid (PNU-100480), AZD-5847, posizolid (AZD-2563), para-aminosalicylic acid, SQ-109, SQ-609, a capuramycin, a caprazene nucleoside, an isothiazoloquinolone, thioridazine, thiacetazone, dirithromycin, roxithromycin, telithromycin, azithromycin, clarithromycin, erythromycin, amikacin, kanamycin, streptomycin, levofloxacin, moxifloxacin, gatifloxacin, linezolid, rifalazil, meropenem, clavulanate, or isoniazid, with the proviso that when the one or more antibiotic compounds is thioridazine, azithromycin, clarithromycin, erythromycin, amikacin, kanamycin, streptomycin, levofloxacin, moxifloxacin, gatifloxacin, linezolid, rifalazil, meropenem, clavulanate, or isoniazid, then an additional antibiotic is also present in the combination. In one embodiment, the additional antibiotic is pyrazinamide.

[0049] In one aspect, the present invention provides embodiments in which the one or more antibiotic compounds comprise a diarylquinolone, rifapentine, rifalazil, or a nitrobenzthiazole. In another aspect, pyrazinamide may also be present in the combination. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE). In one aspect, the present invention provides embodiments in which the one or more antibiotic compounds comprise a nitroimidazole, a benzothiazinone, capreomycin, clofazimine, cycloserine, dapsone, a thiocarbamide, ethambutol, DC-159a, or a nitrobenzthiazole. In another aspect, pyrazinamide may also be present in the combination. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0050] In one aspect, the present invention provides embodiments in which the one or more antibiotic compounds comprise a nitroimidazole, a benzothiazinone, capreomycin, clofazimine, cycloserine, dapsone, a thiocarbamide, ethambutol, or DC-159a. In another aspect, pyrazinamide may also be present in the combination. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0051] In one aspect, the present invention provides embodiments in which the one or more antibiotic compounds comprise capreomycin, clofazimine, cycloserine, dapsone, a thiocarbamide, ethambutol, DC-159a, or a nitrobenzthiazole. In another aspect, pyrazinamide may also be present in the combination. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0052] In one aspect, the present invention provides embodiments in which the one or more antibiotic compounds comprise a diarylquinolone, rifapentine, rifalazil, dapsone, a thiocarbamide, ethambutol, DC-159a, or a nitrobenzthiazole. In another aspect, pyrazinamide may also be present in the combination. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0053] In another aspect, the present invention provides embodiments in which the one or more antibiotic compounds comprise sutezolid (PNU-100480), AZD-5847, posizolid (AZD-2563), para-aminosalicylic acid, SQ-109, SQ-609, a capuramycin, a caprazene nucleoside, an isothiazoloquinolone, thioridazine, thiacetazone, dirithromycin, roxithromycin, telithromycin, azithromycin, clarithromycin, erythromycin, amikacin, kanamycin,

streptomycin, levofloxacin, moxifloxacin, gatifloxacin, linezolid, rifalazil, meropenem, clavulanate, or isoniazid, with the proviso that when the one or more antibiotic compounds is thioridazine, azithromycin, clarithromycin, erythromycin, amikacin, kanamycin, streptomycin, levofloxacin, moxifloxacin, gatifloxacin, linezolid, rifalazil, meropenem, clavulanate, or isoniazid, then an additional antibiotic is also present in the combination. In another aspect, the additional antibiotic is pyrazinamide. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0054] In another aspect, the present invention provides embodiments in which the one or more antibiotic compounds comprise sutezolid (PNU-100480), AZD-5847, posizolid (AZD-2563), para-aminosalicylic acid, SQ-109, SQ-609, a capuramycin, a caprazene nucleoside, an isothiazoloquinolone, thiacezone, dirithromycin, roxithromycin, or telithromycin. In another aspect, pyrazinamide may also be present in the combination. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0055] In another aspect, the present invention provides embodiments in which the one or more antibiotic compounds comprise thioridazine, azithromycin, clarithromycin, erythromycin, amikacin, kanamycin, streptomycin, levofloxacin, moxifloxacin, gatifloxacin, linezolid, rifalazil, meropenem, clavulanate, or isoniazid. In another aspect, pyrazinamide may also be present in the combination. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0056] In one embodiment, the one or more antibiotics comprises bedaquiline (TMC-207), delaminid (OPC67683), PA 824, TBA-354, BTZ-043, SQ-641, cycloserine, dapsone, ethionamide, prothionamide, para-aminosalicylic acid, CPZEN45, ACH-702 or ACH-710.

[0057] An additional object of the present invention provides embodiments in which the one or more antibiotic agents is pyrazinamide in combination with moxifloxacin, linezolid, rifalazil, meropenem, clavulanate, or isoniazid.

[0058] In another embodiment, the oxazolidinone may be linezolid, Sutezolid (PNU-100480), 2-oxazolidone, torezolid, posizolid, eperezolid, radezolid, AZD-5847, or those described in U.S. Patent Nos. 5981528 and 6605630.

[0059] In another embodiment, the diarylquinoline is bedaquiline (TMC-207).

[0060] In a further embodiment, the nitroimidazole may be PA 824, delaminid (OPC-67683), or TBA-354.

[0061] In a further embodiment, the one or more antibiotics suitable for the combinations of the present application comprise bedaquiline (TMC-207), delamanid (OPC67683), PA 824, TBA-354, BTZ-043, SQ-641, cycloserine, dapsone, ethionamide, prothionamide, para-aminosalicylic acid, CPZEN45, ACH-702 or ACH-710.

[0062] One embodiment of the invention provides methods and compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with TMC-207. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0063] One embodiment of the invention provides methods and compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with Rifapentine. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0064] One embodiment of the invention provides methods and compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with oxazolidinone. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0065] One embodiment of the invention provides methods and compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with a nitroimidazole. In a further embodiment, the nitroimidazole is delamanid. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0066] One embodiment of the invention provides methods and compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with SQ-109. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0067] One embodiment of the invention provides methods and compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with TMC-207 and pyrazinamide. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0068] One embodiment of the invention provides methods and compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with rifapentine and pyrazinamide. In a further embodiment, the compound of formula (I)

includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0069] One embodiment of the invention provides methods and compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with oxazolidinone and pyrazinamide. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0070] One embodiment of the invention provides methods and compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with nitroimidazole and pyrazinamide. In a further embodiment, the nitroimidazole is delaminid. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0071] One embodiment of the invention provides methods and compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with pyrazinamide and SQ-109. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0072] One embodiment of the invention provides methods and compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with TMC-207, SQ-109, and pyrazinamide. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0073] One embodiment of the invention provides methods and compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with clavulanate and meropenem. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0074] One embodiment of the invention provides methods and compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with rifapentine, SQ-109, and pyrazinamide. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0075] One embodiment of the invention provides methods and compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination

with oxazolidinone, SQ-109, and pyrazinamide. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0076] One embodiment of the invention provides methods and compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with nitroimidazole, SQ-109, and pyrazinamide. In a further embodiment, the nitroimidazole is delaminid. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0077] One embodiment of the invention provides methods and compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with clavulanate, meropenem, and SQ-109. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).


[0078] In another embodiment, the invention provides methods and compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with one or more of thiacetazone, dirithromycin, roxithromycin, telithromycin, azithromycin, clarithromycin, erythromycin, amikacin, kanamycin, streptomycin, and levofloxacin,. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0079] In another embodiment, the invention provides methods and compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with pyrazinamide and one or more of thiacetazone, dirithromycin, roxithromycin, telithromycin, azithromycin, clarithromycin, erythromycin, amikacin, kanamycin, streptomycin, and levofloxacin. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0080] In another embodiment, the invention provides methods and compositions comprising the compound of formula (I), or a pharmaceutically acceptable salt thereof, in combination with pyrazinamide and one or more of azithromycin, clarithromycin, erythromycin, amikacin, kanamycin, streptomycin, and levofloxacin,. In a further embodiment, the compound of formula (I) includes compounds encompassed by formula (I) including formulae (IA), (IB), (IC), (ID), and (IE).

[0081] The term “capuramycins” as used herein refers to a class of antibiotic useful for treating bacterial infections based on capuramycin. Capuramycin (general formula

C₂₃H₃₁O₁₂N₅) is a nucleoside antibiotic produced by *Streptomyces griseus* 446-S3 active against streptococcus pneumoniae and Mycobacterium smegmatis ATCC 607 and has the following structure:




Examples of capuramycins suitable for the combinations of the present application include capuramycin and the capuramycin analogue SQ-641.


[0082] As used herein, the term “aminocoumarin” refers to a class of antibiotics that act by an inhibition of the DNA Gyrase enzyme involved in the cell division in bacteria. They are derived from *Streptomyces* species. Examples of aminocoumarin antibiotics include novobiocin, cloroblocin, coumermycin, ferulobiocin, 3-chlorocoumarobiocin and 8'-dechloro-3-chlorocoumarobiocin. Additional aminocoumarins suitable for the combinations of the present invention include those described in Li, S. M. and Heide L. *Curr. Med. Chem.* 12:419-27 (2005) and in Friedman, M. et al. *Biochem.*, 46:8462-71 (2007).

[0083] Isothiazoloquinolones suitable for the combinations of the present invention include ACH-710, ACH-702 (described by Pucci, M. J. et al. in *Antimicrob. Agents Chemother.*, 55:2860-71 (2011)), and those disclosed in U.S. Application Publication No. 2012/0114601.

[0084] The term “benzothiazinones” as used herein refers to a class of compounds based on the structure:



or the structure:



useful for treating mycobacterial infection. Examples of benzothiazinones suitable for the combinations of the present invention include BTZ 043, SKLB-TB37 and those disclosed in EP 2468746 and CN102276598,





[0085] Riminophenazine antibiotics suitable for the combinations of the present invention include clofazimine (B663) and B669. The term “diarylquinolone” as used herein refers to a class of compounds useful for treating mycobacterium and includes, but is not limited to, bedaquiline (TMC-207) and R207910. Bedaquiline has an IUPAC name of (1*R*,2*S*)-1-(6-Bromo-2-methoxy-3-quinolyl)-4-dimethylamino-2-(1-naphthyl)-1-phenyl-butan-2-ol and may be synthesized according to the methods disclosed in WO2004/011436 and WO2006/125769.





[0086] The term “rifapentine” as used herein refers to an antibiotic useful for treating bacterial infections. Rifapentine has an IUPAC name of (7*S*,9*E*,11*S*,12*R*,13*S*,14*R*,15*R*,16*R*,17*S*,18*S*,19*E*,21*Z*,26*E*)-26-{{[(4-cyclopentylpiperazin-1-yl)amino]methylidene}-2,15,17,29-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27-trioxo-8,30-dioxo-24-azatetracyclo[23.3.1.1^{4,7}.0^{5,28}]triaconta-1(28),2,4,9,19,21,25(29)-heptaen-13-yl acetate and it may be purchased commercially (e.g., Sigma-Aldrich; Cat. No. R0533).






[0087] The term “rifampin” or “rifampicin” as used herein refers to an antibiotic useful for treating bacterial infections. Rifampin has an IUPAC name of : (7*S*,9*E*,11*S*,12*R*,13*S*,14*R*,15*R*,16*R*,17*S*,18*S*,19*E*,21*Z*)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-{{(E)-[(4-methylpiperazin-1-yl)imino]methyl}-6,23-dioxo-8,30-dioxo-24-azatetracyclo[23.3.1.1^{4,7}.0^{5,28}]triaconta-1(28),2,4,9,19,21,25(29),26-octaen-13-yl acetate and it may be purchased commercially (e.g., Fisher BioReagents (Cat No. BP2679-1) or Sigma-Aldrich (Cat. No. R3501)).





The following table provides structure and sources for some of the antibiotic compounds suitable for the combinations of the present application.






Table 1






Compound (Name and/or structure)	Chemical Name and/or Synthesis/Isolation/Commercial Availability
Bedaquiline 	IUPAC name: (1<i>R</i>,2<i>S</i>)-1-(6-Bromo-2-methoxy-3-quinoly)-4-dimethylamino-2-(1-naphthyl)-1-phenylbutan-2-ol Synthesis: WO2004/011436 and process for chiral resolution in WO 2006/125769.
Rifapentine 	IUPAC Name: (7<i>S</i>,9<i>E</i>,11<i>S</i>,12<i>R</i>,13<i>S</i>,14<i>R</i>,15<i>R</i>,16<i>R</i>,17<i>S</i>,18<i>S</i>,19<i>E</i>,21<i>Z</i>,26<i>E</i>)-26-{{(4-cyclopentylpiperazin-1-yl)amino}methylidene}-2,15,17,29-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27-trioxo-8,30-dioxo-24-azatetracyclo[23.3.1.1^{4,7}.0^{5,28}]triaconta-1(28),2,4,9,19,21,25(29)-heptaen-13-yl acetate *Synthesis/Isolation/Commercial Availability (Sigma-Aldrich; Cat. No. R0533)
 Rifampin (Rifampicin or Rifadin):	IUPAC name: (7<i>S</i>,9<i>E</i>,11<i>S</i>,12<i>R</i>,13<i>S</i>,14<i>R</i>,15<i>R</i>,16<i>R</i>,17<i>S</i>,18<i>S</i>,19<i>E</i>,21<i>Z</i>)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-{{(E)-[(4-methylpiperazin-1-yl)imino]methyl}-6,23-dioxo-8,30-dioxo-24-azatetracyclo[23.3.1.1^{4,7}.0^{5,28}]triaconta-1(28),2,4,9,19,21,25(29),26-octaen-13-yl acetate. Synthesis/Isolation/Commercial Availability: can be purchased from Fisher BioReagents (Cat No. BP2679-1) or Sigma-Aldrich (Cat. No. R3501)
 Pyrazinamide	*IUPAC Name: pyrazine-2-carboxamide Synthesis/Isolation/Commercial Availability: can be purchased from several US sources (Sigma-Aldrich Cat. No. P1736)





Compound (Name and/or structure)	Chemical Name and/or Synthesis/Isolation/Commercial Availability
Isoniazid: (also abbreviated as INH; generic) 	*IUPAC Name: isonicotinohydrazide *Synthesis/Isolation/Commercial Availability: can be purchased from Sigma Aldrich (Cat. No. I3377)
Moxifloxacin 	*IUPAC name: 1-cyclopropyl-7-[(1<i>S</i>,6<i>S</i>)-2,8-diazabicyclo[4.3.0]non-8-yl]-6-fluoro-8-methoxy-4-oxo-quinoline-3-carboxylic acid *Synthesis/Isolation/Commercial Availability: can be purchased from Sigma Aldrich (Cat. No. 32477)
Gatifloxacin (Gatiflo, Tequin, Zymar, BMS, Kyorin) 	*IUPAC name: 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid *Synthesis/Isolation/Commercial Availability: can be purchased from Sigma Aldrich (Cat. No. G7298)
Linezolid 	*IUPAC Name: (<i>S</i>)-<i>N</i>-({3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide Synthesis/Isolation/Commercial Availability: can be purchased from Sigma Aldrich (Cat. No. PZ0014)





Compound (Name and/or structure)	Chemical Name and/or Synthesis/Isolation/Commercial Availability
Sutezolid (PNU-100480, Pfizer): 	Synthesis/Isolation/Commercial Availability: can be purchased from Axon MedChem BV, Postbus 770 Groningen, 9700 AT Netherlands (Cat. No. Axon 1762)
Posizolid (Astra Zeneca) 	IUPAC Name: (5<i>R</i>)-3-[4-[1-[(2<i>S</i>)-2,3-Dihydroxypropanoyl]-3,6-dihydro-2<i>H</i>-pyridin-4-yl]-3,5-difluorophenyl]-5-(1,2-oxazol-3-yloxymethyl)-1,3-oxazolidin-2-one Synthesis/Isolation/Commercial Availability: can be purchased from BOC Sciences, 45-16 Ramsey Road, Shirley, NY 11967 (Cat. No. 252260-02-9)
AZD-5847	*Synthesis/Isolation: Process for preparing the phosphate ester prodrug in WO140236.
PA 824 	*IUPAC name: (6<i>S</i>)-2-nitro-6- {[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5<i>H</i>-imidazo[2,1-<i>b</i>][1,3]oxazine *Synthesis/Isolation/Commercial Availability: can be purchased from BOC Sciences, 45-16 Ramsey Road, Shirley, NY 11967 (Cat. No. 187235-37-6)
Ethambutol 	IUPAC name: (2<i>S</i>,2'<i>S</i>)-2,2'-(Ethane-1,2-diylidimino)dibutan-1-ol *Synthesis/Isolation/Commercial Availability: can be purchased from Sigma Aldrich (Cat. No. E4630)
SQ-109: (Sequella) 	*Synthesis/Isolation/Commercial Availability: can be purchased from Aurora Fine Chemicals LLC, 7929 Silverton Ave., San Diego, CA 92126 (Cat. No. K06.990.223); also see US 6,951,961)




Compound (Name and/or structure)	Chemical Name and/or Synthesis/Isolation/Commercial Availability
SQ-609 (Sequella): 	*IUPAC Name: 1-{{[1-(Adamantan-1-ylmethyl)-4-piperidinyl]methyl}-4-piperidinol *Synthesis/Isolation/Commercial Availability: WO03096987; also Bioorganic and Med Chem Letters 21 (18), pp. 5353-5357 (2011) and Bioorganic and Med Chem Letters 20 (1), pp. 201-205 (2010).
	*Synthesis/Isolation/Commercial Availability: WO2009136965; also Bioorganic and Med Chem Letters 21 (18), pp. 5353-5357 (2011)
Delaminid (OPC-67683, Otsuka) 	Chemical Name: (2<i>R</i>)-2-methyl-6-nitro-2-[(4-{4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl}phenoxy)methyl]-2,3-dihydroimidazo[2,1-<i>b</i>]oxazole *Synthesis/Isolation/Commercial Availability: JP2005330266; WO2004033463; WO2004035547 (process app) also J. Med Chem. 49 (26), pp. 7854-7860 (2006)
Clofazimine (Lamprine) 	IUPAC name: <i>N</i>,5-<i>bis</i>(4-chlorophenyl)-3-(propan-2-ylimino)-3,5-dihydrophenazin-2-amine *Synthesis/Isolation/Commercial Availability: can be purchased from Sigma Aldrich (Cat. No. C8895)



Compound (Name and/or structure)	Chemical Name and/or Synthesis/Isolation/Commercial Availability
Dapsone (Aczone) 	*IUPAC name: 4-[(4-aminobenzene)sulfonyl]aniline *Synthesis/Isolation/Commercial Availability: can be purchased from Sigma Aldrich (Cat. No. A74807)
Rifafour	A combo tablet containing the 4 first line TB agents of Rifampicin (150mg) + Isoniazid (75mg) + Pyrazinamide (400mg) + Ethambutol (275mg).
BTZ 043 	*Synthesis/Isolation/Commercial Availability: can be purchased from BOC Sciences, 45-16 Ramsey Road, Shirley, NY 11967 (Cat. No. 1161233-85-7)
Capreomycin 	*Synthesis/Isolation/Commercial Availability: can be purchased from Sigma Aldrich (Cat. No. C4142)
Cycloserine 	Synthesis/Isolation/Commercial Availability: can be purchased from Sigma Aldrich (Cat. No. C7005 for DL-Cycloserine; C1159 for L-Cycloserine; C6680 for D-Cycloserine)
Ethionamide 	Synthesis/Isolation/Commercial Availability: can be purchased from Sigma Aldrich (Cat. No. E6005)

Compound (Name and/or structure)	Chemical Name and/or Synthesis/Isolation/Commercial Availability
DC-159a 	*Synthesis/Isolation/Commercial Availability: WO2007111023 (in Japanese; Daiichi Pharmaceutical Co.); also Bioorganic and Med Chem Letters 21 (18), pp. 5353-5357 (2011)
Prothionamide 	*Synthesis/Isolation/Commercial Availability: can be purchased from BOC Sciences, 45-16 Ramsey Road, Shirley, NY 11967 (Cat. No. 14222-60-7)
4-aminosalicylic acid 	*Synthesis/Isolation/Commercial Availability: can be purchased from Alfa Aesar, 26 Parkridge Rd., Ward Hill, MA 01835 (Cat. No. B23289)
Rifalazil 	*Synthesis/Isolation/Commercial Availability: can be purchased from BOC Sciences, 45-16 Ramsey Road, Shirley, NY 11967 (Cat. No. 129791-92-0)
CPZEN45 (Caprazamycin analogue) 	*Synthesis/Isolation/Commercial Availability: WO2010038874 and WO2008020560 (both in Japanese); also Bioorganic and Med Chem Letters 21 (18), pp. 5353-5357 (2011)

Compound (Name and/or structure)	Chemical Name and/or Synthesis/Isolation/Commercial Availability
ACH-710 (isothiazoloquinolone)  FIG. 1. Chemical structure of ACH-702.	*Synthesis/Isolation/Commercial Availability: WO2008021491 and WO2007014308 (both in Japanese); also Bioorganic and Med Chem Letters 21 (18), pp. 5353-5357 (2011)
Meropenem (beta lactam class and belongs to the carbapenem subgroup) 	*Synthesis/Isolation/Commercial Availability: can be purchased from Sigma Aldrich (Cat. No. M2574)
Clavulanate (Clavulanate Potassium) (Beta lactamase inhibitors) Clavulanic acid 	*Synthesis/Isolation/Commercial Availability: can be purchased from Sigma Aldrich (Cat. No. 33454)
Thioridiazine 	Synthesis/Isolation/Commercial Availability: can be purchased from Sigma Aldrich (Cat. No. T9025)

Compound (Name and/or structure)	Chemical Name and/or Synthesis/Isolation/Commercial Availability
Q201 (Imidazopyridine) in preclinical development by Qurient Therapeutics)	
Thiacetazone 	Approved drug
Levofloxacin 	*Commercial Availability: can be purchased from Sigma Aldrich (Cat. No. 28266)
SKLB-TB37 	*Synthesis/Isolation: CN102276598A
Azithromycin 	**Commercial Availability: can be purchased from Sigma Aldrich (Cat. No. PZ0007)

Compound (Name and/or structure)	Chemical Name and/or Synthesis/Isolation/Commercial Availability
Clarithromycin  The structure of Clarithromycin is a 14-membered macrolide ring substituted with a 6-methoxy-8-phenyl-8H-chromene-2-carbonyl group at the 11-position and a 2,6-dimethyl-3,4-dihydro-2H-pyran-5-ylmethoxy group at the 13-position. The pyran ring has a 2-ethyl-2-methylpropyl group at the 4-position.	*Commercial Availability: can be purchased from Sigma Aldrich (Cat. No. C9742)
Erythromycin  The structure of Erythromycin is a 14-membered macrolide ring substituted with a 3,4-dihydro-2H-pyran-5-ylmethoxy group at the 11-position and a 2,6-dimethyl-3,4-dihydro-2H-pyran-5-ylmethoxy group at the 13-position. The pyran ring has a 2-ethyl-2-methylpropyl group at the 4-position.	*Commercial Availability: can be purchased from Sigma Aldrich (Cat. No. E6376)
Dirithromycin  The structure of Dirithromycin is a 14-membered macrolide ring substituted with a 6-methoxy-8-phenyl-8H-chromene-2-carbonyl group at the 11-position and a 2,6-dimethyl-3,4-dihydro-2H-pyran-5-ylmethoxy group at the 13-position. The pyran ring has a 2-ethyl-2-methylpropyl group at the 4-position.	*Commercial Availability: can be purchased from Sigma Aldrich (Cat. No. D4065)

Compound (Name and/or structure)	Chemical Name and/or Synthesis/Isolation/Commercial Availability
Roxithromycin 	*Commercial Availability: can be purchased from Sigma Aldrich (Cat. No. R4393)
Telithromycin 	*Approved Drug

[0088] For the compound of formula (I), dosage levels of between about 0.01 and about 100 mg/kg body weight per day, preferably between 0.5 and about 75 mg/kg body weight per day and most preferably between about 1 and 50 mg/kg body weight per day of the active ingredient compound are useful in a monotherapy for the prevention and treatment of bacterial infections.

[0089] Typically, the pharmaceutical compositions of this invention will be administered from about 1 to 5 times per day or alternatively, as a continuous infusion. Alternatively, the compositions of the present invention may be administered in a pulsatile formulation. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical

preparation will contain from about 5% to about 95% active compound (w/w). Preferably, such preparations contain from about 20% to about 80% active compound.

[0090] When the compositions of this invention comprise a combination of a compound of formula (I) and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 10% to 80% of the dosage normally administered in a monotherapy regime.

[0091] Upon improvement of a patient's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence or disease symptoms.

[0092] As the skilled artisan will appreciate, lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, and the patient's disposition to the disease and the judgment of the treating physician.

[0093] According to another embodiment, the invention provides methods for treating or preventing a bacterial infection, or disease state, comprising the step of administering to a patient any compound, pharmaceutical composition, or combination described herein. The term "patient", as used herein, means an animal, preferably a mammal, and most preferably a human.

[0094] The U.S. Department of Health and Human Services Centers for Disease Control and Prevention have published recommendations for the treatment of tuberculosis. Centers for Disease Control and Prevention. *Treatment of Tuberculosis*, American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR 2003; 52(No. RR-11):1-80, incorporated by reference herein as if fully set forth. In these recommendations are disclosed various first-line and second-line drugs used to treat TB as well as recommended treatment regimens including combinations of known compounds, the recommended interval and dosages and range of total doses for both adults and children. In addition, treatment algorithms for TB and active, culture-negative pulmonary TB and inactive TB are provided as well as management of relapse, treatment failure and drug resistance. For the purposes of

this invention, a compound of formula (I) may be added to the specific treatment regimens set forth therein or substituted for one of the components listed in the treatment regimens, either as a first-line or second-line drug.

[0095] The recommended treatment regimens are, in large part, based on evidence from clinical trials and are rated on the basis of a system developed by the United States Public Health Service (USPHS) and the Infectious Diseases Society of America (IDSA). The rating system includes a letter (A, B, C, D, or E) that indicates the strength of the recommendation and a roman numeral (I, II, or III) that indicates the quality of evidence supporting the recommendation (Table 2).

[0096] There are four recommended regimens for treating patients with TB caused by drug-susceptible organisms as set forth in the 2003 guidance document. Each regimen has an initial phase of 2 months followed by a choice of several options for the continuation phase of either 4 or 7 months. The recommended regimens together with the number of doses specified by the regimen are described in Table 3. The initial phases are denoted by a number (1, 2, 3, or 4) and the continuation phases that relate to the initial phase are denoted by the number plus a letter designation (a, b, or c). Drug doses are shown in Tables 4, 5, and 6.

Table 2a- Infectious Diseases Society of America/United States Public Health Service rating system for the strength of treatment recommendations based on quality of evidence

Strength of the recommendation	
A.	Preferred; should generally be offered
B.	Alternative; acceptable to offer
C.	Offer when preferred or alternative regimens cannot be given
D.	Should generally not be offered
E.	Should never be offered
Quality of evidence supporting the recommendation	
I.	At least one properly randomized trial with clinical end points
II.	Clinical trials that either are not randomized or were conducted in other populations
III.	Expert opinion

Table 2b – Drug regimens for culture-positive pulmonary tuberculosis caused by drug-susceptible organisms

Regimen	Initial phase		Continuation phase		Range of total doses (minimal duration)		Rating* (evidence)†	
	Regimen	Drugs	Interval and doses‡ (minimal duration)	Regimen	Drugs	Interval and doses‡§ (minimal duration)	HIV–	HIV+
1	INH		Seven days per week for 56 doses (8 wk)¶	1a	INH/RIF	Seven days per week for 126 doses (18 wk) or 5 d/wk for 90 doses (18 wk)¶	A (I)	A (II)
	RIF			1b	INH/RIF	Twice weekly for 36 doses (18 wk)	A (I)	A (II)¶
	PZA			1c**	INH/RPT	Once weekly for 18 doses (18 wk)	B (I)	E (I)
2	INH		Seven days per week for 14 doses (2 wk), then twice weekly for 12 doses (6 wk) or 5 d/wk for 10 doses (2 wk); † then twice weekly for 12 doses (6 wk)	2a	INH/RIF	Twice weekly for 36 doses (18 wk)	A (II)	B (II)¶
	RIF			2b**	INH/RPT	Once weekly for 18 doses (18 wk)	B (I)	E (I)
	PZA							
3	INH		Three times weekly for 24 doses (8 wk)	3a	INH/RIF	Three times weekly for 54 doses (18 wk)	B (I)	B (II)
	RIF							
	PZA							
4	INH		Seven days per week for 56 doses (8 wk) or 5 d/wk for 40 doses (8 wk)†	4a	INH/RIF	Seven days per week for 217 doses (31 wk) or 5 d/wk for 155 doses (31 wk)¶	C (I)	C (II)
	RIF			4b	INH/RIF	Twice weekly for 62 doses (31 wk)	C (I)	C (II)
	EMB							

Definition of abbreviations: EMB = Ethambutol; INH = isoniazid; PZA = pyrazinamide; RIF = rifampin; RPT = rifapentine.

* Definitions of evidence ratings: A = preferred; B = acceptable alternative; C = offer when A and B cannot be given; E = should never be given.

† Definition of evidence ratings: I = randomized clinical trial; II = data from clinical trials that were not randomized or were conducted in other populations; III = expert opinion.

‡ When DOT is used, drugs may be given 5 days/week and the necessary number of doses adjusted accordingly. Although there are no studies that compare five with seven daily doses, extensive experience indicates this would be an effective practice.

§ Patients with cavitation on initial chest radiograph and positive cultures at completion of 2 months of therapy should receive a 7-month (31 week; either 217 doses [daily] or 62 doses [twice weekly]) continuation phase.

¶ Five-day a week administration is always given by DOT. Rating for 5 day/week regimens is AIII.

** Not recommended for HIV-infected patients with CD4+ cell counts <100 cells/μL.

Options 1c and 2b should be used only in HIV-negative patients who have negative sputum smears at the time of completion of 2 months of therapy and who do not have cavitation on initial chest radiograph (see text). For patients started on this regimen and found to have a positive culture from the 2-month specimen, treatment should be extended an extra 3 months.

Table 3 - Doses of antituberculosis drugs for adults and children

Drug	Preparation	Adults/children	Doses			
			Daily	1x/wk	2x/wk	3x/wk
First-line drugs						
Isoniazid	Tablets (50 mg, 100 mg, 300 mg); elixir (50 mg/5 mL); aqueous solution (100 mg/mL) for intravenous or intramuscular injection	Adults (max.) Children (max.)	5 mg/kg (300 mg) 10–15 mg/kg (300 mg)	15 mg/kg (300 mg)	15 mg/kg (300 mg)	
Rifampin	Capsule (150 mg, 300 mg); powder may be suspended in water and administered; intravenous injection	Adults [§] (max.) Children (max.)	10 mg/kg (600 mg) 10–20 mg/kg (600 mg)	—	10 mg/kg (600 mg)	
Rifabutin	Capsule (150 mg)	Adults [§] (max.) Children	5 mg/kg (300 mg) Appropriate dosing for children is unknown	—	5 mg/kg (300 mg) Appropriate dosing for children is unknown	
Rifapentine	Tablet (150 mg, film coated)	Adults Children	— The drug is not approved for use in children	10 mg/kg (continuation phase) The drug is not approved for use in children	— The drug is not approved for use in children	
Pyrazinamide	Tablet (500 mg, scored)	Adults Children (max.)	See Table 4 15–30 mg/kg (2.0 g)	—	See Table 4	
Ethambutol	Tablet (100 mg, 400 mg)	Adults Children [§] (max.)	See Table 5 15–20 mg/kg daily (1.0 g)	—	See Table 5	
Second-line drugs						
Cycloserine	Capsule (250 mg)	Adults (max.) Children (max.)	10–15 mg/kg/d (1.0 g) in two doses, usually 500–750 mg/d (1.0 g/d) 10–15 mg/kg/d (1.0 g/d)	There are no data to support intermittent administration	There are no data to support intermittent administration	
Etambutol	Tablet (250 mg)	Adults [§] (max.) Children (max.)	15–20 mg/kg/d (1.0 g/d), usually 500–750 mg/d in divided doses or two divided doses [§] 15–20 mg/kg/d (1.0 g/d)	There are no data to support intermittent administration	There are no data to support intermittent administration	
Streptomycin	Aqueous solution (1-g vials) for intravenous or intramuscular administration	Adults (max.) Children (max.)	20–40 mg/kg/d (1 g)	—	20 mg/kg	
Amikacin/ kanamycin	Aqueous solution (500-mg and 750-mg vials) for intravenous or intramuscular administration	Adults (max.) Children (max.)	15–20 mg/kg/d (1 g) Intravenous or intramuscular as a single daily dose	—	15–30 mg/kg	
Capreomycin	Aqueous solution (1-g vials) for intravenous or intramuscular administration	Adults (max.) Children (max.)	15–30 mg/kg/d (1 g) as a single daily dose	—	15–30 mg/kg	
p-Aminosalicylic acid (PAS)	Granules (4-g packets) can be mixed with food; tablets (500 mg) are available in some countries, but not in the United States; a solution for intravenous administration is available in Europe	Adults Children	8–12 g/d in two or three doses 200–300 mg/kg/d in two to four divided doses (1.0 g)	There are no data to support intermittent administration	There are no data to support intermittent administration	
Levofloxacin	Tablets (250 mg, 500 mg, 750 mg); aqueous solution (500-mg vial) for intravenous injection	Adults Children	500–1,000 mg daily ††	There are no data to support intermittent administration	There are no data to support intermittent administration	

Moxifloxacin	Tablets (400 mg); aqueous solution (400 mg/250 ml) for intravenous injection	Adults	400 mg daily	There are no data to support intermittent administration ††	There are no data to support intermittent administration ††	There are no data to support intermittent administration ††
		Children	††			
Gatifloxacin	Tablets (400 mg); aqueous solution (200 mg/20 ml; 400 mg/40 ml) for intravenous injection	Adults	400 mg daily	There are no data to support intermittent administration §§	There are no data to support intermittent administration §§	There are no data to support intermittent administration §§
		Children	§§			

* Dose per weight is based on ideal body weight. Children weighing more than 40 kg should be dosed as adults.

† For purposes of this document adult dosing begins at age 15 years.

‡ Dose may need to be adjusted when there is concomitant use of protease inhibitors or nonnucleoside reverse transcriptase inhibitors.

§ The drug can likely be used safely in older children but should be used with caution in children less than 5 years of age, in whom visual acuity cannot be monitored. In younger children, EMB at the dose of 15 mg/kg per day can be used if there is suspected or proven resistance to INH or RIF.

¶ It should be noted that, although this is the dose recommended generally, most clinicians with experience using cycloserine indicate that it is unusual for patients to be able to tolerate this amount. Serum concentration measurements are often useful in determining the optimal dose for a given patient.

The single daily dose can be given at bedtime or with the main meal.

** Dose: 15 mg/kg per day (1 g), and 10 mg/kg in persons more than 59 years of age (750 mg). Usual dose: 750–1,000 mg administered intramuscularly or intravenously, given as a single dose 5–7 days/week and reduced to two or three times per week after the first 2–4 months or after culture conversion, depending on the efficacy of the other drugs in the regimen.

†† The long-term (more than several weeks) use of levofloxacin in children and adolescents has not been approved because of concerns about effects on bone and cartilage growth. However, most experts agree that the drug should be considered for children with tuberculosis caused by organisms resistant to both INH and RIF. The optimal dose is not known.

‡‡ The long-term (more than several weeks) use of moxifloxacin in children and adolescents has not been approved because of concerns about effects on bone and cartilage growth. The optimal dose is not known.

§§ The long-term (more than several weeks) use of gatifloxacin in children and adolescents has not been approved because of concerns about effects on bone and cartilage growth. The optimal dose is not known.

Table 4 – Suggested pyrazinamide doses, using whole tablets, for adults weighing 40 – 90 kg

	Weight (kg)*		
	40–55	56–75	76–90
Daily, mg (mg/kg)	1,000 (18.2–25.0)	1,500 (20.0–26.8)	2,000† (22.2–26.3)
Thrice weekly, mg (mg/kg)	1,500 (27.3–37.5)	2,500 (33.3–44.6)	3,000† (33.3–39.5)
Twice weekly, mg (mg/kg)	2,000 (36.4–50.0)	3,000 (40.0–53.6)	4,000† (44.4–52.6)

* Based on estimated lean body weight.

† Maximum dose regardless of weight.

Table 5 – Suggested ethambutol doses, using whole tablets, for adults weighing 40 – 90 kg

	Weight (kg)*		
	40–55	56–75	76–90
Daily, mg (mg/kg)	800 (14.5–20.0)	1,200 (16.0–21.4)	1,600† (17.8–21.1)
Thrice weekly, mg (mg/kg)	1,200 (21.8–30.0)	2,000 (26.7–35.7)	2,400† (26.7–31.6)
Twice weekly, mg (mg/kg)	2,000 (36.4–50.0)	2,800 (37.3–50.0)	4,000† (44.4–52.6)

* Based on estimated lean body weight.

† Maximum dose regardless of weight.

[0097] The term “prodrug” refers to compounds which are drug precursors which, following administration and absorption, release the drug in vivo via some metabolic process. In general, a prodrug possesses less biological activity than its parent drug. A prodrug may also improve the physical properties of the parent drug and/or it may also improve overall drug efficacy, for example through the reduction of toxicity and unwanted effects of a drug by controlling its absorption, blood levels, metabolic distribution and cellular uptake.

[0098] The term “parent compound” or “parent drug” refers to the biologically active entity that is released via enzymatic action of a metabolic or a catabolic process, or via a chemical process following administration of the prodrug. The parent compound may also be the starting material for the preparation of its corresponding prodrug.

[0099] The monovalent cations defined by M^+ include ammonium, alkali metal ions such as sodium, lithium and potassium ions, dicyclohexylamine ion, and N-methyl-D-glucamine ion. The divalent cations defined by D^{2+} include, alkaline earth metal ions such as aluminum, calcium and magnesium ions. Also included are amino acid cations such as ions of arginine, lysine, ornithine, and so forth. If M^+ is a monovalent cation, it is recognized that if the definition $2M^+$ is present, each of M^+ may be the same or different. In addition, it is similarly recognized that if the definition $2M^+$ is present, a divalent cation D^{2+} may instead be present. Also, the basic nitrogen-containing groups may be quaternized with such agents as: lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl; diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; aralkyl halides like benzyl bromide and others.

[00100] Various embodiments of the invention, include compounds or salts of formula (IB) as set forth below:

[00101] (1) compounds wherein X is

[00102] (a) $-\text{PO}(\text{OH})\text{O}^-\text{M}^+$;

[00103] (b) $-\text{PO}(\text{O}^-)_2 \cdot 2\text{M}^+$; or

[00104] (c) $-\text{PO}(\text{O}^-)_2 \cdot \text{D}^{2+}$;

[00105] (2) compounds wherein M^+ is

[00106] (a) Li^+ , Na^+ , K^+ , N-methyl-D-glucamine, or $\text{N}(\text{R}^9)_4^+$; or

[00107] (b) Na^+ ;

[00108] (c) each R^9 is independently hydrogen or a $\text{C}_1\text{-C}_4$ alkyl group;

[00109] (3) compounds wherein D^{2+} is

[00110] (a) Mg^{2+} , Ca^{2+} , and Ba^{2+} ; or

[00111] (b) Ca^{2+} ;

[00112] (4) the compound (*R*)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl phosphate; and

[00113] (5) the compound disodium (*R*)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl phosphate.

[00114] It is understood that various alternative embodiments of the compounds or salts of formula (IB) can be selected by requiring one or more of the alternate embodiments listed in (1) through (3) above. For example, further embodiments of the invention can be obtained by combining (1)(a) and (2)(a); (1)(a) and (2)(b); (1)(c) and (3)(a); (1)(c) and (3)(b); (1)(b) and (2)(a); (1)(b) and (2)(b); and the like.

[00115] The prodrugs of the present invention are characterized by unexpectedly high aqueous solubility. This solubility facilitates administration of higher doses of the prodrug, resulting in a greater drug load per unit dosage.

[00116] A "pharmaceutically acceptable derivative or prodrug" means any pharmaceutically acceptable salt, ester, salt of an ester or other derivative of a compound of this invention which, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof. Particularly favored derivatives or prodrugs are those that increase the bioavailability of the compounds of this invention when such compounds are administered to a mammal (e.g., by allowing an orally administered compound to be more readily absorbed into the blood) or which enhance delivery of the parent compound to a biological compartment (e.g., the brain or lymphatic system) relative to the parent species.

[00117] Pharmaceutically acceptable prodrugs of the compounds of this invention include, without limitation, esters, amino acid esters, phosphate esters, metal salts and sulfonate esters.

[00118] Pharmaceutically acceptable salts of the compounds of this invention include those derived from pharmaceutically acceptable inorganic and organic acids and bases. Examples of suitable acid salts include acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptanoate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, palmoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, salicylate, succinate, sulfate, tartrate, thiocyanate, tosylate and undecanoate. Other acids, such as oxalic, while not in themselves pharmaceutically acceptable, may be employed in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable acid addition salts.

[00119] Salts derived from appropriate bases include alkali metal (e.g., sodium and potassium), alkaline earth metal (e.g., magnesium), ammonium and $N^+(C_{1-4} \text{ alkyl})_4$ salts. This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersible products may be obtained by such quaternization.

[00120] Pharmaceutical compositions of this invention comprise a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. Such compositions may optionally comprise an additional therapeutic agent. Such agents include, but are not limited to, an antibiotic, an anti-inflammatory agent, a matrix metalloprotease inhibitor, a lipoxigenase inhibitor, a cytokine antagonist, an immunosuppressant, an anti-cancer agent, an anti-viral agent, a cytokine, a growth factor, an immunomodulator, a prostaglandin or an anti-vascular hyperproliferation compound.

[00121] The term "pharmaceutically acceptable carrier" refers to a non-toxic carrier that may be administered to a patient, together with a compound of this invention, and which does not destroy the pharmacological activity thereof.

[00122] Pharmaceutically acceptable carriers that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances

such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat and self-emulsifying drug delivery systems (SEDDS) such as alpha-tocopherol, polyethyleneglycol 1000 succinate, or other similar polymeric delivery matrices.

[00123] The term "pharmaceutically effective amount" or "therapeutically effective amount" refers to an amount effective in treating or ameliorating a bacterial infection in a patient. The term "prophylactically effective amount" refers to an amount effective in preventing or substantially lessening a bacterial infection in a patient.

[00124] The following definitions describe terms and abbreviations used herein:

Ac	acetyl
Bu	butyl
Et	ethyl
Ph	phenyl
Me	methyl
THF	tetrahydrofuran
DCM	dichloromethane
CH ₂ Cl ₂	dichloromethane
EtOAc	ethyl acetate
CH ₃ CN	acetonitrile
EtOH	ethanol
Et ₂ O	diethyl ether
MeOH	methanol
MTBE	methyl <i>tert</i> -butyl ether
DMF	<i>N,N</i> -dimethylformamide
DMA	<i>N,N</i> -dimethylacetamide
DMSO	dimethyl sulfoxide
HOAc	acetic acid
TEA	triethylamine
TFA	trifluoroacetic acid
TFAA	trifluoroacetic anhydride
Et ₃ N	triethylamine
DIPEA	diisopropylethylamine
DIEA	diisopropylethylamine
K ₂ CO ₃	potassium carbonate
Na ₂ CO ₃	sodium carbonate
Na ₂ S ₂ O ₃	sodium thiosulfate
Cs ₂ CO ₃	cesium carbonate
NaHCO ₃	sodium bicarbonate
NaOH	sodium hydroxide
Na ₂ SO ₄	sodium sulfate


MgSO ₄ ,	magnesium sulfate
K ₃ PO ₄	potassium phosphate
NH ₄ Cl	ammonium chloride
LC/MS	liquid chromatography/mass spectra
GCMS	gas chromatography mass spectra
HPLC	high performance liquid chromatography
GC	gas chromatography
LC	liquid chromatography
IC	ion chromatography
IM	intramuscular
CFU/cfu	colony forming units
MIC	minimum inhibitory concentration
Hr or h	hours
atm	atmospheres
rt or RT	room temperature
TLC	thin layer chromatography
HCl	hydrochloric acid
H ₂ O	water
EtNCO	ethyl isocyanate
Pd/C	palladium on carbon
NaOAc	sodium acetate
H ₂ SO ₄	sulfuric acid
N ₂	nitrogen gas
H ₂	hydrogen gas
<i>n</i> -BuLi	<i>n</i> -butyl lithium
DI	de-ionized
Pd(OAc) ₂	palladium(II)acetate
PPh ₃	triphenylphosphine
<i>i</i> -PrOH	isopropyl alcohol
NBS	<i>N</i> -bromosuccinimide
Pd[(Ph ₃)P] ₄	tetrakis(triphenylphosphine)palladium(0)
PTFE	polytetrafluoroethylene
rpm	revolutions per minute
SM	starting material
Equiv.	equivalents
¹ H-NMR	proton nuclear magnetic resonance
HPMCAS	hydroxypropylmethylcellulose acetate
PVP	polyvinylpyrrolidone
EDTA	ethylenediaminetetraacetic acid
K ₂ EDTA	dibasic potassium ethylenediaminetetraacetate
mCPBA	meta-chloroperoxybenzoic acid
aq	aqueous
Boc ₂ O	di- <i>tert</i> -butyl dicarbonate
DMAP	<i>N,N</i> -dimethylaminopyridine
mL	milliliters
L	liters
mol	moles
g	grams
LCMS	liquid chromatography-mass spectrometry
MHz	megahertz

CDCl ₃	deuteriochloroform
NEt ₃	triethylamine
mmol	millimoles
psi	pounds per square inch
<i>i</i> PrOH	isopropylalcohol
ppm	parts per million
NH ₄ NO ₃	ammonium nitrate
Hz	hertz
Pd(dppf)Cl ₂	[1,1'-Bis(diphenylphosphino)ferrocene]dichloropalladium(II)
L	liters
MeOD	deutero-methanol
CD ₃ OD	deutero-methanol
ee	enantiomeric excess
min	minutes
Bn	benzyl
RBF	round-bottom flask
MeCN	acetonitrile
PES	polyethersulfone
mm	millimeters
μm	micrometers
M	molar
N	normal
Boc	<i>tert</i> -butoxycarbonyl
ESMS	electrospray mass spectrometry
CV	column volume
D ₂ O	deuterium oxide
NH ₃	ammonia
OBD	optimum bed density
mg	milligrams
CLSI	Clinical and Laboratory Standards Institute
ATCC	American Type Culture Collection
MHII	Mueller Hinton II
μL	microliters
WT	wild type
CGSC	Coli Genetic Stock Center
MS	mass spectrometry
IS	internal standard
APCI	atmospheric pressure chemical ionization
MRM	multiple reaction monitoring
<i>m/z</i>	mass-to-charge ratio
LLOQ	lower limit of quantitation
ng	nanograms
UV	ultraviolet
SD	standard deviation
% CV	coefficient of variation
PO	perioral
MC	microcrystalline cellulose
EDTA	ethylenediaminetetraacetic acid or ethylenediaminetetraacetate
PK	pharmacokinetic
PBS	phosphate buffer saline

IV	intravenous
D5W	5% dextrose in water solution
HPMC-AS	hydroxypropyl methylcellulose acetyl succinate
PVP	polyvinylpyrrolidone
CAPT	captisol
ATP	adenosine triphosphate
ADP	adenosine diphosphate
NADH	nicotinamide adenine dinucleotide (reduced form)
NAD ⁺	nicotinamide adenine dinucleotide (oxidized form)
TRIS	tris(hydroxymethyl)aminomethane
mM	millimolar
MgCl ₂	magnesium chloride
KCl	potassium chloride
μM	micromolar
DTT	dithiothreitol
nM	nanomolar
K _i	dissociation constant
IC ₅₀	half maximal inhibitory concentration
μg	micrograms
BSA	bovine serum albumin
LDH	lactate dehydrogenase
PVDF	polyvinylidene fluoride
PBS	phosphate buffered saline
BSL3	Biosafety Level 3
AcN	acetonitrile
V _{MAX}	the maximum initial velocity or rate of a reaction

[00125] Example 1

[00126] Preparation of 2-(2-nitrophenyl)-2,5-dihydrofuran and 2-(2-nitrophenyl)-2,3-dihydrofuran (**3a** & **3b**).




[00127] Mixed 1-bromo-2-nitro-benzene (**1**) (600 g, 99%, 2.941 mol, Alfa Aesar A11686), 1,3-bis(diphenylphosphino)propane (62.50 g, 97%, 147.0 mmol, Alfa Aesar A12931), 1,4-dioxane (2.970 L, Sigma-Aldrich 360481), potassium carbonate (812.9 g, 5.882 mol, JT-Baker 301201), and 2,3-dihydrofuran (**2**) (1.041 kg, 99%, 1.124 L, 14.70 mol, Aldrich 200018). A stream of nitrogen was bubbled through the stirring mixture for 4 hrs, followed by addition of palladium (II) acetate (16.51 g, 73.52 mmol, Strem 461780) and continuation of deoxygenation for another 10 minutes. The reaction mixture was stirred at reflux under nitrogen overnight (NMR of a worked-up aliquot showed complete consumption of

aryl bromide). It was allowed to cool, diluted with hexane (1 L), filtered through a short plug of Florisil® (500 g, -200 mesh), and eluted with EtOAc. The filtrate was concentrated under reduced pressure (2-(2-nitrophenyl)-2,3-dihydrofuran is volatile under high vacuum and may be somewhat unstable at room temperature) giving a mixture of (**3a**) and (**3b**) as a dark brown oil (654.0 g). The crude material was stored in the refrigerator and carried forward without further purification.

[00128] Example 2


[00129] Preparation of 2-tetrahydrofuran-2-yl-aniline (**4**).



[00130] Placed 5% palladium on carbon (16.3 g, 50% wet, 3.83 mmol, Aldrich 330116) in a Parr bottle under nitrogen, followed by MeOH (100 mL, JT-Baker 909333). Added the crude mixture of 2-(2-nitrophenyl)-2,5-dihydrofuran and 2-(2-nitrophenyl)-2,3-dihydrofuran (**3a&3b**) (163 g) dissolved in MeOH (389 mL), followed by NEt₃ (237.6 mL, 1.705 mol, Sigma-Aldrich 471283). Placed the vessel on a Parr shaker and saturated with H₂. Added 30 psi H₂ and shook until consumption complete (LCMS and NMR showed complete reaction). The reaction mixture was purged with nitrogen, filtered through Celite™ and rinsed with EtOAc. The filtrate was concentrated on a rotary evaporator giving a brown oil. Repeated the reaction three more times on the same scale and the batches were combined for purification. The crude product was vacuum distilled (ca. 15 torr) collecting the distillate at 108 - 129°C to give (**4**) as a clear faint yellow oil (427.9 g, average yield was 84%; 98% GCMS purity). LCMS (C18 column eluting with 10-90% CH₃CN / water gradient over 5 minutes with formic acid modifier) M+1: 163.95 (1.46 min). ¹H NMR (300 MHz, CDCl₃): δ 7.15 – 7.04 (m, 2H), 6.77 – 6.62 (m, 2H), 4.85 – 4.77 (m, 1H), 4.18 (s, 2H), 4.12 – 4.02 (m, 1H), 3.94 – 3.85 (m, 1H), 2.25 – 1.95 (m, 4H) ppm.

[00131] Example 2a

[00132] Preparation of (R)-2-(tetrahydrofuran-2-yl)aniline (**4a**).



[00133] Dissolved 33g of compound (**4**) into MeOH (265 ml) which resulted in a concentration of approximately 125mg/ml. The mixture was filtered through a 0.2 micron membrane filter then chromatographed on a ChiralPak® IC column (30mm X 150mm, column temp 35°C, Chiral Technologies) at 100 bar using a Berger multigram supercritical fluid chromatographic system. Mobile phase was (90:10) CO₂:CH₃OH eluting at 350ml/min with UV monitoring at 220 nanometers. Obtained 15.64g of desired product (**4a**) as a green oil. Analytical SFC ([90:10] CO₂:CH₃OH, at 5ml/min on a ChiralPak IC column (4.6 X 100mm) held at 35°C and run at 100bar pressure with UV monitoring at 220nm) showed 95.5% ee with 95% overall purity.

[00134] Example 3

[00135] Preparation of 4-bromo-2-(tetrahydrofuran-2-yl)-aniline (**5**).




[00136] To a stirring solution of 2-(tetrahydrofuran-2-yl)-aniline (**4**) (53.45 g, 327.5 mmol) in methyl tert-butyl ether (MTBE, 641.4 mL) and acetonitrile (213.8 mL) cooled to 2°C was added N-bromosuccinimide (58.88 g, 99%, 327.5 mmol, Aldrich B81255) in 4 portions maintaining internal temperature below about 8°C. The reaction mixture was stirred while cooling with an ice-water bath for 30 minutes (NMR of a worked-up aliquot showed complete consumption of starting material). Added aqueous 1 N Na₂S₂O₃ (330 mL), removed the cold bath and stirred for 20 minutes. The mixture was diluted with EtOAc and the layers were separated. The organic phase was washed with saturated aqueous NaHCO₃ (2x), water, brine, dried over MgSO₄, filtered through a short plug of silica, eluted with EtOAc, and concentrated under reduced pressure to give (**5**) as a very dark amber oil (82.25

g, 77-94% HPLC purity). Carried forward without further purification. LCMS (C18 column eluting with 10-90% CH₃CN / water gradient over 5 minutes with formic acid modifier) M+1: 242.10 (2.89 min). ¹H NMR (300 MHz, CDCl₃) δ 7.22 (d, J = 2.3 Hz, 1H), 7.16 (dd, J = 8.4, 2.3 Hz, 1H), 6.54 (d, J = 8.4 Hz, 1H), 4.79 – 4.73 (m, 1H), 4.15 (s, 2H), 4.10 – 4.01 (m, 1H), 3.93 – 3.85 (m, 1H), 2.26 – 2.13 (m, 1H), 2.12 – 1.97 (m, 3H) ppm.

[00137] Example 4


[00138] Preparation of N-(4-bromo-2-nitro-6-tetrahydrofuran-2-yl-phenyl)-2,2,2-trifluoroacetamide (**6**).



[00139] To trifluoroacetic anhydride (455.3 mL, 3.275 mol, Sigma-Aldrich 106232) stirring at 2°C was slowly added 4-bromo-2-tetrahydrofuran-2-yl-aniline (**5**) (79.29 g, 327.5 mmol) as a thick oil via addition funnel over 15 minutes (reaction temperature rose to 14°C). The remaining oil was rinsed into the reaction mixture with anhydrous 2-methyltetrahydrofuran (39.6 mL, Sigma-Aldrich 414247). The cold bath was removed and ammonium nitrate (34.08 g, 425.8 mmol, Aldrich 467758) was added. The reaction temperature rose to 40°C over about 30 minutes at which time a cold water bath was used to control the exotherm and bring the reaction to room temperature. The cold bath was then removed and stirring continued for another 40 minutes (HPLC showed very little remaining un-nitrated material). The reaction mixture was slowly poured into a stirring mixture of crushed ice (800 g). The solid precipitate was collected by filtration, washed with water, saturated aqueous NaHCO₃ (to pH 8), water again, and hexane. The wet solid was dried first in a convection oven at 50°C for several hours and then under reduced pressure in an oven at 40°C overnight giving (**6**) as a light brown solid (77.86 g, 62% yield; 98% HPLC purity). LCMS (C18 column eluting with 10-90% CH₃CN / water gradient over 5 minutes with formic acid modifier) M+1: 383.19 (3.27 min). ¹H NMR (300 MHz, CDCl₃) δ 9.81 (s, 1H), 8.08 (d, J = 2.2 Hz, 1H), 7.73 (d, J = 2.2 Hz, 1H), 4.88 (dd, J = 9.0, 6.5 Hz, 1H), 4.17 – 4.08 (m, 1H), 4.03 – 3.95 (m, 1H), 2.45 – 2.34 (m, 1H), 2.17 – 2.06 (m, 2H), 1.96 – 1.83 (m, 1H) ppm.

[00140] Example 5


[00141] Preparation of 4-bromo-2-nitro-6-tetrahydrofuran-2-yl-aniline (**6a**).



[00142] Dissolved N-(4-bromo-2-nitro-6-tetrahydrofuran-2-yl-phenyl)-2,2,2-trifluoroacetamide (**6**) (54.00 g, 140.9 mmol) in 1,4-dioxane (162 mL) and added aqueous 6 M NaOH (70.45 mL, 422.7 mmol, JT-Baker 567202). The reaction mixture was stirred at reflux for 2 days (HPLC showed complete conversion), allowed to cool, diluted with MTBE (800 mL), washed with water (2 x 200 mL), saturated aqueous NH_4Cl , water and brine. The mixture was dried over MgSO_4 , filtered, and concentrated under reduced pressure to give (**6a**) as a dark amber oil (40.96 g, 93% yield; overall 92% HPLC plus NMR purity). LCMS (C18 column eluting with 10-90% MeOH / water gradient from 3-5 minutes with formic acid modifier) M+1: 287.28 (3.44 min). ^1H NMR (300 MHz, CDCl_3) δ 8.24 (d, $J = 2.4$ Hz, 1H), 7.41 (d, $J = 2.3$ Hz, 1H), 6.91 (s, 2H), 4.80 (t, $J = 7.2$ Hz, 1H), 4.14 – 4.05 (m, 1H), 3.98 – 3.90 (m, 1H), 2.36 – 2.19 (m, 1H), 2.15 – 2.01 (m, 3H) ppm.

[00143] Example 6

[00144] Preparation of 2-[5-(4-amino-3-nitro-5-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol (**8**).




[00145] Mixed 4-bromo-2-nitro-6-tetrahydrofuran-2-yl-aniline (**6a**) (40.40 g, 92%, 129.5 mmol), 1,4-dioxane (260 mL, Sigma-Aldrich 360481), 2-[5-(4,4,5,5-tetramethyl-1,3,2-

dioxaborolan-2-yl]pyrimidin-2-yl]propan-2-ol (7) (41.05 g, 155.4 mmol), and aqueous 2.7 M Na_2CO_3 (143.9 mL, 388.5 mmol). A stream of nitrogen was bubbled through the stirring mixture for 1 hr, followed by addition of tetrakis(triphenylphosphine)palladium (0) (7.48 g, 6.47 mmol, Strem 462150). The reaction mixture was stirred at reflux for 2 hrs (HPLC showed complete reaction), allowed to cool, diluted with EtOAc, washed with water, saturated aqueous NH_4Cl , brine, dried over MgSO_4 , and filtered through a short plug of Florisil® eluting with EtOAc. The filtrate was concentrated under reduced pressure giving a dark brown oil. Dissolved in CH_2Cl_2 and eluted through a short plug of silica gel with CH_2Cl_2 and then EtOAc. The desired fraction was concentrated on a rotary evaporator until a precipitate formed giving a thick brown slurry, which was triturated with MTBE. The solid was collected by filtration, washed with MTBE, and dried under high vacuum giving (8) as a yellow solid (35.14 g, 99+% HPLC purity). LCMS (C18 column eluting with 10-90% CH_3CN / water gradient over 5 minutes with formic acid modifier) M+1: 345.00 (2.69 min). ^1H NMR (300 MHz, CDCl_3) δ 8.88 (s, 2H), 8.36 (d, J = 2.2 Hz, 1H), 7.56 (d, J = 2.1 Hz, 1H), 7.09 (s, 2H), 4.92 (t, J = 7.2 Hz, 1H), 4.62 (s, 1H), 4.20 – 4.11 (m, 1H), 4.03 – 3.94 (m, 1H), 2.39 – 2.26 (m, 1H), 2.23 – 2.08 (m, 3H), 1.64 (s, 6H) ppm. The filtrate was further concentrated and purified by ISCO silica gel chromatography eluting with 0 to 80% EtOAc / hexane giving a second crop of product (8) as an amber solid (4.46 g, 88% overall yield; 88 % HPLC purity).

[00146] Example 7

[00147] Alternate preparation of 2-[5-(4-amino-3-nitro-5-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol (8).




[00148] Mixed N-(4-bromo-2-nitro-6-tetrahydrofuran-2-yl-phenyl)-2,2,2-trifluoroacetamide (6) (19.00 g, 49.59 mmol), 2-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl]propan-2-ol (7) (14.41 g, 54.55 mmol), aqueous 2.7 M sodium carbonate

(73.48 mL, 198.4 mmol), and 1,4-dioxane (190 mL, Sigma-Aldrich 360481). A stream of nitrogen was bubbled through the stirring mixture for 40 minutes, followed by addition of 1,1'-bis(diphenylphosphino)ferrocene dichloropalladium dichloromethane adduct (2.025 g, 2.480 mmol, Strem 460450). The reaction mixture was stirred at reflux under N₂ for 7 hrs, added another 50 mL of saturated aqueous sodium carbonate, and refluxed for another 16 hrs. The mixture was allowed to cool, then diluted with EtOAc (500 mL) and water (200 mL). The layers were separated and the aqueous phase extracted with EtOAc (200 mL). The combined organic phase was washed with water (500 mL), brine (500 mL), dried over Na₂SO₄, filtered through a Florisil® plug, and concentrated on a rotary evaporator to give crude (**8**) as an orange oil. Crude product was purified by ISCO silica gel chromatography eluting with 20-90% EtOAc / hexane to give (**8**) as an orange solid (15.00 g, 87% yield; 81-88% purity). LCMS (C18 column eluting with 10-90% CH₃CN / water gradient over 5 minutes with formic acid modifier) M+1: 345.35 (2.68 min). ¹H NMR (300 MHz, CDCl₃) δ 8.88 (s, 2H), 8.36 (d, J = 2.2 Hz, 1H), 7.56 (d, J = 2.1 Hz, 1H), 7.09 (s, 2H), 4.92 (t, J = 7.2 Hz, 1H), 4.62 (s, 1H), 4.20 – 4.11 (m, 1H), 4.03 – 3.94 (m, 1H), 2.39 – 2.26 (m, 1H), 2.23 – 2.08 (m, 3H), 1.64 (s, 6H) ppm.

[00149] Example 8

[00150] Preparation of 2-[5-(3,4-diamino-5-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol (**9**).




[00151] To a suspension of 2-[5-(4-amino-3-nitro-5-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol (**8**) (30.10 g, 87.41 mmol) and THF (90 mL) in a Parr bottle under nitrogen was added a slurry of 5% palladium on carbon (3.01 g, 50% wet, 0.707 mmol, Aldrich 330116) in MeOH (90 mL, JT-Baker 909333), followed by NEt₃ (24.37 mL, 174.8 mmol, Sigma-Aldrich 471283). Placed the vessel on a Parr shaker and saturated with H₂. Added 45 psi H₂ and shook until consumption was complete (HPLC showed complete conversion). The reaction mixture was purged with nitrogen, filtered through Celite™ and

rinsed with EtOAc. The filtrate was re-filtered through a 0.5 micron glass fiber filter paper sandwiched between two P5 papers, and concentrated under reduced pressure giving (**9**) as a light brown foam (28.96 g, 98% yield; 93% NMR purity). LCMS (C18 column eluting with 10-90% CH₃CN / water gradient over 5 minutes with formic acid modifier) M+1: 315.32 (1.54 min). ¹H NMR (300 MHz, CDCl₃) δ 8.83 (s, 2H), 6.92 (d, J = 1.8 Hz, 1H), 6.88 (d, J = 1.8 Hz, 1H), 4.90 (dd, J = 7.9, 6.2 Hz, 1H), 4.72 (s, 1H), 4.18 (s, 2H), 4.17 – 4.08 (m, 1H), 3.99 – 3.89 (m, 1H), 3.46 (s, 2H), 2.34 – 2.19 (m, 1H), 2.17 – 2.05 (m, 3H), 1.63 (s, 6H) ppm.

[00152] Example 9

[00153] Preparation of 1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-tetrahydrofuran-2-yl-1H-benzimidazol-2-yl]urea (**11**).




[00154] To a stirring solution of 2-[5-(3,4-diamino-5-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol (**9**) (32.10 g, 102.1 mmol) in 1,4-dioxane (160.5 mL, Sigma-Aldrich 360481) was added pH 3.5 buffer (240.8 mL), prepared by dissolving NaOAc trihydrate (34.5 g) in 1N aqueous H₂SO₄ (240 mL). Added 1-ethyl-3-(N-(ethylcarbamoyl)-C-methylsulfanyl-carbonimidoyl)urea (**10**) (28.46 g, 122.5 mmol, CB Research and Development) and stirred at reflux overnight (HPLC showed 99% consumption of starting diamine). The reaction mixture was cooled to room temperature and poured portion-wise (frothing) into a stirring solution of aqueous saturated NaHCO₃ (480 mL) and water (120 mL) giving pH 8-9. This was stirred for 30 minutes, the solid was collected by filtration, washed copiously with water to neutral pH, and then more sparingly with EtOH. The solid was dried under reduced pressure giving (**11**) as an off-white solid (34.48 g, 82% yield; 99.4% HPLC purity). LCMS (C18 column eluting with 10-90% CH₃CN / water gradient over 5 minutes with formic acid modifier) M+1: 411.41 (1.73 min). ¹H NMR (300 MHz, MeOD) δ 9.02 (s, 2H), 7.62 (s, 1H), 7.37 (s, 1H), 5.31 (s, 1H), 4.23 (dd, J = 14.5, 7.3 Hz, 1H), 4.01 (dd, J =

15.0, 7.1 Hz, 1H), 3.38 – 3.28 (m, 2H), 2.58 – 2.46 (m, 1H), 2.16 – 2.05 (m, 2H), 2.02 – 1.88 (m, 1H), 1.63 (s, 6H), 1.22 (t, $J = 7.2$ Hz, 3H) ppm.

[00155] Example 10

[00156] Chiral chromatographic isolation of 1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2R)-tetrahydrofuran-2-yl]-1H-benzimidazol-2-yl]urea (**12**).



[00157] A racemic sample of 1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-tetrahydrofuran-2-yl]-1H-benzimidazol-2-yl]urea (**11**) (24.60 g) was resolved on a CHIRALPAK® IC® column (by Chiral Technologies) eluting with DCM / MeOH / TEA (60 / 40 / 0.1) at 35°C giving the desired enantiomer (**12**) as a white solid (11.35 g, 45% yield; 99+% HPLC purity, 99+% ee). Analytical chiral HPLC retention time was 6.2 min (CHIRALPAK® IC® 4.6 x 250 mm column, 1 mL/min flow rate, 30°C).

[00158] The structure and absolute stereochemistry of **12** were confirmed by single-crystal x-ray diffraction analysis. Single crystal diffraction data were acquired on a Bruker Apex II diffractometer equipped with sealed tube Cu K-alpha source (Cu $K\alpha$ radiation, $\gamma = 1.54178$ Å) and an Apex II CCD detector. A crystal with dimensions of $1/2 \times 0.05 \times 0.05$ mm was selected, cleaned using mineral oil, mounted on a MicroMount and centered on a Bruker APEXII system. Three batches of 40 frames separated in reciprocal space were obtained to provide an orientation matrix and initial cell parameters. Final cell parameters were obtained and refined after data collection was completed based on the full data set. Based on systematic absences and intensities statistics the structure was solved and refined in acentric $P2_1$ space group.


[00159] A diffraction data set of reciprocal space was obtained to a resolution of 0.9 Å using 0.5° steps using 60 s exposure for each frame. Data were collected at 100 (2) K.

Integration of intensities and refinement of cell parameters were accomplished using APEXII software. Observation of the crystal after data collection showed no signs of decomposition. As shown in Fig. 1, there are two symmetry independent molecules in the structure and both symmetry independent molecules are *R* isomers.

[00160] The data were collected, refined and reduced using the Apex II software. The structure was solved using the *SHELXS97* (Sheldrick, 1990); program(s) and the structure refined using the *SHELXL97* (Sheldrick, 1997) program. The crystal shows monoclinic cell with $P2_1$ space group. The lattice parameters are $a = 9.8423(4) \text{ \AA}$, $b = 10.8426(3) \text{ \AA}$, $c = 19.4441(7) \text{ \AA}$, $\beta = 102.966(3)^\circ$. Volume = $2022.09(12) \text{ \AA}^3$.

[00161] Example 11

[00162] Preparation of the methanesulfonic acid salt of 1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2*R*)-tetrahydrofuran-2-yl]-1*H*-benzimidazol-2-yl]urea (**13**).




[00163] A stirring suspension of 1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2*R*)-tetrahydrofuran-2-yl]-1*H*-benzimidazol-2-yl]urea (**12**) (9.32 g, 22.71 mmol) in absolute ethanol (93.2 mL) was cooled with an ice-water bath. Added methanesulfonic acid (1.548 mL, 23.85 mmol, Sigma-Aldrich 471356), removed cold bath and stirred at room temperature for 20 minutes. It was concentrated on a rotary evaporator at 35°C to a thick slurry, diluted with EtOAc, collected the solid by filtration, washed with EtOAc, and dried under reduced pressure giving an initial crop of (**13**) as a white solid (8.10 g). The filtrate was concentrated on a rotavap giving a yellowish glassy foam, which was dissolved in EtOH, concentrated to a solid slurry, triturated with EtOAc / Et_2O , and collected by filtration. The solid was washed with EtOAc / Et_2O , combined with the first crop, and dried under reduced pressure giving (**13**) as a white solid (9.89 g, 86% yield; 99+% HPLC purity, 99+% ee).

Analytical chiral HPLC shows one enantiomer with retention time of 6.3 min eluting with DCM / MeOH / TEA (60 / 40 / 0.1) on a CHIRALPAK® IC® 4.6 x 250 mm column with 1 mL/min flow rate at 30°C. LCMS (C18 column eluting with 10-90% CH₃CN / water gradient over 5 minutes with formic acid modifier) M+1: 411.53 (1.74 min). ¹H NMR (300 MHz, MeOD) δ 9.07 (s, 2H), 7.79 (s, 1H), 7.62 (s, 1H), 5.30 (t, J = 7.3 Hz, 1H), 4.24 (dd, J = 14.6, 7.3 Hz, 1H), 4.04 (dd, J = 15.0, 7.6 Hz, 1H), 3.40 – 3.30 (m, 2H), 2.72 (s, 3H), 2.65 – 2.54 (m, 1H), 2.20 – 2.07 (m, 2H), 2.04 – 1.90 (m, 1H), 1.64 (s, 6H), 1.23 (t, J = 7.2 Hz, 3H) ppm.

[00164] Example 12

[00165] Preparation of 2-(2-fluoro-6-nitro-phenyl)-2,3-dihydrofuran (**15A**) and 2-(2-fluoro-6-nitro-phenyl)-2,5-dihydrofuran (**15B**).




[00166] 2-Bromo-1-fluoro-3-nitro-benzene (**14**) (200.3 g, 98%, 892.3 mmol, Bosche F6657), 1,4-dioxane (981.5 mL, Sigma-Aldrich 360481), and 2,3-dihydrofuran (**2**) (341.1 mL, 99%, 4.462 mol, Aldrich 200018) were charged in a reaction flask, followed by N,N-diisopropylethylamine (155.4 mL, 892.3 mmol, Sigma-Aldrich 550043) and bromo(tri-tert-butylphosphine)palladium(I) dimer (6.936 g, 8.923 mmol, Johnson Matthey C4099). The mixture was stirred at reflux for 2 hrs (HPLC showed 98% consumption of starting arylbromide). It was allowed to cool, the precipitate was removed by filtration, rinsed with EtOAc, and the filtrate concentrated *in vacuo* to a dark reddish brown semi-solid oil. This was dissolved in CH₂Cl₂, eluted through a plug of silica with CH₂Cl₂, and concentrated *in vacuo* giving a mixture of **15A** and **15B** as a dark amber oil (291.3 g). The crude product was carried forward without further purification. The major product was 2-(2-fluoro-6-nitro-phenyl)-2,3-dihydrofuran (**15A**) (96%): LCMS (C18 column eluting with 10-90% CH₃CN / water gradient over 5 minutes with formic acid modifier) M+1: 210.23 (3.13 min); ¹H NMR (300 MHz, CDCl₃) δ 7.54 (dt, J = 8.0, 1.2 Hz, 1H), 7.43 (td, J = 8.2, 5.2 Hz, 1H), 7.32 (ddd, J = 9.7, 8.3, 1.3 Hz, 1H), 6.33 (dd, J = 4.9, 2.4 Hz, 1H), 5.80 (t, J = 10.9 Hz, 1H), 5.06 (q, J = 2.4 Hz, 1H), 3.18 – 3.07 (m, 1H), 2.94 – 2.82 (m, 1H) ppm. The minor product was 2-(2-fluoro-6-nitro-phenyl)-2,5-dihydrofuran (**15B**) (4%): GCMS (Agilent HP-5MS 30 m x 250

$\mu\text{m} \times 0.25 \mu\text{m}$ column heating at 60°C for 2 min to 300°C over 15 min with a 1 mL/min flow rate) M+1: 210 (11.95 min). ^1H NMR (300 MHz, CDCl_3) δ 7.47 (d, $J = 8.0$ Hz, 1H), 7.43 – 7.34 (m, 1H), 7.30 – 7.23 (m, 1H), 6.21 – 6.15 (m, 1H), 6.11 – 6.06 (m, 1H), 5.97 – 5.91 (m, 1H), 4.89 – 4.73 (m, 2H) ppm.

[00167] Example 13

[00168] Preparation of 3-fluoro-2-tetrahydrofuran-2-yl-aniline (**16**).




[00169] Placed 5% palladium on carbon (37.3 g, 50% wet, 8.76 mmol, Aldrich 330116) in a Parr bottle under nitrogen, followed by MeOH (70 mL, JT-Baker 909333). Added the crude mixture of 2-(2-fluoro-6-nitro-phenyl)-2,3-dihydrofuran and 2-(2-fluoro-6-nitro-phenyl)-2,5-dihydrofuran (**15A&15B**) (186.6 g, 892.1 mmol) dissolved in MeOH (117 mL), followed by NEt_3 (124.3 mL, 892.1 mmol, Sigma-Aldrich 471283). Placed the vessel on a Parr shaker and saturated with H_2 . After adding 45 psi H_2 , the reaction mixture was shaken until consumption of the starting material was complete (HPLC and LCMS showed complete reaction). The reaction mixture was purged with nitrogen, filtered through CeliteTM and rinsed with EtOAc. The filtrate was concentrated on a rotary evaporator giving a brown oil, which was dissolved in Et_2O and washed with water (2x). The ether phase was extracted with aqueous 1 N HCl (5 x 250 mL), which was washed with Et_2O (3x) and then basified with aqueous 6 N NaOH to pH 12-14. The basic aqueous phase was extracted with CH_2Cl_2 (4x), and the combined organic extract washed with saturated aqueous NH_4Cl , dried over MgSO_4 , and filtered through a pad of silica eluting with CH_2Cl_2 to 25% EtOAc / hexane. The desired filtrate was concentrated under reduced pressure giving **16** as a light brown oil (121.8 g, 84% GCMS plus NMR purity). GCMS (Agilent HP-5MS 30 m x $250 \mu\text{m} \times 0.25 \mu\text{m}$ column heating at 60°C for 2 min to 300°C over 15 min with a 1 mL/min flow rate) M+1: 182.0 (11.44 min). LCMS (C18 column eluting with 10-90% CH_3CN / water gradient over 5 minutes with formic acid modifier) M+1: 182.10 (2.61 min). ^1H NMR (300 MHz, CDCl_3) δ 6.97 (td, $J = 8.1, 6.3$ Hz, 1H), 6.43 – 6.35 (m, 2H), 5.21 – 5.13 (m, 1H), 4.54 (s, 2H), 4.16 – 4.07 (m, 1H), 3.90 – 3.81 (m, 1H), 2.23 – 2.00 (m, 4H) ppm. Additional crops were obtained as follows: the combined ether phase was washed with saturated aqueous NaHCO_3 , brine,

dried over Na_2SO_4 , decanted, and concentrated under reduced pressure. The oil was vacuum distilled (ca. 15 torr) collecting the distillate at $101 - 108^\circ\text{C}$. To a stirring solution of the distilled oil in EtOH (1 volume) at 2°C was slowly added 5 M HCl (1 eq) in *i*PrOH. The resulting suspension was brought to room temperature, diluted with EtOAc (3 volumes, vol/vol), and stirred for 2 hrs. The white solid was collected by filtration, washed with EtOAc, and dried under reduced pressure giving a second crop of product as the HCl salt. The mother liquor was concentrated to a slurry, diluted with EtOAc and the solid collected by filtration, washed with EtOAc, and dried *in vacuo* giving the HCl salt as a third crop of the product. LCMS (C18 column eluting with 10-90% CH_3CN / water gradient over 5 minutes with formic acid modifier) M+1: 182.10 (2.58 min). ^1H NMR (300 MHz, CDCl_3) δ 10.73 (br.s, 3H), 7.66 (d, $J = 8.1$ Hz, 1H), 7.33 (td, $J = 8.2, 5.9$ Hz, 1H), 7.13 – 7.05 (m, 1H), 5.26 (dd, $J = 9.0, 6.5$ Hz, 1H), 4.38 – 4.28 (m, 1H), 4.00 – 3.91 (m, 1H), 2.59 – 2.46 (m, 1H), 2.30 – 1.95 (m, 3H) ppm. The overall yield from the three crops was 76%.

[00170] Example 14

[00171] Preparation of 4-bromo-3-fluoro-2-tetrahydrofuran-2-yl-aniline (**17**).




[00172] To a stirring solution of 3-fluoro-2-tetrahydrofuran-2-yl-aniline (**16**) (131.9 g, 92%, 669.7 mmol) in methyl *tert*-butyl ether (1.456 L) and acetonitrile (485 mL) cooled to -20°C was added N-bromosuccinimide (120.4 g, 99%, 669.7 mmol, Aldrich B81255) in 3 portions maintaining a reaction temperature below about -15°C . After complete addition stirring was continued at -15 to -10°C for 30 minutes. ^1H NMR of a worked-up aliquot showed 96% consumption of starting aniline so added another 4.82 g NBS and stirred at -10°C for another 30 minutes. Aqueous 1 N $\text{Na}_2\text{S}_2\text{O}_3$ (670 mL) was added to the reaction mixture. The cold bath was removed, the mixture stirred for 20 minutes, then diluted with EtOAc. The layers were separated and the organic phase was washed with saturated aqueous NaHCO_3 (2x), water, brine, dried over Na_2SO_4 , decanted, and concentrated under reduced pressure giving a dark amber oil. The residue was diluted with hexane and eluted through a short plug of silica eluting with 25% EtOAc / hexane to 50% EtOAc / hexane. The desired

filtrate was concentrated *in vacuo* giving **17** as a dark amber oil (182.9 g, 90% yield; 86% NMR purity). LCMS (C18 column eluting with 10-90% CH₃CN/ water gradient over 5 minutes with formic acid modifier) M+1: 260.12 (3.20 min). ¹H NMR (300 MHz, CDCl₃) δ 7.15 (dd, J = 8.6, 7.6 Hz, 1H), 6.30 (dd, J = 8.7, 1.3 Hz, 1H), 5.19 – 5.12 (m, 1H), 4.58 (s, 2H), 4.16 – 4.07 (m, 1H), 3.90 – 3.81 (m, 1H), 2.23 – 1.99 (m, 4H) ppm.

[00173] Example 15


[00174] Preparation of N-(4-bromo-3-fluoro-6-nitro-2-tetrahydrofuran-2-yl-phenyl)-2,2,2-trifluoroacetamide (**18**).



[00175] To trifluoroacetic anhydride (565.3 mL, 4.067 mol, Sigma-Aldrich 106232) stirring at 2°C was slowly added neat 4-bromo-3-fluoro-2-tetrahydrofuran-2-yl-aniline (**17**) (123.0 g, 86%, 406.7 mmol) as a thick oil *via* addition funnel over about 20 minutes (reaction temperature rose to 13°C). The remaining oil was rinsed into the reaction mixture with anhydrous THF (35 mL). The cold bath was removed and the reaction was heated to 35°C, followed by portion-wise addition of NH₄NO₃ (4.88 g x 20 portions, 1.22 mol, Sigma-Aldrich A7455) over 2.5 hrs maintaining the reaction temperature between 30 and 41°C using an ice-water bath only as needed to control the exotherm. After complete addition the reaction mixture was stirred for another 10 minutes (HPLC showed reaction 99% complete). It was slowly poured into crushed ice (1.23 kg) and stirred for 1 hr to allow formation of a filterable solid precipitate, which was collected and washed with water, sparingly with saturated aqueous NaHCO₃, and water again (to pH 7). The product was dried in a convection oven overnight at 40°C and then under reduced pressure in an oven at 50°C overnight giving **18** as a beige solid (152.5 g, 90% yield; 96% HPLC purity). LCMS (C18 column eluting with 10-90% CH₃CN/ water gradient over 5 minutes with formic acid modifier) M+1: 401.30 (3.41 min). ¹H NMR (300 MHz, CDCl₃) δ 10.56 (s, 1H), 8.19 (d, J = 6.6 Hz, 1H), 5.22 (dd, J = 10.3, 6.4 Hz, 1H), 4.22 (dd, J = 15.8, 7.2 Hz, 1H), 3.99 (dd, J = 16.1, 7.5 Hz, 1H), 2.50 – 2.38 (m, 1H), 2.22 – 2.11 (m, 2H), 1.86 – 1.71 (m, 1H) ppm.

[00176] Example 16


[00177] Preparation of 4-bromo-3-fluoro-6-nitro-2-tetrahydrofuran-2-yl-aniline (**19**).



[00178] A reaction flask was charged with N-(4-bromo-3-fluoro-6-nitro-2-tetrahydrofuran-2-yl-phenyl)-2,2,2-trifluoroacetamide (**18**) (242.3 g, 604.1 mmol), 1,4-dioxane (1.212 L), aqueous 2 M sulfuric acid (362.4 mL, 724.9 mmol), and stirred at reflux for 5 days (HPLC showed 98% conversion). Allowed to cool, diluted with EtOAc, neutralized with saturated aqueous NaHCO₃, separated the layers, and re-extracted the aqueous phase with EtOAc (2x). The combined organic phase was washed with brine (2x), dried over MgSO₄, filtered and concentrated *in vacuo* giving **19** as a greenish brown solid (181.7 g, 94% yield; 95% HPLC purity). The product was carried to the next step without further purification. LCMS (C18 column eluting with 10-90% CH₃CN / water gradient over 5 minutes with formic acid modifier) M+1: 305.20 (3.63 min). ¹H NMR (300 MHz, CDCl₃) δ 8.35 (d, J = 7.3 Hz, 1H), 7.45 (s, 2H), 5.23 – 5.16 (m, 1H), 4.23 – 4.14 (m, 1H), 3.93 – 3.84 (m, 1H), 2.31 – 1.96 (m, 4H) ppm.

[00179] Example 17

[00180] Preparation of 2-[5-(4-amino-2-fluoro-5-nitro-3-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol (**20**).




[00181] To a stirring solution of 4-bromo-3-fluoro-6-nitro-2-tetrahydrofuran-2-yl-aniline (**19**) (525.0 g, 1.721 mol, Bridge Organics Co.) in 1,4-dioxane (4.20 L, Sigma-Aldrich 360481) was added a 1.2 M aqueous solution of NaHCO₃ (4.302 L, 5.163 mol). A stream of

nitrogen was bubbled through the stirring mixture for 2 hrs, followed by addition of 2-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-yl]propan-2-ol (**7**) (545.4 g, 2.065 mol, Bridge Organics Co.) and 1,1'-bis(diphenylphosphino)ferrocene dichloropalladium dichloromethane adduct (42.16 g, 51.63 mmol, Strem 460450). The reaction mixture was stirred at reflux overnight, allowed to cool, diluted with EtOAc (8.4 L), and the layers were separated. The organic phase was washed with saturated aqueous NH₄Cl and then brine. The aqueous phase was re-extracted with EtOAc (4 L) and washed this organic extract with brine. The combined organic phase was dried over MgSO₄, filtered through a short plug of Florisil®, eluted with EtOAc, and the filtrate concentrated on a rotary evaporator giving a dark brown wet solid. This was dissolved in CH₂Cl₂, loaded on a pad of silica gel, eluted with hexane, then 25% EtOAc / hexane, and then 50% EtOAc / hexane. The desired filtrate was concentrated on a rotary evaporator to a thick suspension, and the solid was collected by filtration, triturated with MTBE, and dried *in vacuo* giving **20** as a bright yellow solid (55.8% yield, 90-97% HPLC purity). The filtrate was concentrated and the above purification was repeated giving a second crop of **20** as a bright yellow solid (19.7% yield). The filtrate was again concentrated giving a dark brown oil and this was loaded on a silica column with toluene and minimal CH₂Cl₂. It was eluted with EtOAc / hexane (0% to 50%). The desired fractions were concentrated to a slurry and diluted with MTBE / hexane. The solid was collected by filtration and washed with minimal MTBE giving a third crop of **20** as a bright yellow solid (4.9% yield) with an overall yield of 80% from the three crops. LCMS (C18 column eluting with 10-90% CH₃CN / water gradient over 5 minutes with formic acid modifier) M+1: 363.48 (2.95 min). ¹H NMR (300 MHz, CDCl₃) δ 8.84 (d, J = 1.6 Hz, 2H), 8.27 (d, J = 8.0 Hz, 1H), 7.62 (s, 2H), 5.31 – 5.24 (m, 1H), 4.63 (s, 1H), 4.27 – 4.18 (m, 1H), 3.97 – 3.87 (m, 1H), 2.33 – 2.05 (m, 4H), 1.64 (s, 6H) ppm.

[00182] Example 18


[00183] Preparation of 2-[5-(4,5-diamino-2-fluoro-3-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol (**21**).



[00184] Placed 5% palladium on carbon (14.21 g, 50% wet, 3.339 mmol, Aldrich 330116) in a Parr bottle under nitrogen, followed by MeOH (242 mL, JT-Baker 909333) and NEt₃ (46.54 mL, 333.9 mmol, Sigma-Aldrich 471283). Dissolved 2-[5-(4-amino-2-fluoro-5-nitro-3-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol (**20**) (121.0 g, 333.9 mmol) in hot THF (360 mL), allowed to cool, added to the reaction mixture, and rinsed with another portion of THF (124 mL). Placed the vessel on a Parr shaker and saturated with H₂. Added 45 psi H₂ and shook until consumption was complete (HPLC and LCMS showed complete reaction). The reaction mixture was purged with nitrogen, filtered through Celite™ and rinsed with EtOAc. It was re-filtered through paper (glass microfibre) and the filtrate concentrated *in vacuo*. Repeated the reaction three more times on the same scale and the batches were combined giving **21** as a brown solid (447 g, 99% yield; 93% HPLC purity). LCMS (C18 column eluting with 10-90% CH₃CN / water gradient over 5 minutes with formic acid modifier) M+1: 333.46 (1.79 min). ¹H NMR (300 MHz, CDCl₃) δ 8.81 (d, J = 1.4 Hz, 2H), 6.69 (d, J = 7.3 Hz, 1H), 5.27 – 5.20 (m, 1H), 4.73 (s, 1H), 4.70 (s, 2H), 4.23 – 4.14 (m, 1H), 3.94 – 3.86 (m, 1H), 3.22 (s, 2H), 2.32 – 2.22 (m, 1H), 2.18 – 1.99 (m, 3H), 1.63 (s, 6H) ppm.

[00185] Example 19


[00186] Preparation of 1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-tetrahydrofuran-2-yl]-1H-benzimidazol-2-yl]urea (**22**).



[00187] To a stirring suspension of 2-[5-(4,5-diamino-2-fluoro-3-tetrahydrofuran-2-yl-phenyl)pyrimidin-2-yl]propan-2-ol (**21**) (111.3 g, 334.9 mmol) and 1,4-dioxane (556.5 mL, Sigma-Aldrich 360481) was added 1-ethyl-3-(N-(ethylcarbamoyl)-C-methylsulfanyl-carbonimidoyl)urea (**10**) (93.36 g, 401.9 mmol, CB Research and Development) followed by a pH 3.5 buffer (1.113 L), prepared by dissolving NaOAc trihydrate (158.1 g) in 1N aqueous H₂SO₄ (1.100 L). The reaction mixture was stirred at reflux overnight (HPLC showed complete conversion), cooled to room temperature, and poured portion-wise (frothing) into a stirring solution of aqueous saturated NaHCO₃ (2.23 L) giving pH 8-9. This was stirred for 30 minutes, the solid was collected by filtration, washed copiously with water to neutral pH, and then more sparingly with EtOH. The solid was dried under reduced pressure giving **22** as an off-white yellowish solid (135.2 g, 94% yield; 99% HPLC purity). LCMS (C18 column eluting with 10-90% CH₃CN / water gradient over 5 minutes with formic acid modifier) M+1: 429.58 (2.03 min). ¹H NMR (300 MHz, MeOD) δ 8.95 (d, J = 1.6 Hz, 2H), 7.45 (d, J = 6.5 Hz, 1H), 5.38 (br.s, 1H), 4.27 (dd, J = 14.9, 7.1 Hz, 1H), 4.01 (dd, J = 15.1, 7.0 Hz, 1H), 3.37 – 3.29 (m, 2H), 2.55 (br.s, 1H), 2.19 – 2.07 (m, 2H), 2.02 – 1.82 (br.s, 1H), 1.63 (s, 6H), 1.21 (t, J = 7.2 Hz, 3H) ppm.

[00188] Example 20

[00189] Chiral chromatographic isolation of 1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2R)-tetrahydrofuran-2-yl]-1H-benzimidazol-2-yl]urea (**23**).



[00190] A racemic sample of 1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-tetrahydrofuran-2-yl]-1H-benzimidazol-2-yl]urea (**22**) (133.60 g) was resolved on a CHIRALPAK® IC® column (by Chiral Technologies) eluting with DCM / MeOH / TEA (60 / 40 / 0.1) at 25°C giving the desired enantiomer **23** as an off-white solid (66.8 g, 45% yield; 99.8% HPLC purity, 99+% ee). Analytical chiral HPLC retention time was 7.7 min (CHIRALPAK® IC® 4.6 x 250 mm column, 1 mL/min flow rate, 30°C). The solid was suspended in 2:1 EtOH / Et₂O (5 volumes), stirred for 10 minutes, collected by filtration, washed with 2:1 EtOH / Et₂O, and dried under reduced pressure giving a white solid (60.6 g).

[00191] The structure and absolute stereochemistry of **23** were confirmed by single-crystal x-ray diffraction analysis. Single crystal diffraction data were acquired on a Bruker Apex II diffractometer equipped with sealed tube Cu K-alpha source (Cu K α radiation, $\gamma = 1.54178$ Å) and an Apex II CCD detector. A crystal with dimensions of 0.15 x 0.15 x 0.10 mm was selected, cleaned using mineral oil, mounted on a MicroMount and centered on a Bruker APEXII system. Three batches of 40 frames separated in reciprocal space were obtained to provide an orientation matrix and initial cell parameters. Final cell parameters were obtained and refined after data collection was completed based on the full data set. Based on systematic absences and intensities statistics the structure was solved and refined in acentric *P*2₁ space group.


[00192] A diffraction data set of reciprocal space was obtained to a resolution of 0.85 Å using 0.5° steps using 30 s exposures for each frame. Data were collected at 100 (2) K. Integration of intensities and refinement of cell parameters were accomplished using APEXII software. Observation of the crystal after data collection showed no signs of decomposition.

As shown in Fig. 2, there are two symmetry independent molecules in the structure and both symmetry independent molecules are *R* isomers.

[00193] The data were collected, refined and reduced using the Apex II software. The structure was solved using the *SHELXS97* (Sheldrick, 1990); program(s) and the structure refined using the *SHELXL97* (Sheldrick, 1997) program. The crystal shows monoclinic cell with $P2_1$ space group. The lattice parameters are $a = 9.9016(2) \text{ \AA}$, $b = 10.9184(2) \text{ \AA}$, $c = 19.2975(4) \text{ \AA}$, $\beta = 102.826(1)^\circ$. Volume = $2034.19(7) \text{ \AA}^3$.

[00194] Example 21

Preparation of the methanesulfonic acid salt of 1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2*R*)-tetrahydrofuran-2-yl]-1*H*-benzimidazol-2-yl]urea (**23A**).




[00195] To a stirring suspension of 1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2*R*)-tetrahydrofuran-2-yl]-1*H*-benzimidazol-2-yl]urea (**23**) (15.05 g, 35.13 mmol) in dichloromethane (60 mL, J.T. Baker 931533) and absolute ethanol (15 mL, Pharmco-AAPER 111000200) was added methanesulfonic acid (2.392 mL, 36.89 mmol, Sigma-Aldrich 471356). Stirred at room temperature until a clear solution was observed. Added heptane (300 mL) slowly over about 1 hr and collected the solid precipitate by filtration (using a Whatman qualitative # 3 paper on top of a Whatman GF/F glass microfibre paper). Dried under reduced pressure in a vacuum oven (desiccated with calcium sulfate and potassium hydroxide) overnight at 40°C giving **23A** as a white solid (13.46 g, 99+% HPLC purity, 99+% ee). Analytical chiral HPLC shows one enantiomer with retention time of 8.6 min eluting with CH_2Cl_2 / MeOH / TEA (60 / 40 / 0.1) on a CHIRALPAK® IC® 4.6 x 250 mm column with 1 mL/min flow rate at 30°C. A second crop of white solid product **23A**

(4.36 g, 98% HPLC purity, 99+% ee) was obtained from the filtrate. LCMS (C18 column eluting with 10-90% CH₃CN / water gradient over 5 minutes with formic acid modifier) M+1: 429.58 (2.03 min). ¹H NMR (300 MHz, MeOD) δ 9.00 (d, J = 1.6 Hz, 2H), 7.67 (d, J = 6.1 Hz, 1H), 5.39 (t, J = 7.7 Hz, 1H), 4.30 (dd, J = 14.9, 6.9 Hz, 1H), 4.03 (dd, J = 14.8, 7.7 Hz, 1H), 3.40 – 3.31 (m, 2H), 2.72 (s, 3H), 2.70 – 2.60 (m, 1H), 2.21 – 2.08 (m, 2H), 1.98 – 1.84 (m, 1H), 1.65 (s, 6H), 1.22 (t, J = 7.2 Hz, 3H) ppm.

[00196] The (*R*)-1-ethyl-3-(6-fluoro-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea **23** may then be converted to the phosphate or phosphate salt prodrugs according to the schemes set forth below.

[00197] Scheme 1




[00198] Reagents and conditions: (a) dibenzyl N,N-diisopropylphosphoramidite, tetrazole, 23 °C, DMF; (b) mCPBA, 0-23 °C, DMF; (c) H₂, Pd/C, M⁺OH⁻ or D²⁺(OH⁻)₂, EtOH, H₂O; (d) aq H⁺; (e) aq M⁺OH⁻.

[00199] Compounds of formula **(IB)** may be prepared from compound **23** as shown in Scheme 1. In Step 1, compound **23** is treated with dibenzyl N,N-diisopropylphosphoramidite and tetrazole, followed by meta-chloroperoxybenzoic acid (mCPBA), to afford dibenzyl phosphate **24**. In Step 2, hydrogenolysis of **24** in the presence of M⁺OH⁻ or D²⁺(OH⁻)₂ affords the dianionic form of the compound of formula **(IB)** ($X = -\text{PO}(\text{O}^-)_2 \cdot 2\text{M}^+$ or $-\text{PO}(\text{O}^-)_2$).

$)_2 \cdot D^{2+}$). The free acid form of the compound of formula **(IB)** ($X = PO(OH)_2$) may be obtained by treating the dianionic form with aqueous acid. The monoanionic form of the compound of formula **(IB)** ($X = PO(OH)O^-M^+$) may be obtained by treating the free acid form with one equivalent of M^+OH^- .

[00200] Scheme 2




[00201] Reagents and conditions: (a) Boc_2O , DMF, 23 °C; (b) dibenzyl N,N-diisopropylphosphoramidite, tetrazole, 23 °C, DMF; (c) mCPBA, 0-23 °C, DMF; (d) TFA,

H₂O, MeOH, DCM, 23 °C; (e) H₂, Pd/C, M⁺OH⁻ or D²⁺(OH⁻)₂, EtOH, H₂O; (f) aq H⁺; (g) aq M⁺OH⁻.

[00202] Alternatively, the compounds of formula **(IB)** may be prepared from compound **23** as shown in Scheme 2. In Step 1, compound **23** is treated with di-tert-butyl dicarbonate (Boc₂O) to afford protected benzimidazole compound **25**. In Step 2, compound **25** is treated with dibenzyl N,N-diisopropylphosphoramidite and tetrazole, followed by mCPBA, to afford protected dibenzyl phosphate **26**. In Step 3, compound **26** is treated with trifluoroacetic acid (TFA) to remove the protecting group and afford dibenzyl phosphate **24**. In Step 4, hydrogenolysis of **24** in the presence of M⁺OH⁻ or D²⁺(OH⁻)₂ affords the dianionic form of the compound of formula **(IB)** (X = -PO(O⁻)₂•2M⁺ or -PO(O⁻)₂•D²⁺). The free acid form of the compound of formula **(IB)** (X = PO(OH)₂) may be obtained by treating the dianionic form with aqueous acid. The monoanionic form of the compound of formula **(I)** (X = PO(OH)O⁻M⁺) may be obtained by treating the free acid form with one equivalent of M⁺OH⁻.

[00203] Scheme 3




[00204] Reagents and conditions: (a) Boc_2O , DMAP, DMF, 23 °C; (b) dibenzyl N,N-diisopropylphosphoramidite, tetrazole, 23 °C, DMF; (c) mCPBA, 0-23 °C, DMF; (d) TFA, DCM; (e) aq M^+OH^- or $\text{D}^{2+}(\text{OH})_2$; (f) aq H^+ ; (g) aq M^+OH^- .

[00205] The compounds of formula (IB) may also be prepared from compound 23 as shown in Scheme 3. In Step 1, compound 23 is treated with two equivalents of Boc_2O in the presence of N,N-dimethylaminopyridine (DMAP) to afford bis-protected benzimidazole

compound **28**. In Step 2, compound **28** is treated with dibenzyl N,N-diisopropylphosphoramidite and tetrazole, followed by mCPBA, to afford bis-protected dibenzyl phosphate **29**. In Step 3, compound **29** is treated with TFA to remove the protecting groups. Treatment of the resulting intermediate with aqueous M^+OH^- or $D^{2+}(OH^-)_2$ affords the dianionic form of the compound of formula **(IB)** ($X = -PO(O^-)_2 \cdot 2M^+$ or $-PO(O^-)_2 \cdot D^{2+}$). The free acid form of the compound of formula **(IB)** ($X = PO(OH)_2$) may be obtained by treating the dianionic form with aqueous acid. The monoanionic form of the compound of formula **(I)** ($X = PO(OH)O^-M^+$) may be obtained by treating the free acid form with one equivalent of M^+OH^- .

[00206] Example 22

[00207] Preparation of (*R*)-dibenzyl 2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1*H*-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl phosphate (**24**).




[00208] To 1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2*R*)-tetrahydrofuran-2-yl]-1*H*-benzimidazol-2-yl]urea (**23**) (10.24 g, 23.66 mmol) in a 1 L round bottom flask under N_2 at 23 °C was added DMF (200 mL) followed by a solution of tetrazole (105.2 mL of 0.45 M in MeCN, 47.32 mmol) followed by N-dibenzylphosphoryl-N-isopropyl-propan-2-amine (12.26 g, 11.93 mL, 35.49 mmol). After 4.5 h more N-dibenzylphosphoryl-N-isopropyl-propan-2-amine (4 mL) was added. After stirring a further 16 h the reaction was cooled to 0 °C (ice-water bath) then treated with mCPBA (15.17 g, 61.52 mmol). The mixture was stirred at 0 °C for 30 min then at 23 °C for 30 min after which the reaction mixture was partitioned between water (400 mL) and EtOAc (700 mL). The organic layer was separated, washed with saturated aqueous sodium

bicarbonate (500 mL), 10% aqueous sodium bisulfite (500 mL), saturated aqueous sodium bicarbonate (500 mL), and brine (500 mL) then dried (magnesium sulfate), filtered and concentrated. The residue was purified by MPLC using an ISCO COMBIFLASH brand flash chromatography purification system (330 g column) eluting with a 0-10% EtOH in DCM linear gradient over 16.5 column volumes at a 200 mL/min flow rate. After concentration *in vacuo*, (*R*)-dibenzyl 2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1*H*-benzo[*d*]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl phosphate(**24**) (13.89 g, 20.17 mmol, 85.27%) was obtained as a white solid. ESMS ($M + 1$) = 689.5; ^1H NMR (300 MHz, CD_3OD) δ 8.88 (d, $J = 1.6$ Hz, 2H), 7.37 (d, $J = 6$ Hz, 1H), 7.30 (m, 10H), 5.38 - 5.33 (m, 1H), 5.12 - 5.01 (m, 4H), 4.24 (dd, $J = 6.8, 14.9$ Hz, 1H), 3.98 (dd, $J = 6.9, 15.1$ Hz, 1H), 3.35 - 3.27 (m, 3H), 2.52 (q, $J = 5.9$ Hz, 1H), 2.14 - 2.05 (m, 2H), 1.91 (s, 6H) and 1.22 - 1.14 (m, 3H) ppm.

[00209] Example 23

[00210] Preparation of disodium (*R*)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1*H*-benzo[*d*]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl phosphate (**W**).




[00211] A 1 L Parr vessel was charged with water (200 mL), Pd/C (4 g, 10 wt% dry basis, wet, Degussa type), (*R*)-dibenzyl 2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1*H*-benzo[*d*]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl phosphate(**24**) (13.89 g, 20.17 mmol), EtOH (400 mL) and aqueous 1 M NaOH (40.34 mL, 40.34 mmol). The resulting mixture was hydrogenated under 50 psi H_2 on a Parr shaker apparatus for 40 min. The reaction mixture was filtered through a 0.22 μm polyethersulfone (PES) membrane giving a dark colored filtrate. A water rinse resulted in more dark material crossing the filter membrane. The resulting filtrate was passed through a pad of Celite and the dark material did not elute

until the pad was rinsed with water. The resulting dark solution (approx. 700 mL) was diluted with three volumes of EtOH (2100 mL), filtered through a 0.22 μ m PES membrane (using 4 disposable Corning polystyrene filter systems, #431098) and the filtrate concentrated *in vacuo*. The resulting residue was dissolved in water (100 mL) and EtOH (300 mL), filtered through a 0.22 μ m PES membrane to give a clear yellow solution, then passed through a Celite plug (26 mm diameter x 60 mm height, pre-wet with EtOH) rinsing with EtOH (50 mL) and the filtrate then concentrated. The resulting residue was dissolved in water (250 mL) in a 1 L round bottom flask, then 1 M aqueous HCl (40 mL) was slowly added over 15 min with stirring to give a slurry of white solid. Twenty minutes following completion of the HCl addition, the solid was collected via filtration through a 0.22 μ m PES membrane. The collected solid was washed with water (100 mL), then transferred (still wet) to a 1 L round bottom flask and slurried in MeOH (150 mL) for 30 min. The resulting fine white precipitate was collected via filtration then dried *in vacuo* overnight. The resulting free acid (9.17 g, 18.0 mmol) was treated with water (80 mL) then 1.0 N aq NaOH (36.0 mL, 2 equiv). The resulting solution was frozen and lyophilized to give disodium [1-[5-[2-(ethylcarbamoylamino)-6-fluoro-7-[(2*R*)-tetrahydrofuran-2-yl]-1H-benzimidazol-5-yl]pyrimidin-2-yl]-1-methyl-ethyl] phosphate (**W**) (10.206 g, 18.08 mmol, 89.66%) as a pale, cream-colored solid with consistent analytical data. ESMS ($M + 1$) = 509.4; ^1H NMR (300 MHz, D_2O) δ 8.58 (s, 2H), 6.92 (d, J = 6.3 Hz, 1H), 5.13 (t, J = 7.5 Hz, 1H), 3.98 - 3.81 (m, 2H), 3.04 (q, J = 7.2 Hz, 2H), 2.26 (t, J = 5.7 Hz, 1H), 1.97 - 1.92 (m, 2H), 1.67 (s, 6H) and 1.01 (t, J = 7.2 Hz, 3H) ppm.

[00212] Example 24


[00213] Preparation of Boc-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2*R*)-tetrahydrofuran-2-yl]-1H-benzimidazol-2-yl]urea (**25**).



[00214] To a solution/suspension of 1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methylethyl)pyrimidin-5-yl]-7-[(2*R*)-tetrahydrofuran-2-yl]-1*H*-benzimidazol-2-yl]urea (**23**) (10.72 g, 25.02 mmol) in DMF (250 mL) at 23 °C was added Boc₂O (6.11 g, 28.00 mmol). After 2 hours, 2 M ammonia in MeOH (2 mL) was added to quench any excess Boc₂O. The quenched reaction mixture was partitioned between EtOAc and water (400 mL each), the organic layer separated, washed with water (2 x 400 mL) and brine (400 mL), then dried over MgSO₄, filtered and concentrated to give Boc-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methylethyl)pyrimidin-5-yl]-7-[(2*R*)-tetrahydrofuran-2-yl]-1*H*-benzimidazol-2-yl]urea (**25**) (12.69 g, 23.58 mmol, 94.26%) which was used without further purification. ESMS (*M* + 1) = 529.3; ¹H NMR (300.0 MHz, CDCl₃) δ 9.50 (s, 1H), 9.02 (t, *J* = 5.3 Hz, 1H), 8.91 (d, *J* = 1.6 Hz, 2H), 7.74 (d, *J* = 6.5 Hz, 1H), 5.58 (t, *J* = 7.8 Hz, 1H), 4.64 (s, 1H), 4.22 (q, *J* = 7.4 Hz, 1H), 4.05 (td, *J* = 7.8, 4.3 Hz, 1H), 3.47 (td, *J* = 7.2, 4.3 Hz, 2H), 2.42 - 2.35 (m, 2H), 2.28 - 2.16 (m, 2H), 1.75 (s, 9H), 1.68 (s, 6H) and 1.31 (t, *J* = 7.3 Hz, 3H) ppm.

[00215] Example 25


[00216] Preparation of Boc-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methylethyl)pyrimidin-5-yl]-7-[(2*R*)-tetrahydrofuran-2-yl]-1*H*-benzimidazol-2-yl]urea dibenzyl phosphate (**26**).



[00217] To Boc-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2*R*)-tetrahydrofuran-2-yl]-1*H*-benzimidazol-2-yl]urea (**25**) (12.69 g, 23.58 mmol) and tetrazole (3.304 g, 47.16 mmol) under N₂ at 23 °C was added DCM (240 mL) followed by *N*-dibenzylphosphorylphosphanyl-*N*-isopropyl-propan-2-amine (9.775 g, 9.509 mL, 28.30 mmol). After 3 hours at 23 °C, the reaction was cooled to 0 °C then mCPBA (6.977 g, 28.30 mmol) was added. The resulting solution was stirred for 45 min at 0 °C then for 20 min at 23 °C. The reaction mixture was then partitioned between DCM (50 mL) and saturated aqueous sodium bicarbonate (400 mL). The organic layer was separated, then washed successively with aqueous sodium bisulfite (63 g in 350 mL water) and saturated aqueous sodium bicarbonate (400 mL), then dried over magnesium sulfate, filtered and concentrated *in vacuo*. The residue was purified by MPLC using an ISCO COMBIFLASH brand flash chromatography purification system (330 g silica column) eluting with a 0-100% EtOAc in hexanes linear gradient over 16 column volumes at 200 mL/min. Product containing fractions were evaporated *in vacuo* to give Boc-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2*R*)-tetrahydrofuran-2-yl]-1*H*-benzimidazol-2-yl]urea dibenzyl phosphate (**26**) (11.92 g, 15.11 mmol, 64.09%). ESMS (*M* + 1) = 789.2; ¹H NMR (300.0 MHz, CDCl₃) δ 9.51 (s, 1H), 9.03 (t, *J* = 5.4 Hz, 1H), 8.91 (d, *J* = 1.6 Hz, 2H), 7.73 (d, *J* = 6.5 Hz, 1H), 7.37 - 7.28 (m, 10H), 5.58 (t, *J* = 7.8 Hz, 1H), 5.17 - 5.05 (m, 4H), 4.23 (t, *J* = 7.5 Hz, 1H), 4.05 (td, *J* = 7.8, 4.3 Hz, 1H), 3.53 - 3.44 (m, 2H), 2.39 (dd, *J* = 7.9, 14.5 Hz, 2H), 2.28 - 2.15 (m, 2H), 1.98 (s, 6H), 1.72 (m, 9H) and 1.31 (t, *J* = 7.2 Hz, 3H) ppm.

[00218] Example 26


[00219] Preparation of (*R*)-dibenzyl 2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1*H*-benzo[*d*]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl phosphate (**24**).



[00220] To a solution of Boc-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2*R*)-tetrahydrofuran-2-yl]-1*H*-benzimidazol-2-yl]urea dibenzyl phosphate (**26**) (11.9 g, 15.09 mmol) in DCM (300 mL) at 23 °C was added water (2.325 mL, 129.1 mmol) then TFA (3.441 g, 2.325 mL, 30.18 mmol). After 1 h, only partial conversion was observed by tlc, so more TFA (3.441 g, 2.325 mL, 30.18 mmol) was added. After a further 2.5 h, MeOH (2 mL) was added and the mixture stirred a further 18 hours. The reaction mixture was washed with 1:1 brine:saturated aqueous sodium bicarbonate (200 mL). The aqueous layer was re-extracted with DCM (150 mL), the organic layers combined, then dried (over magnesium sulfate), filtered and concentrated *in vacuo*. The resulting residue was re-dissolved in EtOAc (200 mL) washed with water (150 mL) and brine (100 mL), then dried (magnesium sulfate) filtered and concentrated to give (*R*)-dibenzyl 2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1*H*-benzo[*d*]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl phosphate (**24**) (10.21 g, 14.83 mmol, 98.27%) as a white solid. ESMS (*M* + 1) = 689.4; ¹H NMR (300 MHz, CD₃OD) δ 8.88 (d, *J* = 1.6 Hz, 2H), 7.37 (d, *J* = 6 Hz, 1H), 7.30 (m, 10H), 5.38 - 5.33 (m, 1H), 5.12 - 5.01 (m, 4H), 4.24 (dd, *J* = 6.8, 14.9 Hz, 1H), 3.98 (dd, *J* = 6.9, 15.1 Hz, 1H), 3.35 - 3.27 (m, 3H), 2.52 (q, *J* = 5.9 Hz, 1H), 2.14 - 2.05 (m, 2H), 1.91 (s, 6H) and 1.22 - 1.14 (m, 3H) ppm.

[00221] Example 27


[00222] Preparation of disodium (*R*)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1*H*-benzo[*d*]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl phosphate (**W**).



[00223] A 1 L round bottom flask was charged with (*R*)-dibenzyl 2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1*H*-benzo[*d*]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl phosphate (**24**) (9.37 g, 13.61 mmol), EtOH (300 mL), water (150 mL), Pd/C (10 wt% dry basis, wet, Degussa type, 3 g) and 1 M aqueous NaOH (27.22 mL, 27.22 mmol). The suspension was evacuated for 3 min (needle to pump) then placed under an atmosphere of hydrogen gas (balloon). After stirring 2.5 h at 23 °C, the reaction was filtered through a 0.22 μm PES membrane (disposable Corning filter system, 1 L, polystyrene, #431098) to remove catalyst and washed with EtOH (50 mL). The resulting solution was concentrated, the residue dissolved in water (80 mL), treated with MeCN (80 mL), then frozen and lyophilized to give disodium (*R*)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1*H*-benzo[*d*]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl phosphate (**W**) (7.10 g, 12.81 mmol, 94.12%) as a white solid. ESMS (*M* + 1) = 509.3; ¹H NMR (300 MHz, D₂O) δ 8.58 (s, 2H), 6.92 (d, *J* = 6.3 Hz, 1H), 5.13 (t, *J* = 7.5 Hz, 1H), 3.98 - 3.81 (m, 2H), 3.04 (q, *J* = 7.2 Hz, 2H), 2.26 (t, *J* = 5.7 Hz, 1H), 1.97 - 1.92 (m, 2H), 1.67 (s, 6H) and 1.01 (t, *J* = 7.2 Hz, 3H) ppm.

[00224] Example 28


[00225] Preparation of diBoc-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2*R*)-tetrahydrofuran-2-yl]-1*H*-benzimidazol-2-yl]urea (**28**).



[00226] To a solution/suspension of 1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2*R*)-tetrahydrofuran-2-yl]-1*H*-benzimidazol-2-yl]urea (**23**) (1.333 g, 3.111 mmol) in DMF (30 mL) was added DMAP (38.01 mg, 0.3111 mmol) followed by Boc_2O (1.426 g, 1.501 mL, 6.533 mmol). After 30 min, the reaction mixture was diluted with water and EtOAc (300 mL each), the organic layer separated, washed with water and brine (300 mL each), then dried over magnesium sulfate, filtered and concentrated. The residue was purified by MPLC using an ISCO COMBIFLASH brand flash chromatography purification system (80 g silica column) eluting with a 0-60% EtOAc in hexanes linear gradient over 20 column volumes at 60 mL/min flow rate. Desired product fractions were combined and evaporated to give diBoc-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2*R*)-tetrahydrofuran-2-yl]-1*H*-benzimidazol-2-yl]urea (**28**) (1.43 g, 2.275 mmol, 73.11%) as a clear foam. ESMS ($M + 1$) = 629.3; ^1H NMR (300.0 MHz, CDCl_3) δ 8.95 (d, $J = 1.6$ Hz, 2H), 8.31 - 8.27 (m, 1H), 8.05 (d, $J = 6.5$ Hz, 1H), 5.80 - 5.68 (m, 1H), 4.70 (s, 1H), 4.21 - 4.09 (m, 1H), 3.98 (d, $J = 6.4$ Hz, 1H), 3.42 - 3.37 (m, 2H), 2.45 - 2.00 (m, 4H), 1.65 (s, 6H), 1.62 (s, 9H), 1.37 (s, 9H) and 1.28 - 1.21 (m, 3H) ppm.

[00227] Example 29


[00228] Preparation of diBoc-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2*R*)-tetrahydrofuran-2-yl]-1*H*-benzimidazol-2-yl]urea dibenzyl phosphate (**29**).



[00229] To diBoc-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2*R*)-tetrahydrofuran-2-yl]-1*H*-benzimidazol-2-yl]urea (**28**) (1.13 g, 1.797 mmol) and tetrazole (251.8 mg, 3.594 mmol) at 23 °C under N₂ was added DCM (30 mL) followed by *N*-dibenzylphosphoryl-*N*-isopropyl-propan-2-amine (744.7 mg, 2.156 mmol). After stirring for 18 h, the reaction was cooled to 0 °C then treated with mCPBA (531.5 mg, 2.156 mmol). The reaction was stirred for 15 min at 0 °C, then for 30 min at 23 °C. The resulting solution was then partitioned between EtOAc and saturated aqueous sodium bicarbonate (300 mL each), the organic layer separated, then washed with 10% aqueous sodium bisulfite, saturated aqueous sodium bicarbonate and brine (300 mL each), then dried over magnesium sulfate filtered and concentrated. The residue was purified by MPLC using an ISCO COMBIFLASH brand flash chromatography purification system (80 g silica column) eluting with a 0-80% EtOAc in hexanes linear gradient over 20 column volumes at 60 mL/min flow rate. Desired product fractions were combined and evaporated to give diBoc-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2*R*)-tetrahydrofuran-2-yl]-1*H*-benzimidazol-2-yl]urea dibenzyl phosphate (**29**) (1.03 g, 1.159 mmol, 64.50%) as a clear, glassy oil. ESMS (*M* + 1) = 889.5; ¹H NMR (300.0 MHz, CDCl₃) δ 8.93 (d, *J* = 1.5 Hz, 2H), 8.31 (s, 1H), 8.04 (d, *J* = 6.4 Hz, 1H), 7.36 - 7.26 (m, 10H), 5.83 - 5.70 (m, 1H), 5.16 - 5.05 (m, 4H), 4.24 - 4.18 (m, 1H), 4.03 - 3.97 (m, 1H), 3.42 - 3.36 (m, 2H), 2.43 - 2.05 (m, 4H), 1.98 (s, 6H), 1.64 (s, 9H), 1.40 (s, 9H) and 1.26 (t, *J* = 7.2 Hz, 3H) ppm.

[00230] Example 30

[00231] Preparation of sodium (*R*)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl phosphate (**W**).



[00232] To a solution of diBoc-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2*R*)-tetrahydrofuran-2-yl]-1H-benzimidazol-2-yl]urea dibenzyl phosphate (**29**) (121 mg, 0.1361 mmol) in DCM (10 mL) at 23 °C was added TFA (5 mL). After 2 h, the reaction mixture was concentrated *in vacuo*. The residue was dissolved in MeOH (6 mL) and treated with approx 0.5 mL 2 M NH₃ in MeOH (to fully dissolve the material). The resulting solution was purified in 6 injections on preparative HPLC, reverse phase, Sunfire prep C18 OBD 5 μM column 19 × 100 mm; eluting with a 10-90% aq MeCN w/ 0.1% TFA buffer, linear gradient over 15 min at 20 mL/min flow rate. Fractions containing product were pooled and lyophilized. The resulting material was suspended in MeOH (3 mL), stirred at 23 °C for 30 min, then the precipitate was collected via filtration through a plastic frit. The resulting white solid was re-subjected to a MeOH slurry (3 mL), then collected via filtration to give 68 mg of white solid after drying. The white solid was treated with 0.10 M aq NaOH (2.68 mL, 2 equiv NaOH) to give a solution that was then passed through an Acrodisc CR 13 mm syringe filter with 0.45 μm PTFE membrane, flushing with water (2 mL). The resulting solution was treated with MeCN (3 mL), frozen and lyophilized to give sodium (*R*)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl phosphate (**W**) as a white powder. ESMS (*M* + 1) = 509.2; ¹H NMR (300 MHz, D₂O) δ 8.58 (s, 2H), 6.92 (d, *J* = 6.3 Hz, 1H), 5.13 (t, *J* = 7.5 Hz, 1H), 3.98 - 3.81 (m, 2H), 3.04 (q, *J* = 7.2 Hz, 2H), 2.26 (t, *J* = 5.7 Hz, 1H), 1.97 - 1.92 (m, 2H), 1.67 (s, 6H) and 1.01 (t, *J* = 7.2 Hz, 3H) ppm.

[00233] Example 31

[00234] Susceptibility Testing in Liquid Media

[00235] Compounds of this invention were tested for antimicrobial activity by susceptibility testing in liquid media. Such assays were performed within the guidelines of the latest CLSI document governing such practices: "M07-A8 Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard--Eighth Edition (2009)". Other publications such as "Antibiotics in Laboratory Medicine" (Edited by V. Lorian, Publishers Williams and Wilkins, 1996) provide essential practical techniques in laboratory antibiotic testing. The specific protocols used were as follows:

[00236] Protocol 4. MIC Determination Procedure for *Mycobacterium* species

[00237] Materials

[00238] Round bottom 96-well microtiter plates (Costar 3788) or similar

[00239] Film plate seals (PerkinElmer, TopSeal-A #6005250 or similar)

[00240] Middlebrook 7H10 broth with 0.2% glycerol

[00241] Middlebrook 7H10 agar with 0.2% glycerol

[00242] Middlebrook OADC Enrichment

[00243] Inoculum Preparation for *M. tuberculosis*:

1. Used prepared frozen *M. tuberculosis* stock stored at -70°C . *M. tuberculosis* was grown in 7H10 broth + 10% OADC, then frozen at a concentration of 100 Klett or 5×10^7 cfu/ml,
2. Prepared a 1:20 dilution by removal of 1 ml of the frozen stock and added it to 19 ml of 7H10 broth + 10% OADC (final concentration 2.5×10^6 cfu/ml).
3. From this dilution prepared a second 1:20 dilution, removed 1 ml and added it to 19 ml of fresh broth. This was the final inoculum to add to the 96-well plates.

[00244] Inoculum Preparation for *M. kansasii*, *M. avium*, *M. abscessus* and *Nocardia* spc.:

1. Used prepared frozen stock of culture or a fresh culture grown in 7H10 broth at a concentration of 10 Klett or 5×10^7 /ml.
2. Prepared a 1:20 dilution by removing 1.0 ml of the culture stock and added it to 19 ml of 7H10 broth (final concentration 2.5×10^6 cfu/ml).
3. From this dilution prepared a 1:20 dilution, removed 1 ml and added it to 19 ml of fresh broth (final suspension).

[00245] Plate Preparation:

1. Labeled plates.
2. Added 50 µl of 7H10 broth + 10% OADC to all wells being utilized for MIC determination using a multichannel electronic pipettor.
3. Prepared stock solutions of drugs (e.g. 1 mg/ml concentration) to be tested.
4. Thawed and diluted frozen stock solutions using 7H10 broth + 10% OADC to obtain a working solution 4x the maximum concentration tested (e.g. final concentration 32 µg/ml, highest concentration tested was 8 µg/ml). Dilutions were made from the stock solution. To start at a concentration of 1 µg/ml, the drugs were prepared at 4 µg/ml, so the starting concentration was 1 µg/ml. Removed 25 µl of the 1mg/ml stock and added to 6.2 ml of broth. All dilutions of drugs were done in broth.
5. Added 50 µl of the 4x working solution to the first well of the designated row. Continued for all compounds to be tested. Using a multichannel electronic pipettor, mixed 4X and serial diluted compounds through the 11th well. Discarded remaining 50 µl. Used the 12th well as the positive control.
6. Incubated plates at 37° C *M. tuberculosis* for ~18 days; *M. avium* and *M. kansasii* for ~7 days; *Nocardia* and *M. abscessus* for ~4 days; with film seals.
7. Read visually and recorded the results. The MIC was recorded as the lowest concentration of drug where no growth was observed (optical clarity in the well).

[00246] Protocol 5. Protocol for *Mycobacterium tuberculosis* Serum Shift MIC Assay

[00247] Materials and reagents:

[00248] Costar #3904 Black-sided, flat-bottom 96-well microtiter plates

[00249] Middlebrook 7H9 broth (BD271310) with 0.2% glycerol

[00250] Middlebrook OADC Enrichment

[00251] Fetal Bovine Serum

[00252] Catalase (Sigma C1345)

[00253] Dextrose

[00254] NaCl₂

[00255] BBL Prompt Inoculation System (Fisher b26306)

[00256] Agar plates (Middlebrook 7H11 with 0.2% glycerol and OADC enrichment) with bacteria streaked to single colonies

[00257] Sterile DMSO

[00258] Media prep:

1. For serum shifted MICs, three different media were required which all had a base of 7H9 + 0.2% glycerol. It was important that all media and supplements were sterilized prior to MICs.
2. Prepared all media below and inoculated as described in next section. Tested all compounds against Mtb using each media.
 - a. 7H9 + 0.2% glycerol + 10% OADC ("standard" MIC media).
 - b. 7H9 + 0.2% glycerol + 2 g/L dextrose + 0.85 g/L NaCl + 0.003 g/L catalase (0% FBS).
 - c. 2x 7H9 + 0.2% glycerol + 2 g/L dextrose + 0.85 g/L NaCl + 0.003 g/L catalase combined with equal volume Fetal Bovine Serum (50% FBS).

[00259] Inoculum prep:

1. Using BBL Prompt, picked 5-10 well-separated colonies and inoculated 1 ml sterile saline that came in the kit. Typically plates were two to three weeks of age when used for this assay due to the slow growth of this organism in culture.
2. Vortexed well, then sonicated in water bath for 30 sec providing a suspension of $\sim 10^8$ cells/ml. Actual density could be confirmed by plating out dilutions of this suspension.
3. Prepared inoculum in each of the three media formulations by diluting the BBL Prompt suspension 1/200 (for example: transferred 0.2 ml of cells to 40 ml of medium) to obtain a starting cell density of $\sim 10^6$ cells/ml.
4. Used 100 μ l cells ($\sim 5 \times 10^4$ cells) to inoculate each microtiter well containing 1 μ l of drug in DMSO (see below).

[00260] Drug dilutions, inoculation, MIC determination:

1. Control drug stocks Isoniazid and Novobiocin were prepared at 10 mM in 100% DMSO while Ciprofloxacin and Rifampin were prepared at 1 mM in 50% DMSO and 100% DMSO, respectively. Prepared dilutions- dispensed 100 μ L of the stock solution into the first column of a 96-well plate. Prepared 11-step, 2-fold serial dilutions across the row for each compound by transferring 50 μ l from column 1 into 50 μ l of DMSO in column 2. Continued to transfer 50 μ L from column 2 through column 11 while mixing and changing tips at each column. Left column 12 with DMSO only as a control.
2. Transferred 1 μ l of each dilution into an empty microtiter well prior to the addition of 100 μ l of cells. The starting concentration of Isoniazid and Novobiocin was 100 μ M after the dilution into medium + cells; the starting concentration of Ciprofloxacin and

Rifampin was 10 μ M after the dilution into medium + cells. Compound concentrations decreased in 2x steps moving across the rows of the microtiter plate.

All MICs were done in duplicate at each of the three medium conditions.

3. Test sets of compounds were typically at 10 mM and 50 μ L volume.
4. Used a multichannel pipettor, removed all of the volume from each column of the master plate and transferred into the first column of a new 96-well microtiter plate. Repeated for each column of compounds on master plate, transferring into column 1 of a new 96-well plate.
5. As described above for control compounds, generated 2-fold, 11-point dilutions of each compound using DMSO as diluent. In all cases, left column 12 as DMSO only for a control. Once all dilutions were complete, again transferred 1 μ L of each dilution into an empty microtiter well prior to the addition of 100 μ L of cells as done for the control compounds.
6. All wells were inoculated with 100 μ L of diluted cell suspension (see above).
7. After inoculum addition, mixed plates by gently tapping sides of plate.
8. Plates were incubated in a humidified 37°C chamber for 9 days.
9. At 9 days added 25 μ L 0.01% sterile resazurin to each well. Measured background fluorescence at Excitation 492 nm, Emission 595 nm and returned the plate to the incubator for another 24 hours.

[00261] After 24 hours the fluorescence of each well was measured at Excitation 492 nm, Emission 595 nm.

[00262] Percent inhibition by a given compound was calculated as follows: Percent inhibition = $100 - ([\text{well fluorescence} - \text{average background fluorescence}] / [\text{DMSO control} - \text{average background fluorescence}] \times 100)$. MICs were scored for all three medium conditions as the lowest compound concentration that inhibited resazurin reduction ('%-inhibition') signal $\geq 70\%$ at a given medium condition.

[00263] Table 7 shows the results of the MIC assay for selected compounds of this invention.

[00264] In Table 7 and in subsequent Tables and Examples, "Compound 12" corresponds to 1-ethyl-3-[5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2*R*)-tetrahydrofuran-2-yl]-1*H*-benzimidazol-2-yl]urea and "Compound 13" relates to the mesylate salt of Compound 12. Similarly, "Compound 23" corresponds to 1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-[(2*R*)-tetrahydrofuran-2-yl]-1*H*-benzimidazol-2-yl]urea and

“Compound 23A” relates to the mesylate salt of Compound 23. These are the same numbers used to identify said compounds and salts as used in the Examples above.

[00265] Table 7 – MIC Values of Selected Compounds

Strain/Special Condition	Protocol	MIC (µg/ml)	
		Compound 13	Compound 23A
<i>Mycobacterium avium</i> 103	4	0.47	0.18
<i>M. avium</i> Far	4	0.94	0.23
<i>M. avium</i> 3404.4	4	0.94	0.23
<i>M. kansasii</i> 303	4	Not Done	0.03
<i>M. kansasii</i> 316	4	Not Done	0.06
<i>M. kansasii</i> 379	4	Not Done	<0.015
<i>M. tuberculosis</i> H37Rv ATCC 25618	4	0.37	0.015
<i>M. tuberculosis</i> Erdman ATCC 35801	4	0.25	0.06
<i>M. tuberculosis</i> Erdman ATCC 35801	5	0.045	0.03
<i>M. tuberculosis</i> Erdman ATCC 35801 with Mouse Serum	5	2	0.5
<i>M. abscessus</i> BB2	4	Not Done	1
<i>M. abscessus</i> MC 6005	4	Not Done	1
<i>M. abscessus</i> MC 5931	4	Not Done	0.5
<i>M. abscessus</i> MC 5605	4	Not Done	1.5
<i>M. abscessus</i> MC 6025	4	Not Done	0.75
<i>M. abscessus</i> MC 5908	4	Not Done	1.5
<i>M. abscessus</i> BB3	4	Not Done	0.5
<i>M. abscessus</i> BB4	4	Not Done	2
<i>M. abscessus</i> BB5	4	Not Done	0.5
<i>M. abscessus</i> MC 5922	4	Not Done	0.25
<i>M. abscessus</i> MC 5960	4	Not Done	0.5
<i>M. abscessus</i> BB1	4	Not Done	2
<i>M. abscessus</i> MC 5812	4	Not Done	1
<i>M. abscessus</i> MC 5901	4	Not Done	1
<i>M. abscessus</i> BB6	4	Not Done	0.5
<i>M. abscessus</i> BB8	4	Not Done	0.5
<i>M. abscessus</i> MC 5908	4	Not Done	1
<i>M. abscessus</i> LT 949	4	Not Done	1
<i>M. abscessus</i> BB10	4	Not Done	0.015
<i>M. abscessus</i> MC 6142	4	Not Done	0.5
<i>M. abscessus</i> MC 6136	4	Not Done	0.5
<i>M. abscessus</i> MC 6111	4	Not Done	0.5

Strain/Special Condition	Protocol	MIC (µg/ml)	
		Compound 13	Compound 23A
<i>M. abscessus</i> MC 6153	4	Not Done	1

[00266] Example 32

[00267] Seven-Day Oral (Gavage) Toxicity and Toxicokinetics Study in Rats

[00268] The objectives of this study were: 1) to evaluate the potential toxicity of Compound 13 and Compound 23A when administered orally by gavage to male rats for 7 consecutive days and 2) to assess the toxicokinetics of Compound 13, and Compound 23A after the first and seventh doses.

[00269] Animals

[00270] Species, Source, History, and Justification

[00271] CrI:CD(SD) rats were obtained from Charles River Laboratories of Stone Ridge, NY. The animals were laboratory bred and experimentally naïve. Rats were chosen because they are a species that is commonly used for nonclinical toxicity evaluations.

[00272] Number, Sex, Age, and BodyWeightRange

[00273] Forty rats (20 noncannulated males and 20 males with jugular vein cannulas) were ordered. From these animals, 15 noncannulated males and 15 cannulated males were used. Animals were as uniform in age as possible. The rats were prepubertal to young adult, approximately 9 weeks of age at initiation of dosing. Their supplier-calculated birth date was retained in the study records. The weight range for the animals at the time of allocation to groups was 218.5-306.3 g.

[00274] Study Design

[00275] The rats were assigned as shown in the Table 8 below. Animals received the test article or vehicle by oral gavage for 7 consecutive days and were terminated the day following completion of dosing. The first day of dosing was designated as Day 1 of the study. The animals were evaluated for changes in clinical signs, body weight, and other parameters as described below.

Table 8 - Group Assignment and Dose Levels

Dose Group	No. Animals (M) Main Study	No. Animals (M) Toxicokinetics	Test Article	Dose Level (mg/kg/day)	Doses per Day	Dose Concentration (mg/mL)	Dose Volume (mL/kg)	Animals for Necropsy (Day 8)
A	3	0	Vehicle	0	1	0	10	3
B	3	3	Compound 13	100	1	10	10	6
C	3	3	Compound 13	200	1	20	10	6
D	3	3	Compound 23A	100	1	10	10	6
E	3	3	Compound 23A	300	2	30	10	6
F	0	3	Vehicle	0	2	0	10	3

[00276] Route/Dose

[00277] The vehicle and test article were administered by oral gavage once daily for 7 consecutive days at a dose volume of 10 mL/kg body weight for Group A and Groups B-D, respectively. The test article and vehicle were administered by oral gavage twice daily, approximately 8 hours apart, for 7 consecutive days at a dose volume of 10 mL/kg body weight for Group E and Group F, respectively. The actual volume administered to each animal was calculated and adjusted based on the most recent body weight of each animal.

[00278] **In-Life Observations and Measurements****[00279]** Observations

[00280] Animals were observed for viability at least once in the morning and once in the afternoon, at least 4 hours apart, throughout the study. During the treatment period, daily cageside observations were made and recorded predose and postdose (following the first dose only). The postdosing observations made during treatment occurred at the following times based on C_{max}/T_{max} for the two compounds from previous studies:

[00281] 1 hour postdose for Groups A-F.

[00282] One cageside observation was made on the day of necropsy.

[00283] Unscheduled Observations

[00284] Any findings observed at times other than scheduled observation times were to be recorded on an unscheduled observation or in Provantis; however, no abnormalities were observed throughout the study. Provantis is an electronic data collection, management and reporting system that is commonly used in the art.

[00285] Body Weights

[00286] Prior to start of dosing, body weights were measured for randomization on Day 1. During the treatment, body weights were measured on Day 1 and Day 7. In addition, fasted body weights were measured prior to necropsy for calculation of organ/body weight ratios.

[00287] Food Consumption

[00288] Throughout the study, food consumption was measured daily starting 3 days prior to start of dosing.

[00289] Clinical Pathology Evaluation

[00290] Blood samples for evaluation of hematology, coagulation, and serum chemistry parameters were collected from all animals from the retro-orbital plexus (under CO₂/O₂ anesthesia, for the main study animals) or jugular vein cannula (for the toxicokinetic animals) prior to necropsy. Due to residual heparin used to keep the cannulas patent for the toxicokinetic animals, coagulation samples from these rats, were not able to be analyzed. The animals were fasted overnight prior to blood collection. On the day of blood collection for clinical pathology analyses, the animals were not necropsied until after the blood was collected and the samples judged to be acceptable by the clinical pathology group.

[00291] Hematology

[00292] An appropriate amount of blood was collected in EDTA-containing tubes. The whole blood samples were analyzed for the parameters indicated below in Table 9.

Table 9– Whole Blood Parameters

Red blood cells (RBC) (count and morphology)	Mean corpuscular volume (MCV)
White blood cells (WBC) (total and differential)	Mean corpuscular hemoglobin (MCH)
Hemoglobin concentration (HGB)	Mean corpuscular hemoglobin concentration (MCHC)
Hematocrit (HCT)	Platelet count (PLAT)
Reticulocyte count (ABSRET)	Mean platelet volume (MPV)

[00293] Coagulation

[00294] An appropriate amount of blood was collected in tubes containing sodium citrate and then centrifuged to obtain plasma for the determination of prothrombin time (PT) and activated partial thromboplastin time (APTT).

[00295] Serum Chemistry

[00296] An appropriate amount of blood was collected in tubes without anticoagulant. The sample was allowed to clot and then was centrifuged to obtain serum. The serum was analyzed for the parameters indicated below in Table 10.

Table 10 – Serum Parameters

Sodium (NA)	Calcium (CA)
Potassium (K)	Inorganic phosphorus (PHOS)
Chloride (CL)	Glucose (GLU)
Total bilirubin (TBILI)	Urea nitrogen (BUN)
Alkaline phosphatase (ALKP)	Total protein (TPRO)
Lactate dehydrogenase (LDH)	Albumin (ALB)
Aspartate aminotransferase (AST)	Globulin (GLOB)
Alanine aminotransferase (ALT)	Albumin/globulin ratio (A/G)
Gamma-glutamyltransferase (GGT)	Cholesterol (CHOL)
Creatine phosphokinase (CK)	Triglycerides (TRIG)
Creatinine (CREA)	

[00297] Toxicokinetics

[00298] On the 1st and 7th day of dosing, blood samples (approximately 0.5 mL/sample) were collected from the jugular vein cannula for all toxicokinetic animals at the timepoints listed below into K₃EDTA-containing tubes. Toxicokinetic animals from the control group (Group F) only had a single blood collection sampling from each collection day at the 1-hour timepoint (following the first dose administration of the day). Prior to each collection, a small sample of blood (with heparin blocking solution) was removed from the cannula and discarded. A new syringe was placed on the cannula, and the protocol-required sample was taken. The syringe with the blood sample was removed, and a new syringe with saline attached to the cannula. Blood volume was replaced with an equal volume of saline and then blocking solution placed in the cannula. Each animal was returned to its cage until the next collection timepoint.

[00299] All samples collected during this study were placed in labeled containers. Each label contained the following information: 1) Study number, 2) Animal number, 3) collection interval, 4) Group and Sex, and 5) Date of collection.

[00300] The blood samples were mixed immediately by inverting, then placed on wet ice and centrifuged cold (~1500g, ~10 minutes, ~5 °C) to obtain plasma. The plasma was split into 96-well 1.4-mL polypropylene tubes with pierceable TPE capcluster certified RNase, DNase free caps as 2 aliquots and stored frozen (≤ -70 °C).

Table – 11 - Sample Collection Timepoints

Timepoint	Window¹
Predose	Predose
1 h	± 4 min
2 h ²	± 5 min
4 h	± 5 min
8 h ³	± 5 min
12 h	± 10 min
24 h	± 20 min
48 h ⁴	± 40 min

¹All samples were collected within the collection window.

²Following Day 1 dosing only.

³Obtained from Groups E and F prior to PM dose administration.

⁴Following Day 7 dosing only.

[00301] Termination

[00302] No animal was deemed moribund during the study. All study animals were euthanized and subjected to a necropsy following the protocol-prescribed number of days of treatment. All animals were terminated by exsanguination (severing the abdominal aorta while under deep CO₂/O₂ anesthesia).

[00303] Necropsy

[00304] A necropsy with tissue collection was conducted on all animals terminated during the study. The necropsy included examination of:

carcass and muscular/skeletal system; all external surfaces and orifices;

cranial cavity and external surface of the brain;

neck with associated organs and tissues; and

thoracic, abdominal, and pelvic cavities with their associated organs and tissues.

[00305] All abnormalities were described and recorded.

[00306] Organ Weights

[00307] For all animals euthanized at scheduled necropsies, the kidneys, liver, and prostate gland were weighed. Following weighing, an approximate 1 gram sample of liver and kidney

was weighed, transferred to Precellys 7 mL CK28 Tissue Homogenizing tubes (Cat. No. 0904-01), snap-frozen, and analyzed.

[00308] Organ/body ratios were calculated using the terminal fasted body weight obtained prior to necropsy.

[00309] Tissue Preservation and Bone Marrow Collection

[00310] The tissues and organs indicated below in Table 12 were collected from all animals and were preserved in 10% neutral-buffered formalin with the exception of the testes, epididymides, and eyes. Testes, epididymides, and eyes with optic nerve attached were fixed in Modified Davidson's Solution for ~24-48 hours, rinsed with water, and then transferred to 10% neutral-buffered formalin for storage.

Table 12 – Tissue Collection

Tissue	Submitted at Necropsy	Organ Weight	Histopathology
Animal ID	X		
Adrenal gland (2)	X		
Aorta	X		
Artery, mesenteric	X		
Bone (femur)	X		
Bone marrow (sternum)	X		
Brain	X		
Epididymides (2)	X		
Esophagus	X		
Eyes (2)	X		
Gross lesions	X		

Tissue	Submitted at Necropsy	Organ Weight	Histopathology
Heart	X		
Intestine, cecum	X		
Intestine, colon	X		
Intestine, duodenum	X		
Intestine, jejunum	X		
Intestine, ileum	X		
Intestine, rectum	X		
Kidneys (2)	X	X	X
Liver	X	X	X
Lungs	X		
Lymph node, mandibular	X		
Lymph node, mesenteric	X		
Mammary gland	X		
Nerve, optic	X		
Nerve, sciatic	X		
Parathyroid gland (2) ^a	X		
Pancreas	X		
Pituitary	X		
Prostate	X	X	X

Tissue	Submitted at Necropsy	Organ Weight	Histopathology
Seminal vesicles	X		
Skeletal muscle (<i>biceps femoris</i>)	X		
Skin (abdominal)	X		
Spinal cord, cervical	X		
Spinal cord, thoracic	X		
Spinal cord, lumbar	X		
Spleen	X		
Stomach	X		
Testes (2)	X		
Thymus	X		
Thyroid gland (2) ^a	X		
Tongue	X		
Trachea	X		
Urinary bladder	X		

^aThyroid weighed with parathyroids attached.

[00311] Histopathology

[00312] For all animals scheduled for the terminal necropsy, the kidneys, liver, and prostate were embedded in paraffin, sectioned and stained with hematoxylin and eosin for further examination by light microscopy. For Groups A, D, E, and F only, the remaining

tissues listed above were embedded in paraffin, sectioned and stained with hematoxylin and eosin for further examination by light microscopy.

[00313] Statistical Analysis

[00314] Where appropriate, numeric animal data were evaluated statistically.

[00315] For comparative statistics, Group A (control group) was compared to Groups B and C (treated groups, dosed QD) and Group F (control group, dosed BID) was compared to Group E (treated group, dosed BID). Data were evaluated using the Levene Test for homogeneity of variances and the Shapiro-Wilks Test for normality of distributions, with significance at $p \leq 0.05$. Data determined to be homogeneous and of normal distribution were evaluated by analysis of variance (ANOVA). If the ANOVA verified significance at $p \leq 0.05$, pairwise comparisons of each treated group with the respective control group were made using a parametric test (Dunnett Test) to identify statistical differences ($p \leq 0.05$). Data determined to be nonhomogeneous or of nonnormal distribution were evaluated using a Kruskal-Wallis Test for group factor significance. If significance ($p \leq 0.05$) existed between groups, a nonparametric test (Wilcoxon with Bonferroni-Holm), was used to compare treatment groups to the control group. Food consumption data from animals where spillage occurred was excluded from the applicable time period. Comparative statistics of food consumption data were limited to the Dunnett Test (parametric). Statistics were not performed on pretest food consumption (Day 4 to Day 1).

[00316] Results

[00317] The exposures for different dosage levels of Compound 23A and Compound 13 were dose related. No adverse observations or effects on mean body weight were observed in animals treated with either Compound 13 or Compound 23A. Mean food consumption was reduced during different intervals of the study for animals treated once daily with Compound 13 (100 or 200 mg/kg) and twice daily with Compound 23A (300 mg/kg). However, as the decreased food consumption was not correlated with body weight changes in the Compound 13 and Compound 23A groups, these effects were not considered to be adverse or biologically significant. The mean calcium ion concentration (CA) was statistically lower, while the mean ALT and the AST for the group of rats administered 300 mg/kg Compound 23A twice a day were statistically higher when compared to the controls treated twice a day. No test article-related histopathological findings were noted for animals receiving either Compound 13 or Compound 23A at any dose regimen.

[00318] Within the scope of this study and based on the absence of changes in body weight, clinical pathology, and histopathology, the NOEL (No-Observable-Effect-Level) for Compound 13 administered to male rats once a day for 7 days orally via gavage was 200 mg/kg (844 $\mu\text{g}\cdot\text{hr}/\text{ml}$ Day 7 AUC), while the NOEL for Compound 23A administered once a day was 100 mg/kg (82 $\mu\text{g}\cdot\text{hr}/\text{ml}$ AUC). The NOAEL (No-Observable-Adverse-Effect-Level) for Compound 23A administered to male rats twice a day for 7 days orally via gavage was 300 mg/kg (291 $\mu\text{g}\cdot\text{hr}/\text{ml}$ AUC).

[00319] Therefore, Compounds 13 and 23A did not demonstrate adverse toxicity within the scope of the study at dose levels up to 200 mg/kg/day and 600 mg/kg/day, respectively.

[00320] Example 33

[00321] An Oral Range Finding Toxicity and Toxicokinetic Study in Male Cynomolgus Monkeys

[00322] The objectives of this study were 1) to evaluate the potential toxicity of Compound 23 when administered orally by gavage to male Cynomolgus monkeys for 7 consecutive days; and 2) to assess the toxicokinetics of Compound 23 after the first and seventh doses.

[00323] Animals

[00324] Species, Source, History, and Justification

[00325] Cynomolgus monkeys (*Macaca Fascicularis*) were obtained from Primus Bio-Resources Inc. of PinCourt, Quebec, Canada. Cynomolgus monkeys were chosen because they are a non-rodent species that is commonly used for nonclinical toxicity evaluations.

[00326] Number, Sex, Age, and Body Weight Range

[00327] Eight (2 naïve and 6 non-naïve) males were used in the study. The animals were young adults and weighed between 2 to 4 kg at the onset of dosing.

[00328] Study Design

[00329] The animals were assigned as shown in Table 13 below. Animals received Compound 23 or vehicle by oral gavage once per day for 7 consecutive days and were terminated the day following completion of dosing. The first day of dosing was designated as Day 1 of the study. The actual volume administered to each animal was calculated and adjusted based on the most recent body weight of each animal.

Table 13 – Group Assignment and Dose Levels

Group	Dose Level (mg/kg)	Dose Concentration (mg/mL)	Dose Volume (mL/kg)	Number of animals
1	Control*	0	5	2
2	50	10	5	2
3	100	20	5	2
4	200	40	5	2

* The Control animals received the control/vehicle (20% captisol/1% HPMCAS/1%PVP in 0.01M KCl/HCL buffer) alone

[00330] In-Life Observations and Measurements

[00331] Observations

[00332] Cage-side clinical signs (ill health, behavioral changes etc.) were recorded at least once daily during the study.

[00333] Body Weights

[00334] Body weights were recorded for all animals prior to group assignment and on Days 1 (prior to dosing), 3 and 7 as well as terminally prior to necropsy (fasted).

[00335] Electrocardiography (ECG)

[00336] Electrocardiograms (bipolar limb leads I, II and III, and augmented unipolar leads aVR, aVL and aVF) were obtained for all monkeys once during the pre-treatment period and again on Day 7 (post-dosing).

[00337] The tracings were assessed for gross changes indicative of cardiac electrical dysfunction. The potential presence of abnormalities involving heart rate (lead II), sinus and atrioventricular rhythm or conductivity were determined. Heart rate, PR interval, QRS duration, QT and QTc intervals values were measured.

[00338] Toxicokinetics

[00339] A series of 7 blood samples (approximately 0.5 mL each) were collected from each monkey on Days 1 and 7 at the following time points: predose, 30 minutes and 2, 3, 6, 12 and 24 hours post-dose. For this purpose, each monkey was bled by venipuncture and the samples were collected into tubes containing the anticoagulant, K2EDTA. Tubes were placed on wet ice until ready for processing.

[00340] Clinical Pathology

[00341] Laboratory investigations (hematology, coagulation, clinical chemistry and urinalysis) were performed on all animals prior to start of treatment and prior to termination on Day 8.

[00342] Blood samples were collected by venipuncture following an overnight period of food deprivation consisting of at least 12 hours but no more than 20 hours. Urine was collected from animals deprived of food and water, overnight (at least 12 hours but no more than 20 hours).

[00343] Hematology

[00344] The following parameters were measured on blood samples collected into EDTA anticoagulant: red blood cell count, mean corpuscular hemoglobin (calculated), hematocrit (calculated), mean corpuscular volume, hemoglobin, morphology of cells, white blood cell count, platelet count, white blood cell differential (absolute), reticulocyte (absolute and percentage) and mean corpuscular hemoglobin concentration (calculated).

[00345] Coagulation

[00346] Activated partial thromboplastin time and prothrombin time were measured on blood samples collected into citrate anticoagulant.

[00347] Clinical Chemistry

[00348] The following parameters were measured on blood samples collected into tubes containing clotting activator: a/g ratio (calculated), creatinine, alanine aminotransferase, globulin (calculated), albumin, glucose, alkaline phosphatase, phosphorus (inorganic), aspartate aminotransferase, potassium, bilirubin (total), sodium, calcium, total protein, chloride, triglycerides, cholesterol (total), urea, gamma glutamyltransferase and sorbitol dehydrogenase.

[00349] Urinalysis

[00350] The following parameters were measured on urine samples: bilirubin, protein, blood, sediment microscopy, color and appearance, specific gravity, glucose, urobilinogen, ketones, volume and pH.

[00351] **Termination**

[00352] All animals were euthanized upon completion of the treatment period on Day 8 following an overnight period without food. The monkeys were pre-anesthetized with Ketamine and then euthanized by an intravenous overdose of sodium pentobarbital followed by exsanguination by transection of major blood vessels.

[00353] Necropsy

[00354] A necropsy with tissue collection was conducted on all animals terminated during the study. The necropsy included examination of:

- carcass and muscular/skeletal system;
- all external surfaces and orifices;

cranial cavity and external surface of the brain;
 neck with associated organs and tissues; and
 thoracic, abdominal, and pelvic cavities with their associated organs and tissues.

All abnormalities were described and recorded.

[00355] Tissue Preservation

[00356] On completion of the gross examination and selected organ weighing, the tissues and organs were retained as noted below in Table 14. Neutral buffered 10% formalin was used for fixation and preservation unless otherwise indicated.

Table 14. Tissue and Organ Retention

<i>ORGANS/TISSUES</i>	Retain(•)	Weigh (√)	Examine (€)	<i>ORGANS/TISSUES</i>	Retain(•)	Weigh (√)	Examine (€)
Adrenals	•	√	€	Pituitary	•	√	€
Animal identification	•			Prostate	•	√	€
Aorta (thoracic)	•		€	Rectum	•		€
Blood				Salivary Gland, mandibular	•		€
Bone marrow smears (3)	•			Sciatic nerve	•		€
Brain	•	√	€	Seminal vesicles	•		€
Cecum	•		€	Skeletal muscle	•		€
Colon	•		€	Skin & subcutis (thoracic)	•		€
Epididymides	•d		€	Duodenum	•		€
Esophagus	•		€	Jejunum	•		€
Eyes	•a		€	Ileum	•		€
Femur & marrow	•		€	Spinal Cord, cervical	•		€
Gallbladder	•		€	Spleen	•	√	€
Heart	•	√	€	Sternum & marrow	•		€
Kidneys	•	√	€	Stomach	•		€
Liver (2 lobes)	•	√	€	Testes	•d	√	€
Lungs (2 lobes)	•b	√c	€	Thymus	•	√	€
Lymph Node, mandibular	•		€	Thyroid gland/parathyroids	•	√	€
Lymph Node, mesenteric	•		€	Tongue	•		€
Mammary gland (thoracic)	•		€	Trachea	•c		€
Optic nerves	•a		€	Urinary bladder	•		€
Pancreas	•		€	Abnormal findings	•		
a	Davidson's fluid used for fixation and preservation						
b	Lungs were infused with 10% neutral buffered formalin used for fixation and preservation						
c	Lungs were weighed with trachea						
d	Bouin's fluid used for fixation and preservation						
e	Examined microscopically						

[00357] Histopathology

[00358] For all animals, all tissues indicated above were embedded in paraffin, sectioned and stained with hematoxylin and eosin and examined by light microscopy.

[00359] **Results**

[00360] The exposures for different dosage levels of Compound 23 were dose related.

[00361] There were no clinical signs, or changes in body weights, electrocardiography parameters, clinical pathology parameters, or organ weights that could be attributed to the administration of Compound 23 at doses up to 200 mg/kg/day. Similarly, there were no macroscopic or microscopic findings that could clearly be attributed to the administration of Compound 23 at doses up to 200 mg/kg/day. The no observed effect level (NOEL) for Compound 23 in male Cynomolgus monkeys was determined to be 200 mg/kg/day.

[00362] Example 34

[00363] **PHARMACOKINETIC STUDIES**

[00364] The pharmacokinetic parameters of selected compounds of this invention were determined in the experiments described below. General analytic procedures and specific experimental protocols were employed as follows:

[00365] General Analytic Procedures

[00366] The following general analytic procedures were employed in the pharmacokinetic experiments described below:

[00367] **Sample Analysis.** Concentrations of Compound 23 and Compound W in plasma were determined using a high performance liquid chromatography/tandem mass spectrometry (HPLC/MS/MS) method. Before extraction, plasma samples were diluted using blank plasma 2-, 4-, 5-, or 10-fold, as necessary, depending on the dose level or formulation. Compound 23 and Compound W along with the internal standard (IS) were extracted from (diluted) plasma, 100 μ L each, by direct protein precipitation with acetonitrile (1:4 ratio of plasma/acetonitrile). After centrifugation, the supernatant extract (10 μ L) was injected onto the LC/MS/MS system. The HPLC system included a Waters Xterra MS C18 column, 5 micron, 2.1 mm diameter x 50 mm long eluted with a gradient mobile phase consisting of 0.1% formic acid in water or in acetonitrile.

[00368] The analytes were detected by MS/MS with Atmospheric Pressure Chemical Ionization (APCI) in the mode of multiple reaction monitoring (MRM). The lower limit of quantitation (LLOQ) was 1, 2, 4, 5, 10, or 20 ng/mL, depending on the sample dilution factor. The linear range of the assay was from 1 to 5000 ng/mL. The intra-day and inter-day assay accuracy was within 2% of the nominal values. The intra- and inter-day assay variability was <10%.

[00369] Samples of the dose suspension formulation of Compound W were assayed with an HPLC/UV method after 10-fold to 500- or 1000-fold of dilution with

DMSO:acetonitrile:water (33:33:33) depending on the dose level or formulation. Samples of the dose solution formulation of Compound **W** were assayed with an HPLC/UV method after 10-, 50-, 100 or 500-fold of dilution with DMSO:water (50:50) depending on the dose level or formulation.

[00370] Pharmacokinetic Data Analysis. Plasma concentration-time profiles of Compound **23** and Compound **W** were analyzed by noncompartmental pharmacokinetic methods using WinNonlin® Professional Edition software, Version 5.1.1 (Pharsight Corporation, Mountain View, CA).

[00371] Key pharmacokinetic parameters including AUC_{all} , AUC_{extrap} , C_{max} , t_{max} , Cl_{obs} , $V_{ss_{obs}}$ and $t_{1/2}$ were determined.

[00372] Statistical Data Analysis. Descriptive statistical data of plasma concentrations and pharmacokinetic parameter estimates were calculated, including the mean, standard deviation (SD), and coefficient of variation (%CV) using WinNonlin software, Version 5.1.1 or Microsoft Excel 2000.

[00373] Monkey Oral Study

[00374] Male cynomolgus monkeys (n=3 per dose group) were administered single nominal PO doses of 3, 30 and 300 mg/kg of Compound **W** by gavage. Compound **W** was formulated in 0.5% MC (microcrystalline cellulose). Animals had free access to food and water before and after dosing.

[00375] Blood samples (approximately 0.25 mL each) were collected via a carotid artery catheter prior to dosing and at 0 (predose), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 hours post dose. Each blood sample was collected into a tube that was kept on wet ice and contained potassium EDTA as the anticoagulant. Plasma was separated and stored at approximately -70°C until analysis.

[00376] Plasma samples were analyzed using a liquid chromatography/tandem mass spectrometry (LC/MS/MS) method to determine the concentrations of Compound **23** and Compound **W** with a lower limit of quantitation (LLOQ) of 1 to 20 ng/mL, depending on the sample dilution factor. Plasma concentration vs. time data was subjected to noncompartmental pharmacokinetic (PK) analysis. The results of this analysis are provided in Table 15.

[00377] Table 15. Pharmacokinetic Data from Monkey Oral Study

Dose (mg/kg)	Route	Formulation	Analyte	C _{max} (ug/ml)	AUC (ug*hr/ml)	AUC _{extrap} (ug*hr/ml)	T _{max} (hr)	t _{1/2} (hr)
30	PO	0.5% MC	Compound 23	14.4	24.7	24.8	1.7	13.9
100	PO	0.5% MC	Compound 23	20.9	76.7	76.9	2.3	8.3
300	PO	0.5% MC	Compound 23	23.8	155.1	155	1.2	5.6
30	PO	0.5% MC	Compound W	0.0264	0.0453	0.206	0.83	—
100	PO	0.5% MC	Compound W	0.322	0.432	0.437	0.67	5.31
300	PO	0.5% MC	Compound W	4	3.69	3.76	0.58	13.15

[00378] Monkey IV Study

[00379] Male cynomolgus monkeys (n=3 per dose group) were administered a single nominal IV bolus dose of 1 mg/kg of Compound **W** via a jugular vein cannula. Compound **W** was formulated in D5W (5% dextrose in water solution). Animals had free access to food and water before and after dosing.

[00380] Blood samples (approximately 0.25 mL each) were collected via a carotid artery catheter prior to dosing and at 0 (predose), 5min, 10min, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48 hours postdose. Each blood sample was collected into a tube that was kept on wet ice and contained potassium EDTA as the anticoagulant. Plasma was separated and stored at approximately -70°C until analysis.

[00381] Plasma samples were analyzed using a liquid chromatography/tandem mass spectrometry (LC/MS/MS) method to determine the concentrations of Compound **23** and Compound **W**, with a lower limit of quantitation (LLOQ) of 1 to 20 ng/mL, depending on the sample dilution factor. Plasma concentration vs. time data were subjected to noncompartmental pharmacokinetic (PK) analysis. The results of this analysis are provided in Table 16.

[00382] Table 16. Pharmacokinetic Data from Monkey IV Study

Dose (mg/kg)	Route	Formulation	Analyte	C ₀ (ug/ml)	AUC (ug*hr/ml)	AUC _{extrap} (ug*hr/ml)	Cl (ml/min/kg)	t _{1/2} (hr)	V _{ss} (L/kg)
5	IV	D5W	Compound 23	10.9	3.78	3.81	23.4	6.17	2.09
5	IV	D5W	Compound W	62.4	5.79	5.83	18.2	5.35	1.88

[00383] Rat Oral Study

[00384] Groups of male Sprague Dawley rats (n=3 per dose group) were administered single nominal oral doses of 3, 10, 30, 300 mg/kg of Compound **W** by gavage. Compound **W** was formulated in either 0.5% MC (microcrystalline cellulose) or 20% Captisol, 1% HPMC-AS (hydroxypropyl methylcellulose acetyl succinate), 1% PVP (polyvinylpyrrolidone). Animals had free access to food and water before and after dosing. Blood samples (approximately 0.25 mL each) were collected via a carotid artery catheter prior to dosing and at 0 (predose), 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours post dose. Each blood sample was collected into a tube that was kept on wet ice and contained potassium EDTA as the anticoagulant. Plasma was separated and stored at approximately -70°C until analysis.

[00385] Plasma samples were analyzed using a liquid chromatography/tandem mass spectrometry (LC/MS/MS) method to determine the concentrations of Compound **23** and Compound **W** with a lower limit of quantitation (LLOQ) of 1 to 20 ng/mL, depending on the sample dilution factor. Plasma concentration vs. time data was subjected to noncompartmental pharmacokinetic (PK) analysis. The results of this analysis are provided in Table 17.

[00386] Table 17. Pharmacokinetic Data from Rat Oral Study

Dose (mg/kg)	Formulation	Analyte	C _{max} /C ₀ (ug/ml)	AUC (ug*hr/ml)	AUC _{extrap} (ug*hr/ml)	T _{max} (hr)	t _{1/2} (hr)
3	0.5% MC	Compound 23	0.117	0.311	0.314	0.58	4.06
30	0.5% MC	Compound 23	2.9	22.5	22.6	1.7	2.6
100	0.5% MC	Compound 23	6.6	77.1	77.4	2.5	2.7
300	0.5% MC	Compound 23	11.7	222.8	307.6	—	17.9
300	20% CAPT, 1% HPMC-AS, 1% PVP	Compound 23	16.2	294.6	—	5	—
3	0.5% MC	Compound W	—	—	—	—	—
30	0.5% MC	Compound W	0.022	0.178	0.058	3.3	3.1
100	0.5% MC	Compound W	0.021	0.061	0.066	0.8	7.2
300	0.5% MC	Compound W	2.33	0.324	0.464	1.2	11.3
300	20% CAPT, 1% HPMC-AS, 1% PVP	Compound W	0.6	2.37	4.27	1.8	—

[00387] Rat IV Study

[00388] Groups of male Sprague Dawley rats (n=3 per dose group) were administered single nominal IV bolus doses of 1 and 5 mg/kg of Compound **W** via a jugular vein cannula. Compound **W** was formulated in D5W. Animals had free access to food and water before and after dosing. Blood samples (approximately 0.25 mL each) were collected via a carotid artery catheter prior to dosing and at 0 (predose), 5min, 10min, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24hours post dose. Each blood sample was collected into a tube that was kept on wet ice and contained potassium EDTA as the anticoagulant. Plasma was separated and stored at approximately -70°C until analysis.

[00389] Plasma samples were analyzed using a liquid chromatography/tandem mass spectrometry (LC/MS/MS) method to determine the concentrations of Compound **23** and Compound **W** with a lower limit of quantitation (LLOQ) of 1 to 20 ng/mL, depending on the sample dilution factor. Plasma concentration vs. time data were subjected to noncompartmental pharmacokinetic (PK) analysis. The results of this analysis are provided in Table 18.

[00390] Table 18. Pharmacokinetic Data from Rat IV Study

Dose (mg/kg)	Formulation	Analyte	Cmax/C0 (ug/ml)	AUC (ug*hr/ml)	AUCextrap (ug*hr/ml)	t1/2 (hr)	Cl_obs (ml/min/kg)	Vss_obs (L/kg)
1	D5W	Compound 23	0.247	0.306	0.31	1.8	54.9	3.8
5	D5W	Compound 23	1.2	3.04	3.06	3.6	27.3	4.08
1	D5W	Compound W	4.8	0.416	0.419	0.9	46.7	0.38
5	D5W	Compound W	9.03	1.11	1.12	7.2	84.6	5.8

[00391] Mouse Oral Study

[00392] Groups of female CD-1 mice (n=3 per dose group) were administered single nominal oral doses of 10, 30, 100 mg/kg of Compound **W** by gavage. Compound **W** was formulated in 0.5% MC. Animals had free access to food and water before and after dosing. Blood samples (approximately 0.025 mL each) were collected from the sub-mandibular vein prior to dosing and at 0 (predose), 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24 hours postdose. Each blood sample was collected into a tube that was kept on wet ice and contained potassium EDTA as the anticoagulant. Plasma was separated and stored at approximately -70°C until analysis.

[00393] Plasma samples were analyzed using a liquid chromatography/tandem mass spectrometry (LC/MS/MS) method with a lower limit of quantitation (LLOQ) of 1 to 20 ng/mL, depending on the sample dilution factor. Plasma concentration vs. time data was subjected to noncompartmental pharmacokinetic (PK) analysis. The results of this analysis are provided in Table 19.

[00394] **Table 19.** Pharmacokinetic Data from Mouse Oral Study

Dose (mg/ kg)	Formulation	AUC (0-t) (µg*hr/mL)	Cmax (µg*hr/ ml)	Tmax (hr)
10	0.5% MC	1.7	1.2	0.3
30	0.5% MC	4.1	2.1	0.3
100	0.5% MC	26.6	9.1	0.4

[00395] The studies described above, demonstrate that Compound W is converted *in vivo* into Compound 23 in at least rats, dogs and monkeys.

[00396] Example 35

[00397] ENZYMOLOGY STUDIES

The enzyme inhibition activities of selected compounds of this invention were determined in the experiments described below:

[00398] DNA Gyrase ATPase Assay

[00399] The ATP hydrolysis activity of *S. aureus* DNA gyrase was measured by coupling the production of ADP through pyruvate kinase/lactate dehydrogenase to the oxidation of NADH. This method has been described previously (Tamura and Gellert, 1990, *J. Biol. Chem.*, 265, 21342).

[00400] ATPase assays were carried out at 30°C in buffered solutions containing 100 mM TRIS pH 7.6, 1.5 mM MgCl₂, 150 mM KCl. The coupling system contains final concentrations of 2.5 mM phosphoenol pyruvate, 200 µM nicotinamide adenine dinucleotide (NADH), 1 mM DTT, 30 ug/ml pyruvate kinase, and 10 ug/ml lactate dehydrogenase. The enzyme (90 nM final concentration) and a DMSO solution (3 % final concentration) of the selected compound were added. The reaction mixture was allowed to incubate for 10 minutes at 30°C. The reaction was initiated by the addition of ATP to a final concentration of 0.9 mM, and the rate of NADH disappearance was monitored at 340 nanometers over the course of 10 minutes. The K_i and IC₅₀ values were determined from rate versus concentration profiles.

[00401] Selected compounds of the present invention were found to inhibit *S. aureus* DNA gyrase. Table 20 shows the inhibitory activity of these compounds in the *S. aureus* DNA gyrase inhibition assay.

[00402] **Table 20.** Inhibition of *S. aureus* DNA Gyrase

Selected Compound	K _i (nM)	IC ₅₀ (nM)
Compound 23	9	
Compound W	< 9	54

[00403] **DNA Topo IV ATPase Assay**

[00404] The conversion of ATP to ADP by *S. aureus* TopoIV enzyme was coupled to the conversion of NADH to NAD⁺, and the progress of the reaction was measured by the change in absorbance at 340 nm. TopoIV (64 nM) was incubated with the selected compound (3% DMSO final) in buffer for 10 minutes at 30 °C. The buffer consisted of 100 mM Tris 7.5, 1.5 mM MgCl₂, 200 mM K•Glutamate, 2.5 mM phosphoenol pyruvate, 0.2 mM NADH, 1 mM DTT, 5 µg/mL linearized DNA, 50 µg/mL BSA, 30 µg/mL pyruvate kinase, and 10 µg/mL lactate dehydrogenase (LDH). The reaction was initiated with ATP, and rates were monitored continuously for 20 minutes at 30°C on a Molecular Devices SpectraMAX plate reader. The inhibition constant, K_i, and the IC₅₀ were determined from plots of rate vs. concentration of selected compound fit to the Morrison Equation for tight binding inhibitors.

[00405] Selected compounds of the present invention were found to inhibit *S. aureus* DNA Topo IV. Table 21 shows the inhibitory activity of these compounds in the *S. aureus* DNA gyrase inhibition assay.

[00406] **Table 21.** Inhibition of *S. aureus* DNA Topo IV

Selected Compound	K _i (nM)	IC ₅₀ (nM)
Compound 23	12	
Compound W	30	150

[00407] Example 36

[00408] AQUEOUS SOLUBILITY STUDY

[00409] The aqueous solubilities of compound **23** and compound **W** were determined according to the following procedure.

[00410] **Preparation of Samples.** Aqueous samples of each compound were prepared as follows. Compounds were weighed (20 – 30mg compound) in 4 ml clear vials prior to adding water (0.5mL) and stirring by magnetic stirrer. 1.0N HCl was added to the suspension to adjust the pH to the desired range. After stirring for 96 hours at room temperature, the suspension was filtered through a 0.22 micron filter (Millipore, Ultrafree centrifugal filters, Durapore PVDF 0.22µm, Cat# UFC30GVNB). The filtrate was collected and the pH measured with a pH meter. The filtrate containing compound **W** was diluted 10-fold to provide an appropriate concentration for HPLC analysis. The filtrate containing compound **23** did not require dilution.

[00411] **Preparation of Standard Solutions.** Standard solutions of each compound were prepared according to the following procedure. 1 to 2 mg of each compound was accurately weighed into a 10mL volumetric flask and either water (for compound **W**) or 1:1 methanol:0.1N HCl (for compound **23**) was added to completely dissolve the compounds. Sonication was performed for compound **23** to assist with the dissolution in 1:1 methanol:0.1N HCl. When all solids dissolved, additional solvent was added to adjust the volume of each solution to 10ml. The resulting solutions were thoroughly mixed to give the standard solutions of each compound. Each standard solution was then diluted with solvent by 2-fold, 10-fold, and 100-fold.

[00412] **Solubility Analysis.** Aliquots of each sample and each standard solution were analyzed by HPLC analysis (Agilent 1100, injection volume 10µL, wavelength 271nm, column XTerra® Phenyl 5µm, 4.6x50mm, Part No. 186001144, mobile phase: A: 0.1% TFA in water 0.1% TFA in AcN). Each standard solution was injected three times, and each of the samples was injected twice. Standard curves were obtained by plotting the average of the peak area from the HPLC versus the concentrations of the standard solutions (with appropriate corrections of the weights of the standards based on total water content of the solid as determined by elemental analysis). The concentration of each sample was calculated from the peak area of the aqueous sample from the HPLC results and the slope and intercept of the standard curves. The solubility values listed in Table 22 below were derived from the product of the concentration of the sample and the dilution factor of the sample.

Table 22. Aqueous Solubility of Compounds 23 and W

Compound	Solid form	pH	Solubility (mg/mL)
Compound 23	crystalline	> 3.0	< 0.001
Compound W	crystalline	4.39	0.25

[00413] Example 37

[00414] IN VIVO METABOLISM STUDY IN HEPATIC AND LIVER S9 CELLS

[00415] The conversion of Compound W to Compound 23 was studied in liver and intestinal S9 fractions from rats, dogs, monkeys and humans. Compound W was incubated at 0.1, 0.3, 1, 3, 10, 20, 40, 100, 200, 300 μ M in liver S9 fractions and at 1, 3, 10, 20, 100, 300, 500, 1000 μ M in intestinal S9 fractions. The incubations were done for 0, 5, 10, 15, 30, 45 or 60 minutes. The formation of Compound 23 was quantified by LC/MS-MS and data were fitted to the Michaelis Menten equation. The data in Table 23 below indicates that Compound W rapidly converts to Compound 23 in these hepatic and intestinal S9 fractions.

[00416] **Table 23.** Velocity of formation (V_{MAX}) of Compound 23 from Compound W in Liver and Intestinal S9

	V_{MAX} (liver) (pmoles/min/mg)	V_{MAX} (intestine) (pmoles/min/mg)
Dog	19.3	1162
Monkey	25.2	1974
Rat	45.5	958
Human	45.8	ND*

*ND: Parameters not determined, rate of formation did not saturate

[00417] Example 38

[00418] **Mouse *M. tuberculosis* (Erdman) Lung Infection Model)**

[00419] Animals: female Balb/c mice (5–7 weeks of age; 6/group) were obtained from Jackson Laboratories (Bar Harbor, ME) and were housed and maintained in a biosecurity level 3 (BSL3) facility in accordance with the *Guide to the Care and Use of Experimental Animals*.

[00420] **Bacterial strain and stocks**

[00421] *M. tuberculosis* ATCC 35801 (strain Erdman) was obtained from the ATCC (Manassas, VA, USA). The organism was grown in 20 tubes of modified 7H10 broth (pH 6.6; 7H10 agar formulation with agar and malachite green omitted) with 10% OADC (oleic acid, albumin, dextrose, catalase) enrichment (BBL Microbiology Systems, Cockeysville, MD, USA) and 0.05% Tween 80 for 5–10 days on a rotary shaker at 37°C. The cultures were

pooled and diluted to 100 Klett units [equivalent to 5×10^7 colony forming units (cfu)/mL] (Photoelectric Colorimeter; Manostat Corp., New York, NY, USA). The culture was aliquotted and frozen at -70°C . On the day of infection, the culture was thawed and the final inoculum was determined. The final inoculum size was determined by diluting to 5×10^{-2} and plating 0.1 mL, in triplicate, on 7H10 agar plates (BBL Microbiology Systems) supplemented with 10% OADC enrichment. The plates were incubated at 37°C in ambient air for 4 weeks.

[00422] Mouse *M. tuberculosis* (Erdman) infection model

[00423] For intranasal infection, groups of mice were anaesthetized by intramuscular delivery of a telazol (45 mg/kg)/xylazine (7.5 mg/kg) cocktail (Lederle Parenterals, Carolina, Puerto Rico and Bayer Corp., Shawnee Mission, KS, USA, respectively) and subsequently infected intranasally with $\sim 10^2$ viable *M. tuberculosis* in a 20 μL volume. The timetable for the experiment was as follows: on study day 0, intranasal infection and then on study day 24, early controls were sacrificed for lung burden determination and treatment was started. 28 days post initiation of treatment (52 days post infection) all treated mice and late controls were sacrificed for lung burden determination.

[00424] For bacterial load determination mice were sacrificed by CO_2 asphyxiation. Right lungs were aseptically removed and ground in a sealed tissue homogenizer (IdeaWorks! Laboratory Devices, Syracuse, NY, USA). The number of viable organisms was determined by serial dilution and titration on 7H10 agar plates. Plates were incubated at 37°C in ambient air for 4 weeks prior to counting.

Table 23a. Compound 23A Reduces *M. Tuberculosis* Burdens in the Mouse *M. Tuberculosis* 28 Day Lung Infection Model

Treatment Group	Average Lung Burden (Log cfu/lungs)	Log Reduction vs. Early Control	Log Reduction vs. Late Control
Early Control	4.98		
Late Control (10 mL/Kg Vehicle)	5.20	-0.22	
10 mg/kg BID Compound 23A	5.08	-0.10	0.13
30 mg/kg BID Compound 23A	4.11	0.86	1.09
100 mg/kg BID Compound 23A	3.22	1.76	1.98
100 mg/kg QD Moxifloxacin	2.94	2.04	2.26

[00425] Balb/c mice (6/group) were challenged IN (intranasally) with *M. tuberculosis* (Erdman; ATCC) at 1×10^2 cfu/mouse. After 24 days, a single group of mice (Early Control (EC)) was euthanized and the lungs harvested, homogenized and plated to quantitate *M. tuberculosis* burdens. The additional groups of infected mice were treated via oral gavage with Vehicle at 10 ml/kg (10% VitE-TPGS; Late Control, LC) or with Compound 23A administered at 10, 30, or 100 mg/kg BID for 28 days. An additional control group was treated with Moxifloxacin administered at 100 mg/kg QD. After 28 days of treatment, the groups were euthanized and the lungs harvested, homogenized and plated to quantitate *M. tuberculosis* burdens. Burdens from the right lung for each mouse and the median for each group of mice were recorded and summarized above in Table 23a.

[00426] Results: In summary and as shown above in Table 23a, twice daily oral dosing of Compound 23A exhibited *in vivo* efficacy against an experimentally induced lung *M. tuberculosis* infection in Balb/c mice. 28 days of treatment with compound 23A at 30 or 100 mg/kg provided reductions in lung burden vs early controls. In addition, Moxifloxacin provided lung burden reduction compared to vehicle treated controls. Compound 23A demonstrated dose-dependent reductions of 0.13, 1.09 and 1.98 log reductions versus vehicle control (Late) when administered at 10, 30, and 100 mg/kg. In addition, doses of 30 and 100 mg/kg of Compound 23A reduced bacterial burdens versus the early control by 0.7-1.5 logs suggesting Compound 23A has bactericidal activity. The potent anti-tuberculosis drug Moxifloxacin at 100 mg/kg QD provided lung burden reduction versus the early and late controls as previously published. The reductions were similar to those provided by Compound 23A administered at 100 mg/kg indicating that compound 23A has bactericidal activity against *M. tuberculosis*.

Table 23b. Compound W Reduces *M. Tuberculosis* Burdens in the Mouse *M. Tuberculosis* 28 Day Lung Infection Model

Treatment Group	Median Lung Burden (Log cfu/lungs)	Log Reduction vs. Early Control	Log Reduction vs. Late Control
Early Control	4.98		
Late Control	4.36	0.62	
10 mg/kg BID Compound W	4.34	0.64	0.02
30 mg/kg BID Compound W	3.00	1.98	1.36

100 mg/kg BID Compound W	2.35	2.63	2.01
100 mg/kg QD Moxifloxacin	2.94	2.04	1.42

[00427] Balb/c mice (6/group) were challenged IN (intranasally) with *M. tuberculosis* (Erdman; ATCC) at 1×10^2 cfu/mouse. After 24 days, a single group of mice (Early Control (EC)) was euthanized and the lungs harvested, homogenized and plated to quantitate *M. tuberculosis* burdens. The additional groups of infected mice were treated via oral gavage with Vehicle at 10 ml/kg (10% VitE-TPGS; Late Control, LC) or with Compound W administered at 10, 30, or 100 mg/kg BID for 28 days. An additional control group was treated with Moxifloxacin administered at 100 mg/kg QD. After 28 days of treatment the groups were euthanized and the lungs harvested, homogenized and plated to quantitate *M. tuberculosis* burdens. Burdens from the right lung for each mouse and the median for each group of mice were recorded and summarized above in Table 23b.

[00428] Results: In summary, and as shown above in Table 23b, Compound W exhibited robust *in vivo* efficacy against an experimentally induced *M. tuberculosis* lung infection in Balb/c mice. After 28 days of treatments at 30 and 100 mg/kg BID there were decreases in bacterial density compared to early and time-matched vehicle controls. Compound W demonstrated dose-dependent reductions of 0.2, 1.36 and 2.02 log reductions versus vehicle control when administered at 10, 30 and 100 mg/kg. In addition, doses of 10, 30, and 100 mg/kg BID of Compound W reduced bacterial burdens versus the early control by 0.64-2.63 logs suggesting Compound W has bactericidal activity against *M. tuberculosis*. The potent anti-tuberculosis drug Moxifloxacin, at 100 mg/kg QD, provided lung burden reduction versus the early and late controls as previously published. The reductions were less than those provided by Compound W administered at 100 mg/kg and similar to those at 30 mg/kg BID Compound W indicating that compound W exhibits anti-tuberculosis activity on par or better than Moxifloxacin in this assay.

[00429] Example 39

[00430] In vitro drug combination studies

[00431] To evaluate additional potential 2-drug combinations, these are compared first in an *in vitro* checkerboard experiments performed either in complete 7H9 broth or in whole blood inoculated with *M. tuberculosis* H37Rv in log phase growth. Concentrations of 0, 0.25x MIC, MIC, 4x MIC and (if clinically relevant) 16x MIC are tested for each compound.

Pyrazinamide combinations may also be examined at pH 6.0, where its MIC is 50 µg/ml. For combinations with promising results, a similar checkerboard may be performed against nutrient-starved *M. tuberculosis* in PBS, to gain insight into the combination's activity against non-replicating organisms. Duplicate wells will be used for each concentration pair. Activity will be assessed by quantitative CFU counts performed after 0 and 7 days of incubation. Samples will be washed with PBS prior to plating.

[00432] Example 40

[00433] **In vitro drug combination studies using the whole blood assay**

[00434] The activity of selected 2-drug combinations against intracellular bacilli is also compared in a whole blood culture assay in which blood from healthy volunteers is inoculated with an aliquot of *M. tuberculosis* and increasing concentrations of drug in a checkerboard fashion similar to that described above. Drug concentrations of 0, 0.25x MIC, MIC, 4x MIC and (if clinically relevant) 16x MIC is tested for each drug. Viable CFU counts are estimated after 0 and 3 days of incubation by washing the cells, osmotically lysing them, inoculating the lysate into MGIT liquid culture bottles and incubating on the cultures on the MGIT system, where the time-to-positivity results are applied to a standard curve to estimate the change in log CFU for treatment groups compared to pre-treatment and drug-free controls.

[00435] Example 41

[00436] **In vitro drug combination studies using the hollow fiber cartridge system**

The hollow fiber cartridge system (HFS) is purchased from FiberCell (Frederick, MD) and is used for the measurement of bactericidal and sterilizing activity for drug combinations. The peripheral compartments of HFS is inoculated with 7.5 log₁₀ CFU of *M. tuberculosis* in log-phase growth and is incubated at 37°C under 5% CO₂. The peripheral compartment of each HFS is sampled on days 0, 7, 14, 21, and 28 and samples are washed twice with normal saline to remove any drug carryover. The bacterial cultures are inoculated on Middlebrook 7H10 agar supplemented with 10% OADC to enumerate the total bacillary population as well as on agar supplemented with either drug or experimental compound to determine the resistant subpopulations.

[00437] Drugs and experimental compounds are administered to the central compartment of each HFS via a computer-controlled syringe pump. For pharmacokinetic matching, drugs and experimental compounds are administered at the same time to achieve a

peak concentration of both isoniazid and rifampin at 1 h. The central compartments of the HFSs are sampled 12 times during the first 48 h and drug and experimental compound concentrations are then measured.

[00438] The results of the bactericidal-effect experiments are useful in the design of experiments for measuring sterilizing effect. Pharmacokinetic and statistical analysis uses the ADAPT 5 program, which has the maximum-likelihood solution via the expectation maximization algorithm. A one-compartment model with first-order input and elimination is utilized and a two-way analysis of variance (ANOVA) with Bonferroni posttest correction is used to compare bacterial burden from triplicate HFSs at each time point in GraphPad Prism version 5.00 (GraphPad Software, CA).

[00439] Example 42

[00440] In vivo Mouse *M. tuberculosis* (Erdman) Lung Infection Model

Animals: female BALB/c mice (5–7 weeks of age; 6/group), are obtained from Jackson Laboratories, (Bar Harbor, ME) and are housed and maintained in a BSL3 facility in accordance with the *Guide to the Care and Use of Experimental Animals*.

[00441] Bacterial strain and stocks

[00442] *M. tuberculosis* ATCC 35801 (strain Erdman) is obtained from the ATCC (Manassas, VA, USA). The organism is grown in 20 tubes of modified 7H10 broth (pH 6.6; 7H10 agar formulation with agar and malachite green omitted) with 10% OADC (oleic acid, albumin, dextrose, catalase) enrichment (BBL Microbiology Systems, Cockeysville, MD, USA) and 0.05% Tween 80 for 5–10 days on a rotary shaker at 37°C. The cultures are pooled and diluted to 100 Klett units [equivalent to 5×10^7 colony forming units (cfu)/mL] (Photoelectric Colorimeter; Manostat Corp., New York, NY, USA). The culture is aliquotted and frozen at -70°C . On the day of infection, the culture is thawed and the final inoculum is determined. The final inoculum size is determined by diluting to 5×10^{-2} and plating 0.1 mL, in triplicate, on 7H10 agar plates (BBL Microbiology Systems) supplemented with 10% OADC enrichment. The plates are incubated at 37°C in ambient air for 4 weeks.

[00443] Mouse *M. tuberculosis* (Erdman) infection model

[00444] Intranasal infection groups of mice were anaesthetized by intramuscular delivery of a telazol (45 mg/kg)/xylazine (7.5 mg/kg) cocktail (Lederle Parenterals, Carolina, Puerto Rico and Bayer Corp., Shawnee Mission, KS, USA, respectively) and subsequently infected intranasally with $\sim 10^2$ viable *M. tuberculosis* in a 20 μL volume. The timetable for the experiment was as follows: day 0, intranasal infection; on study day 24 early controls

were sacrificed for lung burden determination and treatment is started. 56 days post initiation of treatment and 80 days post infection, one group of treated mice and late controls were sacrificed for lung burden determination (end of treatment phase). A second group of mice and late controls were sacrificed for lung burden determination 112 days post initiation of treatment (136 days post infection; observation phase).

[00445] For bacterial load determination mice were sacrificed by CO₂ asphyxiation. Right lungs were aseptically removed and ground in a sealed tissue homogenizer (IdeaWorks! Laboratory Devices, Syracuse, NY, USA). The number of viable organisms was determined by serial dilution and titration on 7H10 agar plates. Plates were incubated at 37°C in ambient air for 4 to 6 weeks prior to counting.

[00446] Groups for three compound combination studies:

[00447] Early Controls

[00448] Late Controls

[00449] TMC-207 25mg/kg + pyrazinamide 150mg/kg + Rifapentine 10mg/kg

[00450] TMC-207 25mg/kg + Compound W 100mg/kg + pyrazinamide 150mg/kg

[00451] TMC-207 25mg/kg + Moxifloxacin 100mg/kg + pyrazinamide 150mg/kg

[00452] Compound W 100 mg/kg + Rifapentine 10mg/kg + pyrazinamide 150mg/kg

[00453] Moxifloxacin 100mg/kg + Rifapentine 10mg/kg + pyrazinamide 150mg/kg

[00454] Compound W 100 mg/kg + Moxifloxacin 100mg/kg + pyrazinamide 150mg/kg

[00455] Compound W 100 mg/kg + linezolid 100mg/kg + pyrazinamide 150mg/kg

[00456] Compound W 100 mg/kg + PA-824 100mg/kg + pyrazinamide 150mg/kg

[00457] Compound W 100 mg/kg + clofazimine 20mg/kg + pyrazinamide 150mg/kg

[00458] **Formulation preparation:**

[00459] Group #3: TMC-207 was formulated in 20% Hydroxypropyl-B-Cyclodextrin and treatment occurred in the morning. In the afternoon, (minimum of 2 hrs between dosing) all other compounds were combined for the groups of mice in one tube and dissolved by first adding 50% polyethylene glycol until dissolved and then adding 50% double distilled H₂O.

[00460] **Table 24.** Combination Experiment 1. Sterilizing potency of Compound W in a TB infection model when used in combination with known antibiotics against TB.

Bacterial load by CFU *in vivo* against Mtb Erdman in eight week model is listed below for both the end of treatment phase and the observation phase.

Compounds	End of Treatment Phase	Observation Phase
-----------	------------------------	-------------------

Early Control	4.2	4.2
Late Control	4.5	4.2
Rifapentine, TMC-207, pyrazinamide	0	0
Moxifloxacin, TMC-207, pyrazinamide	0	0
Compound W, TMC-207, pyrazinamide	0	0
Moxifloxacin, Rifapentine, pyrazinamide	0	0
Compound W, Rifapentine, pyrazinamide	0	0

[00461] **Table 25.** Combination Experiment 2. Sterilizing potency of Compound W in TB infection model when used in combination with known antibiotics against TB. Bacterial load by CFU *in vivo* combinations against Mtb Erdman in eight week model .

Compounds	End of Treatment Phase
Early Control	5.7
Late Control	5.6
Isoniazid, Rifapentine, pyrazinamide	0
Compound W, Moxifloxacin, Pyrazinamide	0
Compound W, Moxifloxacin, Rifapentine	0
Compound W, Linezolid, Pyrazinamide	0
Compound W, PA-824, Pyrazinamide	0
Compound W, Clofazimine, Pyrazinamide	1.7

[00462] Results: In summary, and as shown above in Tables 24 & 25, Compound W exhibited *in vivo* efficacy against an experimentally induced *M. tuberculosis* lung infection in BALB/c mice. After 56 days of treatments at 100 mg/kg BID, the tuberculosis infection was sterilized compared to early and time-matched vehicle controls, suggesting that Compound W has bactericidal activity against *M. tuberculosis*.

[00463] BALB/c mice (6/group) are challenged IN with *M. tuberculosis* (Erdman; ATCC) at a dose of 1×10^2 cfu/mouse. After 24 days a single group of mice (Early Control (EC)) is euthanized and the lungs harvested, homogenized and plated to quantify *M. tuberculosis* burdens. Compounds are administered at 10, 30, or 100 mg/kg BID for 28 days. After 28 days of treatment the groups are euthanized and the lungs harvested, homogenized and plated to quantify *M. tuberculosis* burdens.

[00464] References

[00465] Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Ejim L, Farha MA, Falconer SB, Wildenhain J, Coombes BK, Tyers M, Brown ED, Wright GD. Nat Chem Biol. 2011 Jun;7(6):348-50.

[00466] Selection of a moxifloxacin dose that suppresses drug resistance in *Mycobacterium tuberculosis*, by use of an *in vitro* pharmacodynamic infection model and

mathematical modeling. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL. J Infect Dis. 2004 Nov 1;190(9):1642-51.

[00467] Pharmacokinetics and whole-blood bactericidal activity against *Mycobacterium tuberculosis* of single doses of PNU-100480 in healthy volunteers. Wallis RS, Jakubiec WM, Kumar V, Silvia AM, Paige D, Dimitrova D, Li X, Ladutko L, Campbell S, Friedland G, Mitton-Fry M, Miller PF. J Infect Dis. 2010 Sep 1;202(5):745-51.

[00468] Example 43

[00469] **Evaluation of the Anti-Tuberculosis Activity of Compounds in Mice**

[00470] PHASE 1 – Evaluation of Compounds as Monotherapy Against Established TB in Mice

[00471] Methods

[00472] The experimental scheme is presented in Table 26. BALB/c mice were infected with ~100 CFU of virulent *M. tuberculosis* H37Rv in order to produce a stable infection with *M. tuberculosis* of ~10⁶ organisms in the lung at the initiation of treatment 5 weeks later (Day 0 or D0). Drugs were prepared in an appropriate vehicle. Treatment was administered daily, 5 days per week, by esophageal gavage unless subcutaneous injection was required. Outcomes were lung CFU counts after 4 weeks of treatment. Quantitative cultures of lung samples were performed in duplicate on OADC-enriched 7H11 agar medium. Group mean differences in lung CFU counts were compared using one-way ANOVA with Dunnett's post-test (GraphPad Prism 4) to adjust for multiple comparisons.

[00473] Explanation of treatment groups

[00474] **Untreated:** This was the negative control group. Five mice were sacrificed the day after *M. tuberculosis* infection (D-34) and on the day of treatment initiation (D0) to determine the number of bacilli implanted and the extent of multiplication from D-35 to D0, respectively. Additional mice were sacrificed 4 weeks for microbiological characterization of the natural history of infection.

[00475] **Isoniazid (INH):** mice in this control group received this first-line drug known for its strong bactericidal activity against actively multiplying organisms but reduced activity against non-actively multiplying organisms.

[00476] **Rifampin (RIF):** mice in this control group received this first-line drug known for its strong bactericidal activity against non-actively multiplying organisms.

[00477] Pyrazinamide (PZA): mice in this control group received this first-line drug known for its strong but slow bactericidal activity against actively replicating organisms under slightly acidic environmental conditions.

[00478] Test compound W (W): mice in this group received compound W ("W") at one of 3 doses.

[00479] Table 26. Experimental scheme for dose-ranging activity study

Regimen [dose(mg/kg)]	No. of mice killed by time point			
	D-34	D0	Wk 4	Total
Untreated	5	5	5	15
INH (10)			5	5
RIF (10)			5	5
PZA (150)			5	5
W (10)			5	5
W (30)			5	5
W (100)			5	5
Total	5	5	35	45

[00480] Table 27. *In vivo* activity of compound W against *M. tuberculosis* H37Rv

Sample (conc.)	Log cfu	Log Reduction
Untreated Control	6.00	N/A
Isoniazid control (10 mg/kg)	5.01	0.99
Rifampin control (10 mg/kg)	4.38	1.62
Pyrazinamide control (150 mg/kg)	4.22	1.78
Compound W (10 mg/kg)	6.38	0
Compound W (30 mg/kg)	5.51	0.49
Compound W (100 mg/kg)	5.35	0.65

[00481] Results

[00482] In this model, we found that Compound W had dose-dependent activity that, at 30 and 100 mg/kg, was superior to no treatment ($p < 0.01$ by one-way ANOVA with Dunnett's post-test).

[00483] The experiment will also include a PK study to determine the 24-hour serum and lung PK profile for each test compound and dose in infected mice during the 2nd week of treatment. Mice will be sacrificed according to the scheme in Table 28, around the dose administered on Wednesday or Thursday during the 2nd week of treatment. Three mice will be sacrificed for each drug and dose at the indicated time points before and after drug administration. At the time of sacrifice, mice will be anesthetized with isoflurane, using the

drop method, and exsanguinated by cardiac puncture. Serum will be harvested and frozen at -80°C. The right lung will be harvested, homogenized thoroughly and frozen at -80°C.

Table 28. Scheme for serum and lung PK sub-study

No of mice killed by time point						
0h	0.5h	1h	2h	4h	8h	Total
3	3	3	3	3	3	18

[00484] To perform serum and lung PK for all 3 doses of both drugs, a total of 108 mice will be required.

[00485] PHASE 2 – Evaluation of Compound Activity in Combination with Existing TB Drugs

[00486] 1) Experiment to identify the best companion drugs for the test compounds

[00487] The interaction of Compounds A and/or B with existing TB drugs will be evaluated first in 2 *in vitro* models to inform the design of long-term combination therapy studies with 3- and/or 4-drug combinations that utilize relapse rate as the measure for stable cure and thereby promote the most efficient use of limited resources.

[00488] Methods

[00489] *In vitro* checkerboard assay

[00490] Potential 2-drug combinations will be compared first in *in vitro* checkerboard experiments performed either in complete 7H9 broth or in whole blood inoculated with *M. tuberculosis* H37Rv in log phase growth. Drug concentrations of 0, 0.25x MIC, MIC, 4x MIC and (if clinically relevant) 16x MIC will be tested for each drug. PZA will be evaluated at normal pH, where its MIC against *M. tuberculosis* H37Rv is 250 µg/ml. It may also be examined at pH 6.0, where its MIC is 50 µg/ml. For combinations with promising results, a similar checkerboard may be performed against nutrient-starved *M. tuberculosis* in PBS, to gain insight into the combination's activity against non-replicating organisms.

[00491] A sample experimental scheme for a checkerboard experiment is presented in Table 29. Duplicate wells will be used for each concentration pair. Activity will be assessed by quantitative CFU counts performed after 0 and 7 days of incubation. Samples will be washed with PBS prior to plating.

[00492] *In vitro* whole blood assay

[00493] Activity of selected 2-drug combinations against intracellular bacilli will be compared in a whole blood culture assay in which blood from healthy volunteers is

inoculated with an aliquot of *M. tuberculosis* and increasing concentrations of drug in a checkerboard fashion similar to that described above. Drug concentrations of 0, 0.25x MIC, MIC, 4x MIC and (if clinically relevant) 16x MIC will be tested for each drug, as depicted in Table 29. Viable CFU counts are estimated after 0 and 3 days of incubation by washing the cells, osmotically lysing them, inoculating the lysate into MGIT liquid culture bottles and incubating on the cultures on the MGIT system, where the time-to-positivity results are applied to a standard curve to estimate the change in log CFU for treatment groups compared to pre-treatment and drug-free controls.

[00494] Rationale for drugs to be tested

[00495] **Isoniazid (INH):** first-line drug known for its strong bactericidal activity against actively multiplying organisms but reduced activity against non-actively multiplying organisms.

[00496] **Rifampin (RIF):** first-line drug known for its moderate activity against actively multiplying organisms, but strong bactericidal activity against non-actively multiplying organisms (sterilizing activity).

[00497] **Pyrazinamide (PZA):** first-line drug known for having pH-dependent activity against *M. tuberculosis in vitro*, but significant sterilizing activity in mice, presumably against *M. tuberculosis* inside activated macrophages.

[00498] **Moxifloxacin (MXF):** key second-line drug known for its strong bactericidal activity against actively multiplying organisms but reduced activity against non-actively multiplying organisms. MXF is being studied in clinical trials to evaluate whether it belongs as a first-line TB drug.

[00499] **Linezolid (LZD):** second-line drug commonly used in salvage therapy for recalcitrant drug-resistant TB. LZD may also serve as a surrogate for new oxazolidinones in clinical development.

[00500] **Cmpd A (A):** Test compound A.

[00501] **Cmpd B (B):** Test compound B.

[00502] Table 29. Sample scheme for checkerboard experiment

	Concentration of Drug 1				
Conc of Drug 2	0	0.25x MIC	MIC	4x MIC	16x MIC
0					
0.25x MIC					
MIC					
4x MIC					
16x MIC					

[00503] 2) Experiment to evaluate the sterilizing activity of novel combinations including test compounds of formula (I).

[00504] At present, the gold standard for measuring a regimen's sterilizing activity in the mouse model is the assessment of relapse after discontinuation of therapy. With available regimens as standard comparators, such experiments require 7-10 months to complete due to the requirement for a treatment-free follow-up period of ≥ 3 months to determine the proportion of mice with culture-positive relapse. Because of the time- and cost-consuming nature of such experiments, it is imperative to utilize the most efficient study designs possible. By establishing the relative activity of various 2-drug building blocks in the short-term infection model as described above, the most promising regimens can be carried forward into 1 or 2 relapse-based studies to compare the activity of such regimens to that of the standard first-line regimen and/or that of more potent experimental regimens.

[00505] A sample experimental scheme is presented in Table 30. In this example, the effect of adding test compound A to the first-line regimen or substituting it for INH is examined, as is the substitution of test compound B for ethambutol or amikacin in an idealized second-line regimen comprised of existing drugs. In each case, the regimens in question are truncated after treatment of reduced duration in order to demonstrate whether the incorporation of test compound could have a treatment-shortening effect. The primary endpoint is the proportion of mice with positive cultures (i.e., relapse) 3 months after the discontinuation of therapy. Mice will be infected by the aerosol route with approximately $4 \log_{10}$ CFU on Day -14. The infection will incubate for 14 days before mice are randomized into treatment groups as indicated and treatment is begun. The indicated regimens will be administered as described above. Group mean lung CFU counts will be compared by one-way ANOVA with Bonferroni's post-test to adjust for multiple comparisons. Additional cohorts of 15 mice will be held for 3 months after completing various durations of treatment

before being sacrificed for relapse determination. The entire lung homogenate will be plated on 7H11 agar. The proportions of mice with culture-positive relapse will be compared using Fisher's Exact test with adjustment for multiple corrections.

[00506] Table 30. Example of an experimental scheme to assess the sterilizing activity of promising regimens containing test compounds

Time point and No. of mice to sacrifice**							
Regimen*	D-13	D0	M2	M4 (+3)	M5 (+3)	M6 (+3)	Total
2RHZ/3RH	6	6	5	5 (15)	5 (15)		57
2RHZA/3RHA			5	5 (15)	5 (15)		45
2RAZ/3RA			5	5 (15)	5 (15)		45
2MEZAmk/4ME			5	5	5 (15)	5 (15)	50
2MBZAmk/4MB			5	5	5 (15)	5 (15)	50
2MEZB/4MEB			5	5	5 (15)	5 (15)	50
Total	6	6	30	30 (45)	30 (90)	15 (45)	297
*R, RIF 10mg/kg; H, INH 10mg/kg; Z, PZA 150mg/kg; A, Test compound A; B, Test compound B; M, MXF 100mg/kg; E, ethambutol 100 mg/kg; Amk, amikacin 30 mg/kg **Time points are shown in days (D) (day -13 [D-13] or day 0 [D0]) or months (M) (e.g., 2 months = M2) of treatment. (+3) indicates that the mice are held for 3 months after the completion of treatment at the indicated time point.							

[00507] Explanation of treatment groups

[00508] **2RHZ/3RH:** first-line regimen control consisting of 2 months of RIF, INH, and PZA, followed by 3 months of RIF and INH.

[00509] **2RHZA/3RHA:** test regimen in which test compound A is added to the first-line regimen.

[00510] **2RAZE/3RA:** test regimen in which test compound A is substituted for INH in the first-line regimen.

[00511] **2MEZAmk/4ME:** second-line regimen control consisting of 2 months of MXF, ethambutol, PZA and amikacin, followed by 4 months of MXF and ethambutol.

[00512] **2MEZAmk/4ME:** test regimen in which test compound B is substituted for ethambutol in the second-line regimen.

[00513] **2MEZAmk/4ME:** test regimen in which test compound B is substituted for amikacin in the second-line regimen.

[00514] Example 44

[00515] **Minimal Inhibitory Concentration (MIC) of Compound 23A in *M. tuberculosis* (“Mtb”) Bacterial Broth Culture Against Diverse Mtb Isolates and Various Species of *Mycobacteria***

[00516] To determine the MIC of Compound 23A, 96-well microtiter plates were used (Corning #3904) to culture *M. tuberculosis* in Middlebrook 7H9 broth (BD271310) containing ADC enrichment, while agar plates were used to sub-culture various isolates of Mtb streaked to single colonies. Cell suspensions were made containing $\sim 10^8$ cells/ml following sonication and then diluted 1/200 by transferring 0.2 ml of cells to 40 ml sterile 7H9 broth with ADC supplement (a final concentration of $\sim 10^6$ cells/ml). 100 μ l of Mtb cells were then ($\sim 5 \times 10^4$ cells) added each microtiter well containing 1 μ l of test compounds in DMSO (see below). Microtiter plates were incubated in a humidified 37°C chamber for 9 days and bacterial growth was measured by either visual inspection or by adding 30 μ l of 0.01% sterile resazurin to each well and measuring the background fluorescence at an Excitation of 492 nm/emission of 595 nm after 24 hours. The minimum inhibitory concentrations (MICs) were defined as the lowest concentration of an antimicrobial that inhibits the growth of bacteria by $\geq 70\%$.

[00517] Table 31. MICs (μ g/ml) of Compound 23A and Moxifloxacin (as a comparator) in an expanded set of *Mycobacterium tuberculosis* (Mtb) strains

Organism	23A	Moxifloxacin
Mtb H37Rv	0.015, 0.015	0.03, 0.03
Mtb Erdman	0.06, 0.06	0.03, 0.03
Mtb CDC1551	0.015, 0.015	0.015, 0.015
Mtb HN878 (Beijing-Type)	0.015, 0.015	0.03, 0.015
Mtb GN9	0.03, 0.03	0.03, 0.015
<i>M. avium</i> 103	0.12, 0.23	NT
<i>M. avium</i> Far	0.23, 0.23	NT
<i>M. avium</i> 3404.4	0.23, 0.23	NT
<i>M. kansasii</i> 303	0.03, 0.03	0.03, 0.03
<i>M. kansasii</i> 316	0.06, 0.06	0.03, 0.03
<i>M. kansasii</i> 379	<0.015, <0.015	0.03, 0.03
<i>M. smegmatis</i>	6.25	NT

[00518] **Conclusion:** Compound 23A is potently active against a diverse range of Mtb species.

[00519] Table 32. MICs ($\mu\text{g/ml}$) of Compound 23A in Drug Resistant Mycobacteria in Broth Culture (again using Moxifloxacin as comparator)

Organism	Cmpd 23A	Moxifloxacin
<i>M. tuberculosis</i> Erdman	0.125, 0.06	0.03, 0.015
<i>M. tuberculosis</i> Levo ^R 2D	0.015, 0.015	2, 2
<i>M. tuberculosis</i> Levo/Gat ^R 2C	0.06, 0.06	8, 8
<i>M. tuberculosis</i> 5	0.125, 0.125	8, 4

[00520] *M. tuberculosis* Levo^R 2D and *M. tuberculosis* Levo/Gat^R 2C are laboratory derived resistant strains of *M. tuberculosis* Erdman; they are single-drug resistant strains. *M. tuberculosis* 5 is an XDR strain.

[00521] **Conclusion:** Compound 23A is also active against drug resistant Mtb

[00522] **Table 33.** MIC ($\mu\text{g/ml}$) determination against geographically and genetically diverse strains of Mtb for Compound 23 compared to control compound Moxifloxacin

M. tuberculosis strain	Cmpd 23A	Moxifloxacin
Erdman	0.06	0.03
GN9	0.06	0.03
AH13	0.50	0.5
HH915336	0.015	0.015
CDC1551	0.06	0.03
H37Rv	0.125	0.06
BW9	0.125	0.008
Rv ATCC	0.06	0.06
AH517	0.06	0.03
H10460	0.5	0.25
Wg565	0.015	1.00
C913	0.06	0.03
H13571	0.06	0.03
MC19062	0.125	0.015
LL	0.015	0.015
W10	0.125	0.030
210	0.06	0.015
W33	0.06	0.5

[00523] **Conclusion:** compound 23A is active against a diverse range of Mtb strains and isolates.

[00524] The Minimum bactericidal concentration (MBC) assay was determined similar to the MIC. At the end of the MIC assay, cell culture wells including compound incubated with Mtb were selected and 50 μ L of sample was added onto 6 well agar plates in duplicate (changing tips for every well). The plates were incubated in a humidified 37°C chamber for 2-3 weeks and the colony forming units (cfus) were then counted for MBC. For wells containing over 200 colonies, the MBC could not be determined as there were too many to count. However, wells containing in the range of 5 – 50 colonies per well were useful for enumerating CFU. The MBC is the concentration at which 99% killing (2 log scales) occurs relative to the Day 0 background CFU.

[00525] **Table 34.** Minimum bactericidal concentrations against *M. tuberculosis* H37Rv

Sample (conc.)	Log cfu	Log Reduction
Untreated Control	6.13	N/A
Isoniazid control (0.125 μ g/mL)	4.28	1.85
Compound 23A (0.039 μ g/mL)	5.36	0.77
Compound 23A (0.078 μ g/mL)	3.75	2.38
Compound 23A (0.156 μ g/mL)	1.04	5.09
Compound 23A (0.312 μ g/mL)	1.32	4.81
Compound 23A (0.625 μ g/mL)	1.04	5.09

[00526] **Table 35.** The same MBC assay described above was used to determine the log killing reduction in CFU of Cmpd 23A, Moxifloxacin and a combination of Cmpd 23A with Moxifloxacin against *M. tuberculosis* Erdman over a one month period of incubation. The results (measured as log reduction) showed slow killing kinetics of Compound 23A at 4X MIC and additive potency when combined with Moxifloxacin.

Days	Control Log cfu	Compound 23A Log Reduction	Moxifloxacin Log Reduction	Compound 23A w/ Moxifloxacin Log Reduction
0	6	0	0	0
1	7.3	0.2	0.4	0.5
2	8.1	0.2	1.6	1.0
3	8.1	1.0	2.8	0.9
7	7.0	1.9	2.2	2.0
14	7.0	1.9	1.4	2.5
21	7.0	2.2	0.0	3.2
28	7.0	3.0	0.2	4.3

[00527] **Conclusion:** Compound 23A exhibits good bactericidal activity against H37Rv and Erdman isolates of *M. tuberculosis*. Compound 23A has improved bactericidal activity compared to Moxifloxacin over an extended time period.

[00528] Example 45

[00529] **MIC Determination in the Low-Oxygen-Recovery Assay (LORA) for Nonreplicating *M. tuberculosis***

[00530] Screening for new antimicrobial agents is routinely conducted only against actively replicating bacteria. However, it is now widely accepted that a physiological state of non-replicating persistence (NRP) is responsible for antimicrobial tolerance in many bacterial infections. In tuberculosis, the key to shortening the 6-month regimen lies in targeting this NRP subpopulation. Therefore, Compound 23A was tested in a high-throughput, luminescence-based low oxygen- recovery assay (LORA), developed to screen antimicrobial agents against NRP *Mycobacterium tuberculosis* as described by Cho et al 2007. Cho SH, Warit S, Wan B, Hwang CH, Pauli GF, Franzblau SG; "Low-Oxygen-Recovery Assay for High-Throughput Screening of Compounds against Nonreplicating *Mycobacterium tuberculosis*" Antimicrob Agents Chemother. 2007 April; 51(4): 1380–1385
doi: 10.1128/AAC.00055-06.

[00531] Results:

[00532] The LORA MIC for Compound 23A was 0.25 ug/mL, indicating that the test compound retained activity against non-replicating, persistent *Mycobacterium tuberculosis*. In contrast Moxifloxacin was inactive (MIC >40 ug/ml) and gatifloxacin was 10-fold less active (MIC = 3.6 ug/ml).

[00533] Example 46

[00534] **Efficacy Against Intracellular *M. tuberculosis***

[00535] Cultures of recombinant *M. tuberculosis* (Mtb) expressing luciferase were maintained in 7H9 broth supplemented with 0.05% Tween 80, 10% ADC, and 20 ug/ml kanamycin, (25 ml in a filter-cap 125 ml plastic Erlenmeyer flask), at 37°C with static incubation. Immediately prior to infection of macrophages or cell lines, the Mtb cultures were sonicated in suspension for 10 seconds and diluted to a density of 8×10^5 cells/ml for a multiplicity of infection (MOI) of 2:1. Prior to *M. tuberculosis* infection, PMA-activated THP-1 or J774 cells were adjusted to a cell density of $2\text{--}3 \times 10^5$ cells/ml in 25 mM HEPES -

buffered RPMI-1640 media (without phenol red; medium #2) supplemented with 10% FBS, L-glutamine, and 0.05 mM β -mercaptoethanol.

[00536] Test compounds were dispensed into sterile round bottom 96 well tissue culture plates at the desired concentration in 1 μ l volumes of DMSO (0.5 % DMSO final). Just prior to treatment of Mtb-infected cells with the compound, supernatant containing un-ingested Mtb from each well was removed and replaced with 100 μ l fresh media. Cell cultures were incubated remaining plates at 37°C, 5% CO₂, in humidified chamber and the endpoint luciferase of all test and control plates was determined 5 days (120 hours) after infection by adding 100 μ l of Bright Glow reagent to each well, incubating for 10 minutes at room temperature, covering with adhesive top seal and reading the luminescence in Tecan Spectrafluor +, at a gain of 150 at maximum integration time. IC₅₀ was defined the concentration of an antimicrobial that inhibited the growth of intracellular bacteria by 50%

[00537] Results: The effects of Compound 23A on intracellular replication on Mtb were examined in two different cell types (THP-1 and J774) and three different Mtb strains (Erdman, H37Ra and CDC1551). Three other gyrase-target antibiotics were used as controls. Compound 23A was efficacious against all three intracellular Mtb strains in both cell types.

[00538] Table 36.

Mtb Strain/Cell type	23A	Moxifloxacin	Gatifloxacin	Novobiocin
Erdman (MIC)	0.06	0.03	0.25	61.00
Mtb H37Ra in THP1 Cells (IC₅₀)	0.03	0.33	0.20	2.10
Mtb CDC1551 in J774 Cells (IC₅₀)	0.12	0.21	0.94	NT
Mtb H37Rv in J774 Cells (IC₅₀)	0.21	NT	NT	NT
Mtb Erdman in J774 Cells (IC₅₀)	<0.17	NT	NT	NT

[00539] Table 37. Comparison of Compound 23A vs. Standard TB Drugs in Culture and Intracellular Macrophage (THP1) Assay

Compound	MIC (μg/mL)	
	Broth	Macrophage Cells
23A	0.01	0.03
Isoniazid	0.21	0.012
Rifampin	0.03	0.008
Ethambutol	2.55	1.26
Pyrazinamide	>12.3	>2.5
Linezolid	0.53	0.37
Moxifloxacin	0.12	0.33

[00540] Mtb H37Ra was used as the test strain. The data show that Compound 23A has at least equivalent potency as approved anti-TB agents.

[00541] Example 47

[00542] **Efficacy of Compound 23A in Combination with Approved TB Agents**

[00543] A checkerboard approach was used to determine the effect of co-administration of Compound 23A with approved anti-TB agents, using both broth culture and Intracellular. In order to assess whether the effects were antagonistic, additive or synergistic the Fractional Inhibitory Concentration (FIC) Index was calculated as follows:

$$[00544] \quad \text{FIC}_{\text{index}} = \frac{\text{MIC}_A \text{ with B}}{\text{MIC}_A} + \frac{\text{MIC}_B \text{ with A}}{\text{MIC}_B}$$

[00545] The combination is considered antagonistic if the FIC_{index} is great then 4, indifferent or additive if the FIC_{index} is between 0.5 and 4, and synergistic if the index is less

than 0.5. The results are tabulated below and show that Compound 23A was generally additive to the effect of approved anti-TB agents and may be synergistic when used in combination with TMC207 and Clofazimine. None of the drug combinations used showed antagonistic effects.

[00546] Table 38.

Cmpd 23A with	Mtb in Broth Culture		Intracellular Mtb	
	Additive	Synergy	Additive	Synergy
Isoniazid	0.75		0.75	
Rifampin	0.63		2.00	
Moxifloxacin	1.00		1.00	
TMC-207	1.00			0.50
Amikacin	2.00		2.00	
Linezolid*		0.50	2.00	
PA-824	2.00		1.00	
Ethambutol	0.63		2.00	
Clofazimine	2.00			0.50

[00547] Example 48

[00548] **Culture of Non-replicating (NRP) *M. tuberculosis* H37Ra (luciferase)**

[00549] *M. tuberculosis* (H37Ra, pMV361, with luciferase) cells were grown in 7H9 broth supplemented (with 0.2% glycerol, 0.05% Tween 80, 10% ADC, and 20 µg/ml kanamycin) in a Flat-cap 125 ml plastic Erlenmeyer flask. Methylene blue was added as a redox indicator (to give a final concentration of 1.5 µg/mL) to the flask to monitor oxygen depletion. The flask was placed on a magnetic stirrer, and stirred with a magnetic bead at 180 rpm, inside a 37°C incubator, until the methylene blue indicator was completely decolorized (about 14 days). The NRP Mtb was transferred to a 1.5 ml centrifuge tube, mixed well and adjusted to an optical density (OD₆₀₀) of 0.02, which is the equivalent of approximately $\sim 10^8$ cells/ml. The suspension was then diluted 1/200 by transferring 0.2 ml of cells to 40 ml sterile 7H9 broth with 10% ADC supplement ($\sim 5 \times 10^5$ cells/ml) and added to a tissue culture plate (Thermo #260251) containing experimental and control compounds. Each well was thoroughly mixed with a manual multichannel pipettor and the plates were covered with sealing films (Axygen #BF-400-S) and incubated in a humidified hypoxic box containing 2 EZ anaerobic sachets (BD) for 7 days at 37°C. After 7 days, the sealing film was removed from the plates, each well was mixed and the cell supernatants transferred to a new 1.5 ml centrifuge tube. The tubes were centrifuged at 13,000 rpm for 5 minutes, the supernatant was discarded and replaced with 1 ml of 7H9 broth with 10% ADC supplement.

100 μ l of each cell suspension was transferred into sterile tissue culture plates (Costar3903) and 6 ~ 8 copies of each plate were prepared for different time points. 100 μ l of Steady-Glo detection reagent was added to each well, incubated for 15 minutes at room temp., covered with an adhesive top seal and the luminescence read on a BioTek Synergy 2, at a gain of 165. The endpoint luciferase was measured at days 3, 7, 10, and 14. Results indicated as IC50's read on day 14 are shown below in **Table 39**.

[00550] **Table 39.**


Compound	IC ₅₀
Isoniazid	>50 μ g/mL
Rifampin	< 0.05 μ g/mL
Moxifloxacin	6 μ g/mL
Compound 23A	1 μ g/mL

[00551] **Conclusion:** Compound 23A is active against non-replicating tuberculosis.

WHAT IS CLAIMED IS:

1. A method of controlling, treating or reducing the advancement, severity or effects of a mycobacterium disease comprising administering to a patient in need thereof a therapeutically effective amount of:

(a) a compound of formula




wherein R is hydrogen or fluorine; X is hydrogen, $-\text{PO}(\text{OH})_2$, $-\text{PO}(\text{OH})\text{O}^-\text{M}^+$, $-\text{PO}(\text{O}^-)_2 \cdot 2\text{M}^+$, or $-\text{PO}(\text{O}^-)_2 \cdot \text{D}^{2+}$; M^+ is a pharmaceutically acceptable monovalent cation; and D^{2+} is a pharmaceutically acceptable divalent cation; or a pharmaceutically acceptable salt thereof; in combination with:

(b) one or more antibiotic compounds comprising a diarylquinoline, rifapentine, rifalazil, a nitroimidazole, a benzothiazine, capreomycin, clofazimine, cycloserine, dapsone, a thiocarbamide, ethambutol, DC-159a, a nitrobenzthiazole, sutezolid (PNU-100480), AZD-5847, posizolid (AZD-2563), para-aminosalicylic acid, SQ-109, SQ-609, a capuramycin, a caprazene nucleoside, an isothiazoloquinolone, thioridazine, thiacetazone, dirithromycin, roxithromycin, telithromycin, azithromycin, clarithromycin, erythromycin, amikacin, kanamycin, streptomycin, levofloxacin, moxifloxacin, gatifloxacin, linezolid, rifalazil, meropenem, clavulanate, or isoniazid,


with the proviso that when the one or more antibiotic compounds is thioridazine, azithromycin, clarithromycin, erythromycin, amikacin, kanamycin, streptomycin, levofloxacin, moxifloxacin, gatifloxacin, linezolid, rifalazil, meropenem, clavulanate, or isoniazid, then an additional antibiotic is also present in the combination.

2. The method of claim 1, wherein the one or more antibiotic compounds comprises bedaquiline (TMC-207), delamanid (OPC67683), PA 824, TBA-354, SKLB-TB37, BTZ-043, SQ-641, cycloserine, dapsone, ethionamide, prothionamide, para-aminosalicylic acid, CPZEN45, ACH-702 or ACH-710.
3. The method of claim 2, wherein said one or more antibiotic compounds comprises bedaquiline, rifapentine, moxifloxacin, linezolid, delamanid, or PA 824.
4. The method of claim 1, wherein said one or more antibiotic compounds comprises moxifloxacin, linezolid, rifalazil, meropenem, clavulanate, pyrazinamide, or isoniazid.
5. The method of claim 2, wherein at least one of the antibiotics is pyrazinamide.
6. The method of any one of claims 1-5, wherein the compound of formula (I) is a compound of the formula




wherein R is hydrogen or fluorine; or a pharmaceutically acceptable salt thereof.

7. The method of any one of claims 1-5, wherein the compound of formula (I) is a compound of formula



wherein X is $-\text{PO}(\text{OH})_2$, $-\text{PO}(\text{OH})\text{O}^-\text{M}^+$, $-\text{PO}(\text{O}^-)_2 \cdot 2\text{M}^+$, or $-\text{PO}(\text{O}^-)_2 \cdot \text{D}^{2+}$; M^+ is a pharmaceutically acceptable monovalent cation; and D^{2+} is a pharmaceutically acceptable divalent cation; or a pharmaceutically acceptable salt thereof.

8. The method of any one of claims 1-5, wherein the compound of formula (I) is a compound of formula



wherein R is hydrogen or fluorine; or a pharmaceutically acceptable salt thereof.

9. The method of any one of claims 1-5, wherein the compound of formula (I) is (*R*)-1-ethyl-3-(5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea, or a pharmaceutically acceptable salt thereof.

10. The method of any one of claims 1-5, wherein the compound of formula (I) is (*R*)-1-ethyl-3-(6-fluoro-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea, or a pharmaceutically acceptable salt thereof.

11. The method of any one of claims 1-5, wherein the salt of formula (I) is a methanesulfonic acid salt of (*R*)-1-ethyl-3-(5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea.

12. The method of any one of claims 1-5, wherein the salt of formula (I) is a methanesulfonic acid salt of (*R*)-1-ethyl-3-(6-fluoro-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea.

13. The method of any one of claims 1-5, wherein X is $-\text{PO}(\text{OH})\text{O}^-\text{M}^+$, $-\text{PO}(\text{O}^-)_2 \cdot 2\text{M}^+$, or $-\text{PO}(\text{O}^-)_2 \cdot \text{D}^{2+}$; M^+ is selected from a group consisting of Li^+ , Na^+ , K^+ , N-methyl-D-glucamine, and $\text{N}(\text{R}^9)_4^+$, wherein each R^9 is independently hydrogen or a C_1 - C_4 alkyl group; D^{2+} is selected from a group consisting of Mg^{2+} , Ca^{2+} , and Ba^{2+} .

14. The method according to claim 13, wherein X is $-\text{PO}(\text{OH})\text{O}^-\text{M}^+$ or $-\text{PO}(\text{O}^-)_2 \cdot 2\text{M}^+$; M^+ is selected from a group consisting of Li^+ , Na^+ , K^+ , N-methyl-D-glucamine, and $\text{N}(\text{R}^9)_4^+$, wherein each R^9 is independently hydrogen or a C_1 - C_4 alkyl group.


15. The method according to claim 13, wherein X is $-\text{PO}(\text{O}^-)_2 \cdot 2\text{M}^+$; M^+ is selected from a group consisting of Li^+ , Na^+ , K^+ , N-methyl-D-glucamine, and $\text{N}(\text{R}^9)_4^+$, wherein each R^9 is independently hydrogen or a C_1 - C_4 alkyl group.

16. The method according to claim 13, wherein M^+ is Na^+ .

17. The method according to any one of claims 1-5, wherein the compound of formula (I) is disodium (*R*)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl phosphate.

18. The method according to any of claims 1-5, wherein the mycobacterial disease is caused by *M. tuberculosis*, *M. avium intracellulare*, *M. ulcerans*, *M. kansasii*, *M. fortuitum*, *M. abscesses*, *M. leprae*, *M. africanum*, *M. marinum*, *M. avium paratuberculosis*, or *M. bovis*, *M. chelonae*, *M. scrofulaceum*, *M. xenopi*, *M. intracellulare*, or *M. microti*.

19. A method according to claim 1 wherein the compound of formula (I) is administered with only one antibiotic, wherein the antibiotic is rifapentine, TMC-207, SQ-109, a nitroimidazole, or an oxazolidinone.
20. A method according to claim 19, wherein the antibiotic is rifapentine.
21. A method according to claim 19, wherein the antibiotic is TMC-207.
22. A method according to claim 19, wherein the antibiotic is SQ-109.
23. A method according to claim 19, wherein the antibiotic is a nitroimidazole.
24. A method according to claim 19, wherein the antibiotic is an oxazolidinone.
25. A method according to any of claims 19 – 24, further comprising administering pyrazinamide.
26. A method according to any of claims 19-24, wherein the compound of formula (I) is (*R*)-1-ethyl-3-(6-fluoro-5-(2-(2-hydroxypropan-2-yl)pyrimidin-5-yl)-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-2-yl)urea, or a pharmaceutically acceptable salt thereof
27. A method of treating tuberculosis comprising administering a therapeutically effective amount of:
- (a) a compound of formula (I):




wherein R is hydrogen or fluorine; X is hydrogen, $-\text{PO}(\text{OH})_2$, $-\text{PO}(\text{OH})\text{O}^+\text{M}^+$, $-\text{PO}(\text{O}^-)_2 \cdot 2\text{M}^+$, or $-\text{PO}(\text{O}^-)_2 \cdot \text{D}^{2+}$; M^+ is a pharmaceutically acceptable monovalent cation; and D^{2+} is a pharmaceutically acceptable divalent cation; or a pharmaceutically acceptable salt thereof; in combination with:

(b) one or more antibiotic compounds comprising a diarylquinolone, rifapentine, rifalazil, a nitroimidazole, a benzothiazinone, capreomycin, clofazimine, cycloserine, dapsone, a thiocarbamide, ethambutol, DC-159a, a nitrobenzthiazole, sutezolid (PNU-100480), AZD-5847, posizolid (AZD-2563), para-aminosalicylic acid, SQ-109, SQ-609, a capuramycin, a caprazene nucleoside, an isothiazoloquinolone, thioridazine, moxifloxacin, gatifloxacin, linezolid, rifalazil, meropenem, clavulanate, or isoniazid, with the proviso that when the one or more antibiotic compounds is thioridazine, moxifloxacin, gatifloxacin, linezolid, rifalazil, meropenem, clavulanate, or isoniazid, then an additional antibiotic is also present in the combination.

28. A method of inhibiting the growth of drug sensitive and drug resistant mycobacteria cells wherein the mycobacteria cell is drug sensitive and drug resistant *M. tuberculosis*, drug resistant *M. tuberculosis*, *M. avium intracellulare*, *M. ulcerans*, *M. kansasii*, *M. fortuitum*, *M. abscesses*, *M. leprae*, *M. africanum*, *M. marinum*, *M. avium paratuberculosis*, *M. bovis*, or a mixture thereof; the method comprising contacting the drug sensitive and drug resistant mycobacteria cells with:

(a) a compound of formula (I):



wherein R is hydrogen or fluorine; X is hydrogen, $-\text{PO}(\text{OH})_2$, $-\text{PO}(\text{OH})\text{O}^-\text{M}^+$, $-\text{PO}(\text{O}^-)_2 \cdot 2\text{M}^+$, or $-\text{PO}(\text{O}^-)_2 \cdot \text{D}^{2+}$; M^+ is a pharmaceutically acceptable monovalent cation; and D^{2+} is a pharmaceutically acceptable divalent cation; or a pharmaceutically acceptable salt thereof; in combination with:

(b) one or more antibiotic compounds comprising a diarylquinolone, rifapentine, rifalazil, a nitroimidazole, a benzothiazinone, capreomycin, clofazimine, cycloserine, dapsone, a thiocarbamide, ethambutol, DC-159a, a nitrobenzthiazole, sutezolid (PNU-100480), AZD-5847, posizolid (AZD-2563), para-aminosalicylic acid, SQ-109, SQ-609, a capuramycin, a caprazene nucleoside, an isothiazoloquinolone, thioridazine, moxifloxacin, gatifloxacin, linezolid, rifalazil, meropenem, clavulanate, or isoniazid, with the proviso that when the one or more antibiotic compounds is thioridazine, moxifloxacin, gatifloxacin, linezolid, rifalazil, meropenem, clavulanate, or isoniazid, then an additional antibiotic is also present in the combination.

29. The method of any of claims 1-5, wherein the one or more antibiotic compounds are TMC-207 and pyrazinamide.

30. The method of any of claims 1-5, wherein the one or more antibiotic compounds are rifapentine and pyrazinamide.

31. The method of any of claims 1-5, wherein the one or more antibiotic compounds are oxazolidinone and pyrazinamide.

32. The method of any of claims 1-5, wherein the one or more antibiotic compounds are nitroimidazole and pyrazinamide.

33. The method of claim 33, wherein nitroimidazole is delaminid.

34. The method of any of claims 1-5, wherein the one or more antibiotic compounds are pyrazinamide and SQ-109.

35. The method of any of claims 1-5, wherein the one or more antibiotic compounds are TMC-207, SQ-109, and pyrazinamide.

36. The method of any of claims 1-5, wherein the one or more antibiotic compounds are SQ-109, clavulanate and meropenem.



37. The method of any of claims 1-5, wherein the one or more antibiotic compounds are rifapentine, SQ-109, and pyrazinamide.

38. The method of any of claims 1-5, wherein the one or more antibiotic compounds are oxazolidinone, SQ-109, and pyrazinamide.

39. The method of any of claims 1-5, wherein the one or more antibiotic compounds are nitroimidazole, SQ-109, and pyrazinamide.

40. The method of claim 40, wherein nitroimidazole is delaminid.

41. The method of any of claims 1-5, wherein the one or more antibiotic compounds are clavulanate, meropenem, and SQ-109.

**FIG. 1****FIG. 2**

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2013/050564

A. CLASSIFICATION OF SUBJECT MATTER INV. A61K31/506 A61K45/06 A61P31/04 A61P31/06 A61K31/132 A61K31/454 A61K31/47 A61K31/496 A61K31/4965 A61K31/498 A61K31/5377		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) A61K A61P		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, BIOSIS, CHEM ABS Data, EMBASE, WPI Data		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2012/010222 A1 (CHARIFSON PAUL [US] ET AL CHARIFSON PAUL S [US] ET AL) 12 January 2012 (2012-01-12) claims claims 25-27 ----- -/--	1-41
☒ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
26 September 2013		08/10/2013
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Lemarchand, Aude

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2013/050564

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PAUL S. CHARIFSON ET AL: "Novel Dual-Targeting Benzimidazole Urea Inhibitors of DNA Gyrase and Topoisomerase IV Possessing Potent Antibacterial Activity: Intelligent Design and Evolution through the Judicious Use of Structure-Guided Design and Stucture-Activity Relationships", JOURNAL OF MEDICINAL CHEMISTRY, vol. 51, no. 17, 11 September 2008 (2008-09-11), pages 5243-5263, XP055021427, ISSN: 0022-2623, DOI: 10.1021/jm800318d page 5247; figure 3 page 5245; table 1 abstract -----	1-41
A	WO 2006/022773 A1 (VERTEX PHARMA [US]; CHARIFSON PAUL S [US]; DEININGER DAVID D [US]; GRI) 2 March 2006 (2006-03-02) claims -----	1-41
X,P	WO 2012/097269 A1 (VERTEX PHARMA [US]; LE TIRAN ARNAUD [FR]; GRILLOT ANNE-LAURE [FR]; CHA) 19 July 2012 (2012-07-19) page 22, paragraph 108 - page 24, paragraph 114 claims -----	1-41
X,P	US 2012/184741 A1 (SHANNON DEAN [US] ET AL) 19 July 2012 (2012-07-19) page 11, paragraph 132-136 page 7, paragraph 84 page 9, paragraph 114-115 part of table 2A starting from the entry "Mycobacterium avium 103"; page 29 -----	1-41
X,P	WO 2012/097273 A1 (VERTEX PHARMA [US]; SHANNON DEAN [US]; LUISI BRIAN [US]; KRAWIEC MARIU) 19 July 2012 (2012-07-19) page 22, paragraph 110-111 page 23, paragraph 115 page 26, paragraph 127 - page 28, paragraph 132 claims -----	1-41
X,P	WO 2012/177707 A1 (VERTEX PHARMA [US]; BENNANI YOUSSEF LAAFIRET [CA]; CHARIFSON PAUL S [U]) 27 December 2012 (2012-12-27) pages 23-24, paragraph 106-111; claims claim 16 -----	1-41

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2013/050564

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2012010222	A1	12-01-2012	NONE
WO 2006022773	A1	02-03-2006	AT 433980 T 15-07-2009
		AU 2004322641 A1 02-03-2006	
		CA 2577758 A1 02-03-2006	
		DK 1789419 T3 10-08-2009	
		EP 1789419 A1 30-05-2007	
		ES 2325026 T3 24-08-2009	
		HR P20090491 T1 30-11-2009	
		KR 20070048762 A 09-05-2007	
		PT 1789419 E 17-09-2009	
		SI 1789419 T1 31-12-2009	
		US 2005038247 A1 17-02-2005	
		US 2009325935 A1 31-12-2009	
		WO 2006022773 A1 02-03-2006	
		ZA 200701629 A 25-09-2008	
WO 2012097269	A1	19-07-2012	AR 084863 A1 10-07-2013
		AU 2012205415 A1 01-08-2013	
		CA 2824516 A1 19-07-2012	
		TW 201309677 A 01-03-2013	
		US 2012184512 A1 19-07-2012	
		WO 2012097269 A1 19-07-2012	
US 2012184741	A1	19-07-2012	AR 084862 A1 26-06-2013
		AU 2012205416 A1 01-08-2013	
		CA 2824401 A1 19-07-2012	
		TW 201309676 A 01-03-2013	
		US 2012184741 A1 19-07-2012	
		WO 2012097270 A1 19-07-2012	
WO 2012097273	A1	19-07-2012	AU 2012205419 A1 01-08-2013
		CA 2824403 A1 19-07-2012	
		TW 201309678 A 01-03-2013	
		US 2012184564 A1 19-07-2012	
		WO 2012097273 A1 19-07-2012	
WO 2012177707	A1	27-12-2012	TW 201313732 A 01-04-2013
		US 2013157979 A1 20-06-2013	
		WO 2012177707 A1 27-12-2012	